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The anticancer drug cisplatin is in widespread use but its mechanism of action is only poorly
understood. Moreover, human cancers acquire resistance to the drug, which limits its
clinical utility. A paradox in the field is how loss of mismatch DNA repair leads to clinical
resistance to this widely used drug.
The phenomenon of cisplatin tolerance in mismatch repair deficient cells was initially
discovered in E. coli, where methylation deficient dam mutants show high sensitivity to
cisplatin and dam mutants with an additional mutation in either of the mismatch repair genes
mutS or mutL show near wildtype levels of resistance. A prevalent explanation for this
observation is the abortive repair model, which proposes that in dam mutants, where the
strand discrimination signal is lost, mismatch repair attempts futile cycles of repair opposite
cisplatin-DNA adducts. Previous findings have supported this model to the extent that
MutS, the E. coli mismatch recognition protein, specifically recognizes DNA modified with
cisplatin. However it has recently been shown that MutS binding to cisplatin adducts may
contribute to toxicity by instead preventing the recombinational repair of a cisplatin-modified
substrate, and we have previously shown that recombination is an essential mechanism for
tolerating cisplatin damage. In the present study, we examined the global transcriptional
responses of wildtype, dam, dam mutS, and mutS mutant E. coli after treatment with a toxic
dose of cisplatin. We also determined any dose-response at the transcriptional level of
several SOS response genes and other genes involved in DNA repair by real time RT-PCR.
Furthermore, we performed single-cell electrophoresis in order to determine the effect of
mismatch repair on the level of double-strand break formation in cisplatin-treated cells. Our
results show that Dam-deficient strains exhibit unique gene regulation that may be due to
mismatch-repair induced DNA damage in the absence of adenine methylation. In addition,
cisplatin treatment induces double-strand break formation and the SOS response in a dose-
dependent manner, and both break formation and the SOS response are greatest in the
hypersensitive dam mutant strain. The higher level of cisplatin-induced double-strand
breaks in the dam mutant may be dependent on functional mismatch repair.
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Chapter 1: Understanding the basic mechanisms of a
successful anticancer agent
Abstract
Approved by the FDA in 1978, cisplatin is currently one of the most widely used anticancer
agents (61,326). The drug is particularly effective against testicular germ cell tumors, where
cisplatin-based chemotherapy affords cure rates exceeding 90%. Cisplatin's potent toxic
effects are believed to be due to its reaction with DNA to form primarily intrastrand
crosslinks. These crosslinks induce major structural distortions in DNA including unwinding
and bending of the duplex towards the major groove. These structural alterations interfere
with essential DNA metabolic processes such as replication and transcription. Furthermore,
cisplatin adducts attract cellular proteins with affinity for damaged and/or non-canonical DNA
structures, resulting in various effects including repair shielding of the adducts, hijacking of
proteins essential for transcription and the repair of other types of DNA damage, and the
activation of programmed cell death (apoptosis). Despite the success of cisplatin in the
treatment of germ cell tumors, other cancers may be either inherently drug resistant or
acquire cisplatin resistance after initial treatment. In vitro resistance models show that cells
may overcome the toxic effects of cisplatin by several different mechanisms including (1) a
reduction the effective intracellular concentration of cisplatin (via reduced uptake or
increased efflux of drug or via cellular thiols that inactivate the drug), (2) up-regulation of
DNA repair pathways to reduce the number of cisplatin-DNA adducts by excision repair, (3)
increased tolerance through the up-regulation of replicative and recombinational bypass
mechanisms, and (4) an intrinsic balance of pro- and anti-apoptotic proteins that favor
survival over apoptosis. The high sensitivity of testicular germ cell tumors may result from a
an inherently reduced DNA repair capability as well as a naturally low threshold for the
activation of apoptosis. To mimic the remarkable success of cisplatin in the treatment of
testicular germ cell tumors, many second generation platinum compounds have been
developed for other tumor types in the hope of overcoming both the dose-limiting toxicity
and drug resistance associated with cisplatin treatment.
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Chapter 1 Introduction: Understanding the basic
mechanisms of a successful anticancer agent
The story of cis-diamminedichloroplatinum(ll) (cisplatin) marks one of the most
remarkable successes in the development of antitumor drugs. Although cisplatin has been
known to chemists since 1845 (415), its important biological activity as an anticancer agent
was discovered serendipitously only 40 years ago. Experiments designed to study the
effects of electric fields on bacteria unexpectedly demonstrated that a chemical agent
produced at the platinum electrode inhibited cell division and caused filamentous growth
(597,599). Cisplatin, one of the molecules produced, showed antitumor activity in mice and
was the first heavy metal to be systematically evaluated for anticancer therapy (187,598).
Today, cisplatin is one of the most widely used agents in anticancer therapy (61). This
introduction outlines the basic research on cisplatin while focusing on the cellular responses
to cisplatin treatment.
1.1 Cisplatin in the clinic
Cisplatin was approved by the FDA in 1978 and has been most successfully used in
the treatment of testicular germ cell tumors (TGCTs). TGCTs are the most common tumor
type diagnosed in young men between the ages 15 and 34 (58). In 1970, 95% of men with
metastatic TGCTs died from the disease (187,452), but today cure rates exceed 90% for all
newly diagnosed patients and 70-80% of patients with metastatic disease are cured
(58,187,728), making testicular cancer one of the most curable malignancies (Table 1.1).
The impressive cure rates of testicular cancer are in large part due to the discovery of
cisplatin and the introduction of platinum-based chemotherapies.
TGCTs develop from the germ cells, which give rise to the sperm, and are classified
as seminomatous or nonseminomatous tumors. Seminomas account for approximately half
of TGCTs and are characterized by homogenous sheets of cells with a clear cytoplasm
(452). By contrast, most non-seminomas consist of multiple cell types, including embryonic
carcinoma cells-totipotent cells that are capable of differentiating into embryonic and extra-
embryonic tissues (58,452). While -20% of TGCTs contain a mixture of seminomas and
non-seminomas, these histopathological types may originate from a common cell (452).
Depending on the stage of disease (i.e., stage , II, or III), men with TGCTs are treated with
surgery, radiotherapy or chemotherapy, or a combination thereof. Cisplatin is one the major
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chemotherapeutic agents used to treat TCGTs; it was originally used in combination with
vinblastine and bleomycin (the agents employed as standard chemotherapy before the
advent of cisplatin (187)) in a regimen that cured more than half of the men treated (187).
Vinblastine has since been replaced with etoposide, and this new drug combination has
resulted in improved response rates and reduced toxicity (452). In addition to TGCTs,
cisplatin and its analogs are used to treat ovarian tumors, where platinum-based regimens
extend life but unfortunately only rarely cure the disease (192,283). Other tumors for which
platinum-based regimens are employed as a first-line therapy include cancers of head and
neck, small and non-small cell lung cancer, bladder, cervical, and esophageal cancers
(61,579). Regimens that include cisplatin are also used as a second- and third-line therapy
against a number of other cancers, such as breast, prostate, and brain tumors (160).
Despite the success of cisplatin in the treatment of TGCTs, the utility of the drug in
treating other cancers is limited by two important shortcomings: toxicity and intrinsic or
acquired clinical resistance. Cisplatin-induced toxicity, while proving effective in killing
cancer cells, is accompanied by harmful side-effects that reduce the dose and duration of
platinum-based regimens. Dose-limiting side effects include nephrotoxicity, emetogenesis
(vomiting) and various central and peripheral neurotoxicities (422). To protect against
unwanted adverse effects, co-administration of thiols such as N-acetylcysteine (NAC) are
increasingly used in clinical trials of platinum chemotherapy; NAC can prevent cisplatin-
induced ototoxicity, nephrotoxicity, and gastrointestinal toxicity (109,166,519,633). In
addition, delivery methods such as polymeric micelles may provide alternatives to standard
administration methods that reduce toxicity (701). Reproductive toxicity is also observed
with cisplatin treatment; reduction in sperm counts is common, but is generally temporary
and reversible (304,744). Importantly, hematologic toxicity is uncommon with cisplatin,
which allows the drug to be used in combination regimens with second and third agents that
have complementing side effects (422,424). Accordingly cisplatin is widely used in
regimens involving multiple other drugs including bleomycin and etoposide mentioned
above, paclitaxel, docetaxel, gemcitabine, doxorubicin, vinorelbine, irinotecan, 5-fluorouracil,
cyclophosphamide, and ifosfamide (61,470,728) (Table 1.1). In addition to the dose-limiting
side effects, clinical resistance presents a major limitation of cisplatin chemotherapy
(228,638). Some malignancies, such as colorectal and non-small cell lung cancers, are
intrinsically resistant to cisplatin, whereas other cancers, such as ovarian and small-cell lung
carcinomas, acquire resistance after initial cisplatin treatment; consequently relapse rates
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can be very high (36,503). Platinum analogs and second generation platinum compounds
have shown some success in overcoming both the dose-limiting toxicity and clinical
resistance associated with cisplatin, and these compounds are briefly discussed in Section
1.5.
Table 1.1 Survival rates for the eleven major cancer types and TGCT
Cancer type 5-year survival First-line or adjuvant chemotherapies
rate*
Pancreatic cancer 1.6% combination of 5-fluorouracil (5FU), gemcitabine,
_ paclitaxel, and/or cisplatin (692,693)
Lung cancer 1.7% taxane-cisplatin combination therapy (e.g., paclitaxel
or docetaxel combined with cisplatin, carboplatin
sometimes substituted for cisplatin); cisplatin or
carboplatin with gemcitabine; cisplatin and
_ etoposide (61,115)
Bladder cancer 5.9% gemcitabine in combination with cisplatin (600)
Colorectal cancer 6.9% 5-FU/leucovorin or capecitabine with eitherColorectal cancer 6.9%
oxaliplatin or irinotecan (368,595)
Cervical cancer 8.6% cisplatin and 5-FU (61)
Renal cancer 9.2% gemcitabine-containing combinations for
immunotherapy-resistant advanced cancers (574)
Melanoma 15.9% dacarbazine (DTIC), alone or in combination with
BCNU (1,3-bis(2- chloroethyl)-1 -nitrosourea) or
cisplatin, or in combination with cisplatin and
vinblastine; temozolomide (12)
Breast cancer 19.8% paclitaxel in combination with gemcitabine;
tamoxifen (for estrogen positive cancers); 5-FU,
anthracyclines (doxorubicin, epirubicin); or the
"Dartmouth regimen": DTIC, BCNU, cisplatin, and
tamoxifen (21,193,231,437)
Ovarian cancer 23.3% combination of a platinum (cisplatin or carboplatin)
and a taxane (paclitaxel or docetaxel) (10)
Endometrial 26.1% doxorubicin and cisplatin, topotecan (295)
cancer
Prostate cancer 29.8% one or more of the following: estramustine, cisplatin,
etoposide, mitoxantrone, vinblastine, placitaxel, and
docetaxel (11)
Testicular germ 70-80% cisplatin, bleomycin, and etoposide (58,187,452)
cell cancer
Table 1.1: *Survival rates for metastatic cancer taken from Masters and Koberle (452) and
survival rates listed here may be lower than rates reported elsewhere (10-12). Estimated
14
incidence and death rates in 2005 for the cancer types listed are available at Cancer Statistics,
2005 <http://CAonline.AmCancerSoc.org>.
1.2 DNA is the ultimate target of cisplatin
Cisplatin is administered to patients intravenously at doses ranging from 20-120
mg/m2 (58,422). While it is still unclear how the drug enters cells, once inside cells, cisplatin
undergoes aquation hydrolysis to form the active compound (Fig. 1.1). The aquated drug
reacts with many cellular targets including DNA, RNA, and protein; however it is the reaction
of cisplatin with DNA to form cisplatin-DNA adducts that is ultimately responsible for the
drug's toxic effects (775). The first line of support for DNA as the key cellular target was the
filamentous growth of E. coli induced by cisplatin; such filamentous growth was shown to be
induced by other DNA-damaging treatments such as hydroxyurea and UV- and ionizing
radiation (303,745). In addition, DNA was shown to contain more adducts per molecule
compared to RNA and protein (6,546). The most revealing studies, however, showed that
DNA repair status altered cellular sensitivity to cisplatin; DNA repair-deficient E. coli and
human cells were shown to be more sensitive compared to their repair-proficient
counterparts, suggesting that differential ability to repair cisplatin-DNA adducts leads to
differential sensitivity to the drug (33,173,175,176,636). Later studies correlating the level of
cisplatin-DNA adducts with clinical response also point to DNA adducts as the major lesions
eliciting toxicity (584,585).
Cisplatin reacts with the N7 atom of purines, with binding to guanine-N7
thermodynamically favored over adenine-N7 (167,586,587). In vitro (182,209) and in vivo
(112,521) studies to identify the major DNA adducts formed by cisplatin have shown that the
major adduct is the 1,2-intrastrand crosslink between two adjacent guanines (1,2-d(GpG)),
which comprises -65% of the total adduct spectrum. The intrastrand crosslink between an
adjacent guanine and adenine (1,2-d(ApG)) comprises -25% of the total adduct spectrum
while the remaining adducts consist of 1,3-intrastrand crosslinks between two non-adjacent
guanines (1,3-d(GpNpG)) and interstrand crosslinks (8-10%) as well as monofunctional
adducts to a single guanine (2-3%). The intrastrand crosslinks produce major structural
distortions to the DNA, including unwinding and bending of the helix resulting in
destabilization of the duplex. The major 1,2-d(GpG) and 1,2-d(ApG) intrastrand crosslinks
cause the helix to bend 40-60° toward the major groove and unwind the helix by -13 ° (161);
the 1,3-d(GpNpG) adduct induces bending by 35-50° and unwinding by 230, although
different techniques and studies yield different values for bending and unwinding (326,352).
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The different DNA-adduct spectrums produced by cisplatin and its therapeutically
inactive isomer trans-diamminedichloroplatinum(ll) (trans-DDP or transplatin, Fig. 1.2)
provide insight as to the types of adducts that are responsible for eliciting the former drug's
toxic effects. Transplatin reacts with the N7 of purines or the N3 of cytosines and forms
primarily intrastrand crosslinks between two guanines or a guanine and a cytosine
separated by a base (i.e., 1,3-d(GpNpG) or 1,3-d(GpNpC)) as well as interstrand crosslinks
between complementary guanine and cytosine residues, with interstrand crosslinks
comprising -20% of the transplatin total adduct spectrum (65,183,184). Although transplatin
adducts also generate structural alterations in DNA, this isomer induces alterations that
differ somewhat from the alterations produced by cisplatin adducts. For example, the 1,3
transplatin crosslink confers flexibility to the helix, serving as a hinge without directionality
(39), whereas the cisplatin intrastrand crosslinks bend the helix towards the major groove.
The different adducts and DNA structural alterations formed by the potent anticancer agent
cisplatin and its clinically ineffective isomer transplatin most likely result in differential
recognition and processing of the adducts by cellular proteins. Indeed, it has been shown
that transplatin-modified DNA is more efficiently repaired than DNA modified by cisplatin,
which may explain why the latter drug is highly cytotoxic (116,277,565,573). Moreover, the
different adducts formed by cisplatin are differentially repaired, with the major 1,2-d(GpG)
intrastrand crosslink undergoing excision repair synthesis at 15-20 fold less efficiency than
the 1,3-d(GpNpG) adduct (308,492,777).
1.3 Downstream events of cisplatin-DNA adduct formation
The major DNA structural distortions induced by cisplatin lead to important cellular
consequences. The distorted structure interferes with essential cellular processes such as
DNA replication and transcription. Furthermore, the DNA structural changes caused by
cisplatin attract certain nuclear proteins to the adduct site, triggering various events
including apoptosis. The following sections highlight the downstream cellular events
following cisplatin-DNA adduct formation.
1.3.1 Cellular proteins that recognize cisplatin-modified DNA: implications in
repair and repair shielding
Perhaps one of the most significant events following cisplatin-DNA adduct formation
is the binding of cellular proteins to the adducts. The first reports of such activity identified
proteins with unknown enzymatic activities that bound specifically to cisplatin adducts
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(113,172,689). Later it was discovered that proteins with high mobility group (HMG)
domains bind specifically to the major d(GpG) and d(ApG) intrastrand crosslinks but not to
the minor 1,3-intrastrand d(GpNpG) crosslink (79,563), and a recent study demonstrated the
association of native nuclear HMG-box proteins with the major 1,2-dGpG crosslink (784).
'The HMG domain is a common DNA-binding motif found in proteins belonging to the
HMG1/2 superfamily. Proteins of this family may contain multiple HMG domains and may
exhibit either structure or sequence specific binding. All HMG-box proteins, however, have
a high affinity for distorted DNA structures, including cruciform DNA, which may explain why
they recognize and bind to cisplatin-DNA adducts. Table 1.2 lists several HMG domain
proteins and their affinity for cisplatin-modified DNA.
Table 1.2 The binding affinity of HMG-box proteins for cisplatin-modified DNA
HMG box protein Cisplatin substrate* Binding affinity, Kd Reference(s)
Structure-specific single 1,2-d(GpG) ND (79,763)
recognition protein 1
(SSRP1), human
non-histone, chromatin Globally modified DNA -0.3 nM (48,310,698)
associated calf HMG1
non-histone, chromatin Globally modified DNA -0.2 nM (48,310)
associated calf HMG2
rat HMG1 single 1,2-d(GpG) 370 nM (563)
human UBF single 1,2-d(GpG) 60 pM 690
mtTFA single 1,2-d(GpG) 100 nM (110)
yeast transcription factor single 1,2-d(GpG) 250 nM (77,461)
Ixrl
mouse testis specific single 1,2-d(GpG) 24 nM (528)
HMG
sex determining factor single 1,2-d(GpG) 120 nM (691)
SRY
Table 1.2: *Sequence context influences the structural alterations induced by cisplatin and
may thereby affect the binding affinity of HMG proteins (122,180,564). ND, not determined
The important cellular consequences of HMG-box protein recognition of cisplatin-
DNA adducts were first demonstrated in vivo in S. cerevisiae; a yeast strain with a deletion
for the protein Ixr1 (intrastrand crosslink recognition protein 1), which is a member of the
HMG-box protein family, was 2-6 fold less sensitive to cisplatin and accumulated one-third
as many platinum-DNA lesions as the parental strain expressing Ixrl (77). Furthermore, this
protein bound specifically to DNA modified with cisplatin but not to DNA containing
crosslinks formed by the geometric isomer transplatin, and yeast lacking Ixrl did not show
differential sensitivity to transplatin. Additional experiments demonstrated that the
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differential effect of Ixrl on cisplatin sensitivity was significantly decreased in a series of
yeast strains deficient in nucleotide excision repair (NER), establishing direct links between
protein recognition of the adducts, sensitivity, and DNA repair. It was also later shown that
two HMG-box proteins, HMGB1 (HMG-box 1 protein, formerly called HMG1) and the human
mitochondrial transcription factor (h-mtTFA), could specifically inhibit the excision repair of
the 1,2-d(GpG) crosslink by cell extracts (308). This finding led to the hypothesis that HMG-
containing proteins mediate toxicity to cisplatin by blocking the repair of cisplatin-DNA
adducts. Since these initial studies, evidence has been presented both in vitro and in vivo in
support of the view that HMG box proteins sensitize cells to cisplatin by shielding cisplatin-
DNA adducts from repair (77,409,460,461,547,548,691,776,777).
In addition to HMG-box proteins, many other cellular proteins have been shown to
bind cisplatin-modified DNA. Not unexpectedly, many of these proteins are involved DNA
damage recognition and play important roles in DNA damage repair pathways. For
example, the protein RPA (replication protein A) exhibits a binding preference for cisplatin-
damaged DNA over undamaged DNA (548,549,625). RPA is a multiple subunit single-
stranded DNA-binding protein that is required for various processes in cellular DNA
metabolism including replication, NER, and homologous recombination. RPA also interacts
with many proteins including other repair proteins (e.g., XPA, XPG, Rad 51, and Rad52)
(138,284,495,673,674) as well as proteins involved in DNA damage signaling and cell cycle
control (e.g., p53 (478)). Of relevance to cisplatin-induced toxicity, the relative binding
affinities of RPA to the different cisplatin adducts correlate with the efficiency of repair of the
adducts; while RPA shows higher binding affinity for the 1,3-d(GpNpG) adduct than for the
1,2-d(GpG) adduct (549), it is the 1,3-intrastrand crosslink that is more efficiently repaired in
excision repair assays (308,777). Other NER proteins that show binding affinity for
cisplatin-DNA adducts include proteins of the Xeroderma pigmentosum (XP)
complementation groups A and E. The proteins of the XP complementation groups, of
which there are eight (A through G, and XP-Variant) were initially identified from the cells of
XP patients who suffer a hypersensitivity to sunlight and from manifestations such as UV-
induced skin lesions and multiple skin cancers (120,405,627). The XPA protein is involved
in DNA damage recognition and like RPA was shown to exhibit higher binding affinity for
cisplatin-damaged DNA than for undamaged DNA (18,341,393). The recognition of cisplatin
damage by XPA may play an important role in clinical responses to cisplatin, as sensitive
testicular tumor cell lines express low levels of XPA and show a reduced capacity to repair
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cisplatin damage (381,739) and XPA-deficient fibroblasts are hypersensitive to cisplatin
treatment (168). Another XP protein thought to be involved in damage recognition, XPE,
also recognizes cisplatin-modified DNA (113); the purified protein binds cisplatin adducts but
shows no affinity for transplatin adducts (551). The importance of cisplatin damage
recognition by NER proteins is underscored by studies correlating NER gene expression
and repair capacity with response to cisplatin, with reduced NER capacity leading to
hypersensitivity to cisplatin treatment (168,380,381,403,569,739,789) while increased NER
confers increased tolerance to the drug (114,146,147,208,663,767).
The damage recognition proteins of DNA repair pathways other than NER also show
affinity for cisplatin-damaged DNA. It has recently been shown that the human glycosylase
AAG, which is involved in the first step of base excision repair, binds cisplatin-modified DNA
in vitro (353). Currently known AAG substrates include alkylated bases such as 3-
methyladenine, 3-methylguanine, 7-methylguanine, 1,N6 -ethenoadenine, N2,3-
ethenoguanine as well as the deamination product hypoxanthine and oxidized guanine (7,8-
dihydro-8-oxoguanine, or 8-oxoG) (754). Although AAG binding to cisplatin does not lead to
excision of the adduct, cisplatin adducts may serve as molecular decoys, luring the enzyme
away from its natural damaged-base substrates and thereby reducing the repair of other
types of DNA damage (353). Another DNA glycosylase, the E. coil MutY and its human
homologue hMYH, also bind cisplatin-modified substrates in vitro (Kartalou et al.,
unpublished results). MutY is a glycosylase that excises adenine opposite oxidized guanine
(8-oxoG). Thus MutY serves as a mismatch protein and helps protect the genome against
mutations arising from the error-prone bypass of oxidized bases. MutY also shows activity
on adenine mispair substrates such as A:G and A:C, albeit with much lower activity
(261,654). In addition to binding to cisplatin-DNA adducts in vitro, both bacterial MutY and
hMYH retain their ability to excise adenine in the mismatch substrate G:A when the guanine
is part of a cisplatin intrastrand crosslink (Kartalou et al., unpublished results). Importantly,
cisplatin induces SOS-dependent G to T transversions at the platinated guanine in E. coil,
suggesting that platinated guanine mispairs with adenine in vivo (66,761,762). While both
bacterial MutY and hMYH demonstrate excision of adenine opposite guanine when the
guanine is platinated in the aforementioned study, the results of Fourrier et al. (223) show
that MutY does not display enzymatic activity on adenine opposite platinated guanine,
although this data was obtained under different experimental conditions. In addition to DNA
glycosylases, damage recognition proteins of the DNA mismatch repair system also
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specifically recognize cisplatin-modified DNA. The E. coli mismatch recognition protein
MutS (91,778) and its human homologue MutSa (179,473,756) both bind the major cisplatin
'1,2-d(GpG) adduct with affinities comparable to the binding affinities for a G:T mispair. The
binding constant of purified hMSH2 is estimated to be 67 nM (Kd(app)) for a 162-bp probe
modified with -6 cisplatin adducts (473). While damage recognition by repair proteins is
expected to help protect the cells against the damage, paradoxically mismatch repair
proteins sensitize cells to cisplatin damage. The role of mismatch repair in mediating
cisplatin-induced toxicity will be discussed in detail in Sections 1.3.4 and 1.4.4 and in the
following chapters.
In addition to the aforementioned repair proteins, still other proteins have
demonstrated binding affinity for cisplatin-DNA adducts. These proteins include DNA
binding proteins such has Histone H1 (758), TATA binding protein (TBP) (121), and Y-box-
binding protein (YB-1) as well as proteins involved in DNA repair and metabolism, which
include photolyase, T4 endonuclease VII, and the human Ku autoantigen. The cellular
consequences of these protein interactions with cisplatin-modified DNA are reviewed
elsewhere (references (326) and (352)). Recently, it was shown that poly(adenosine
diphosphate-ribose)polymerase-1 (PARP-1) also binds cisplatin-modified DNA in cells (784),
and this finding is consistent with more recent data showing that PARP-1 recognizes
distortions in the DNA helical backbone and binds to three- and four-way junctions, hairpins,
cruciforms, and stably unpaired duplex regions, all of which induce PARP-1 enzymatic
activity (426). PARP-1 catalyzes the successive addition of ADP-ribose to acceptor proteins
to form branched polymers (144), and PARP interactions with effectors in DNA repair,
recombination, replication, and transcription support a role for poly(ADP-ribosyl)ation in DNA
metabolism (414). Cisplatin was shown to increase poly(ADP-ribosyl)ation in treated cells
(88,784) and pre-treatment with a PARP-1 inhibitor increases sensitivity to cisplatin in non-
small cell lung carcinoma xenografts and cell lines (477). While the latter result suggests
that PARP-1 may play a protective role following cisplatin damage, perhaps by facilitating
repair of adducts, more work is necessary to determine the role of PARP-1 binding in
mediating sensitivity to cisplatin.
1.3.2 Inhibition of replication
Early studies demonstrated that cisplatin-DNA adducts can block DNA polymerases
in vitro (266,333). Later studies using SV40 DNA and either HeLa or 293 human cell
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extracts or SV40 DNA in monkey CV-1 cells also showed that cisplatin inhibited DNA
replication (116,277). Another study showed that both HIV-1 reverse transcriptase (RT) and
T7 DNA polymerase strongly paused at one nucleotide preceding the first platinated
guanine and at the positions opposite the two platinated guanines of the 1,2-d(GpG)
intrastrand crosslink (676). Furthermore, a different study using site-specific adducts in
M13 genomes tested the ability of the different cisplatin-adducts to block various
polymerases including E. coli DNA polymerase I (Klenow fragment), bacteriophage T7 DNA
polymerase, bacteriophage T4 DNA polymerase, Taq polymerase, and the major replicative
E. coli DNA polymerase III holoenzyme (123). This study showed that bypass of the
cisplatin adducts occurred approximately 10% of the time and that the major 1,2-d(GpG)
intrastrand crosslink is the most inhibitory adduct. In addition, polymerases with low 3' to 5'
exonuclease activity were shown to possess greater bypass ability than those polymerases
with high 3' to 5' exonuclease activity, suggesting that bypass of cisplatin adducts may lead
to mutagenesis (see Section 1.3.5).
Ciccarelli et al. showed that both cisplatin and the trans isomer are equally effective
at inhibiting replication when equimolar amounts are bound to SV40 DNA (116). While
transplatin is less effective in inducing cell death, other factors must contribute to cisplatin-
induced toxicity. One possibility is that cisplatin adducts are retained longer than the
transplatin adducts and can therefore persist to block replication, and the less efficient repair
of cisplatin versus transplatin adducts (116,277,565,573) is consistent with this possibility.
Alternatively, other mechanisms, perhaps in conjunction with replication inhibition, may be
important in mediating cisplatin-induced toxicity. The observation that cells deficient in DNA
repair die at cisplatin concentrations that do not inhibit DNA replication (659) and the ability
of error-prone polymerases to bypass a cisplatin-damaged template (288,455,704,707)
provide support for other mechanisms playing a role in cisplatin-induced toxicity.
1.3.3 Inhibition of transcription
Direct inhibition of RNA polymerase progression
In addition to blocking DNA polymerases, cisplatin-DNA adducts have been shown to
inhibit transcription by blocking RNA polymerase progression. The first clues for a role of
transcription inhibition in cisplatin toxicity came from early studies by Sorenson and Eastman
(658-660). Using repair-proficient and -deficient Chinese hamster ovary (CHO) cells, they
showed that replication inhibition by cisplatin did not correlate directly with sensitivity to
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cisplatin; rather, CHO cells treated with cisplatin continued through S phase (i.e., DNA
synthesis continued) to arrest in G2, and the duration of G2 arrest did directly correlate with
toxicity (659). Furthermore, repair-deficient CHO cells required lower cisplatin
concentrations to arrest in G2 than the repair-proficient cells, indicating that the persistence
of cisplatin adducts may interfere with the transcription of genes essential for entry into
mitosis. Later studies by Corda et al. (127,128) showed that the major cisplatin adducts
could block progression of both wheat germ RNA polymerase II and the E. coli RNA
polymerase in vitro. Moreover, the cisplatin adducts were better inhibitors of RNA
polymerase than the transplatin adduct tested, trans-d(GpTpG) intrastrand crosslink (129).
Other studies in human and hamster cell lines also confirm that cisplatin adducts are more
effective blockers of transcription than the transplatin adducts. By transfecting a plasmid
containing a -galactosidase expression vector into NER-proficient and -deficient cell lines,
Mello et al. demonstrated that the cisplatin-damaged plasmid inhibited expression of 3-gal
with greater efficiency than did the trans-DDP-modified plasmid, and this differential
inhibition (2-3 fold) was not due to differential repair of the adducts (474). One important
result of blocking RNA polymerase progression during transcription is the ubiquitination and
degradation of the enzyme; recent studies have shown that cisplatin as well as UV damage
induce the ubiquitination and degradation of the RNA polymerase II large subunit (Pol II LS)
(71,404,581).
Inhibition via transcription factor hijacking
The studies described above indicate that the presence of cisplatin-DNA adducts can
serve as an effective block to RNA polymerase progression and can therefore directly inhibit
gene expression. However cisplatin-DNA adducts can also inhibit gene expression
indirectly by attracting transcription factors that bind to the adduct site; transcription factor
binding to cisplatin adducts diverts these factors away from their normal DNA binding sites,
and in such a way cisplatin adducts can act as molecular decoys for essential transcriptional
activators, thereby "hijacking" these activators and inhibiting gene expression. Several lines
of evidence support transcription factor hijacking of as a potential mechanism in cisplatin
toxicity. First, studies have identified the nucleolar transcription factor human upstream
binding factor (hUBF) as the protein most strongly attracted to therapeutic platinum-DNA
adducts (690,782). This protein, which shows sequence homology to high mobility group
box 1 protein (HMGB1) (327), is a critical positive regulator of ribosomal RNA (rRNA)
synthesis, and rRNA is essential in protein synthesis for proliferating cells. hUBF binds to a
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cisplatin adduct (Kd(app) = 60 pM) and to its cognate rRNA promoter sequence (Kd(app) = 18
pM) with comparable affinities (690), leading to the proposal that cisplatin adducts may act
as molecular decoys for the transcription factor in vivo. Importantly, the level of cisplatin
adducts required to effectively compete with ribosomal promoters for hUBF binding in vitro is
well below the levels of adducts found in patients treated with the drug (- 5 X 104 lesions per
cell (584)). The hijacking of hUBF was tested in a reconstituted system in which the effect of
cisplatin on rRNA gene transcription was determined. Zhai et al. (782) showed that while
hUBF could stimulate transcription of an rDNA minigene, an increase in cisplatin
adduct/promoter ratio decreased hUBF-activated transcription whereas transplatin adducts
had virtually no effect on rRNA transcription level. Taken together the data show that
cisplatin adducts specifically inhibit hUBF function by preventing the activator from binding
to its normal site on DNA. Other lines of evidence in support of transcription factor hijacking
include studies by Jordan and Carmo-Fonseca showing that cisplatin treatment of HeLa
cells causes a redistribution of hUBF within the nucleolus, which would be consistent with a
hijacking event in vivo (345); such a redistribution was not observed following treatment with
transplatin. In addition, Vichi et al. showed that the TATA box binding protein TBP/TFIID
binds selectively to cisplatin or UV-damaged DNA (713), which extends the hijacking model
to transcriptional activators other than hUBF. Lastly, Cullinane et al., using human cell
extracts, showed that transcription from an undamaged adenovirus major late promoter
fragment was reduced in the presence of increasing amounts of cisplatin damage on an
exogenous plasmid, suggesting that cisplatin damage may be trapping an essential factor
for transcription initiation (141).
Other consequences of hijacking
As discussed previously, HMG-box protein binding to cisplatin lesions can serve as
shields to DNA repair, and as discussed above the affinity for HMG-box proteins for cisplatin
adducts may lead to transcription factor hijacking. It is of interest to note that in addition to
transcription factor hijacking, HMG-box protein binding to cisplatin adducts may hijack
proteins involved in cellular processes other than transcription. For example HMGB1, which
exhibits affinity for cisplatin adducts (23,79,355), has recently been shown to act as a
cytokine and to possess proinflammatory activity (reviewed in Lotz and Tracey (427));
moreover, a recent report shows that HMGB1 can induce sprouting of endothelial cells in
vitro (623). HMGB1 can therefore act as an angiogenetic factor in addition to its role as a
nuclear transcription factor. Consequently, by the hijacking hypothesis, the binding of
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HMGB1 to cisplatin adducts may also eliminate a pro-growth extracellular signal. As will be
discussed below, HMG-box protein binding to cisplatin adducts may also interfere with DNA
damage response pathways.
1.3.4 Induction of cell cycle arrest and cell death pathways
The formation of cisplatin-DNA adducts and their recognition by cellular proteins
ultimately leads to apoptosis and the induction of cell death pathways. Many proteins that
bind cisplatin-modified DNA interact with other proteins at sites of DNA damage to form
multi-protein complexes that initiate DNA repair, cell cycle arrest, and/or cell death. As
mentioned above, the protein RPA binds cisplatin-modified DNA. While this protein is
important in NER, RPA is also a phosphorylation target for DNA-dependent protein kinase
(DNA-PK) and the ataxia telangiectasia-mutated gene (ATM) protein kinase, and recent
observations suggest that RPA phosphorylation status plays a significant modulatory role in
the cellular response to DNA damage (reviewed in Binz (49)).
p53 in response to cisplatin damage
RPA interacts with many proteins involved in the DNA damage signaling response
network, including p53 (478) The tumor suppressor p53 can activate the transcription of
numerous target genes that are involved in the activation of G1 and G2/M cell cycle
checkpoint arrest and in the initiation of apoptosis (reviewed in (562,647,719)). One target
of p53 transactivation is the cyclin-dependent kinase inhibitor p2 1WAF/CIP1/SD11 (p21), which
plays a crucial role in DNA repair, cell differentiation, and apoptosis through regulation of the
cell cycle, with p21 promoting cell cycle arrest over p53-mediated apoptosis (236).
Expression of p53 and p21 was stimulated within 5 to 10 minutes by cisplatin in p53-positive
LX-1 small cell lung carcinoma cells (752). Induction of p21 following p53 stabilization in
response to cisplatin was also demonstrated in the cisplatin sensitive ovarian carcinoma cell
line A2780, and one study showed that the upstream mediators of this response include
phosphatidylinositol 3-kinase (PI3-kinase or P13K, a protein that transmits signals from
receptors that promote cell survival (687)) and its downstream targets serine/threonine
kinases AKT1 and AKT2 (v-akt murine thymoma viral oncogene homologue), which were
required for full induction of p21 following cisplatin treatment (483). However, while
suppression of PI3K/AKT signaling inhibited p21 expression, it did not result in alterations in
drug sensitivity of A2780 cells or in the expression of the proapoptotic protein BAX following
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cisplatin treatment, suggesting that cell death induced by cisplatin may proceed
independently of the cell protective effects of P13K and AKT (483).
In addition to cell cycle-arrest and apoptosis, p53 also plays an important role in NER
through the transcriptional regulation of genes involved in the recognition of adducts in
genomic DNA. Loss of p53 function results in deficient global genomic repair (a subset of
NER that removes lesions from the whole genome) but not of transcription-coupled repair (a
subset of NER that removes lesions in the transcribed regions of the genome) of
cyclobutane dimers (220,221,265). NER proteins whose expression is regulated by p53-
stimulated transcription include p48 (314), the protein product of the DDB2 (damage-specific
DNA binding protein) gene defective in XP group E (XPE) cells, XPC, and GADD45 (growth
arrest and DNA damage 45), a DNA damage inducible protein that may facilitate chromatin
unwinding in regions of damaged DNA. In addition, the direct binding of p53 to the NER
TFIIH factors XPB and XPD inhibits their helicase activities and these interactions may be
involved in p53-mediated apoptosis and DNA repair pathways (407,733,734). p53 also
interacts with Rad51 in vitro and may play additional roles in other DNA repair mechanisms
such as recombination repair (81).
The human breast cancer associated protein BRCA1 plays a modulatory role in the
p53 pathway and may play a role in the response to cisplatin. BRCA1 is a substrate of the
ATM kinase and is found associated with multiple other proteins following DNA insult at
nuclear foci, the supposed sites of DNA damage. Like p53, BRCA1 facilitates the repair of
DNA damage and specifically enhances global genomic repair, though one study showed
that BRCAl-stimulated repair is independent of p53 (269). BRCA1 co-localizes with Rad51
in S-phase cells and increased levels of BRCA1 are found in a drug-resistant ovarian cancer
subline (312). Increased BRCA1 is associated with more proficient DNA repair and cisplatin
resistance, and accordingly inhibition of BRCA1 results in decreased DNA repair, increased
sensitivity to cisplatin and enhanced apoptosis (312). BRCA1 and p53 may cooperate to
transactivate DNA repair genes as well as p21 and GADD45.
Other proteins in the p53 response pathway have been shown to be involved in
cisplatin-induced signaling and apoptosis. Among these proteins is aurora kinase A, which
acts upstream of p53 and phosphorylates p53 at Ser315 leading to its ubiquitylation by
murine double minute 2 (MDM2) and subsequent proteolytic degradation (361) (see Section
1.4.4 on p53 in cisplatin resistance). Katayama et al. (361) recently showed that inhibition of
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aurora kinase A by siRNA leads to decreased phosphorylation of p53 at Ser315 and
consequently increased steady-state levels of p53; the effects on p53 stability were
accompanied by increased cell-cycle arrest at the G2-M transition as well as increased
sensitivity to cisplatin. Conversely, cells stably transfected with aurora kinase A were
resistant to cisplatin-induced apoptosis and showed substantially less induction of p53. The
apoptotic response regulated by aurora kinase A is mediated by p53, as aurora kinase A
expression had no effect on the stability of the p53-related proteins p63 and p73 in
untreated and cisplatin-treated cells.
While p53 may play an important role in cisplatin-induced apoptosis, defects in the
p53 pathway, either upstream or downstream of p53, may affect sensitivity to cisplatin. For
example, a checkpoint kinase upstream of p53 required for p53 transcriptional activation,
Chk2, exhibits reduced expression in a majority of invasive germ cell tumors (28). Thus
reduced Chk2 activity may result in reduced expression of p53 target genes, including DNA
repair genes, thereby making TGCTs more susceptible to DNA damage by cisplatin.
Similarly, decreased levels of p21, which promotes survival over p53-induced apoptosis
(571,786)), may make TGCTs more susceptible to cisplatin damage, as p21 was rarely
detectable in the seminoma and embryonal carcinoma components of the combined germ
cell tumors (29).
The AKT pathway
AKT kinase, a substrate of P13-kinase, acts upstream of p53 and promotes cell
survival by down-regulating apoptotic pathways. Interestingly, activation of P13-kinase and
its downstream target, the AKT/PKB serine-threonine kinase, results in phosphorylation of
MDM2, an antagonist of p53 that is also induced by p53 (270); phosphorylation of MDM2 by
AKT is necessary for translocation of MDM2 from the cytoplasm into the nucleus (459),
where the protein can regulate p53. AKT was shown to protect cells from apoptotic death
induced by cisplatin (107,148). Dominant-negative AKT sensitizes ovarian cancer cells to
cisplatin, but this effect requires functional p53 (225). AKT exerts its pro-survival effects by
phosphorylating several mediators of apoptosis, including the X-linked inhibitor of apoptosis
(XIAP). Phosphorylation of XIAP by AKT stabilizes XIAP and prevents both auto-
ubiquitylation and cisplatin-induced ubiquitylation activities (148). Increased levels of XIAP
are associated with decreased cisplatin-induced caspase 3 activity and apoptosis in ovarian
cancer cell lines (19,225). AKT also promotes cell survival by inactivating (via
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phosphorylation) other apoptotic pathway proteins including Bad, Forkhead proteins, and
GSK-3P (154). AKT also phosphorylates IKB kinase, which subsequently activates nuclear
transcription factor-KB (NF-KB). NF-KB promotes cell survival by stimulating the expression
of genes suppressing apoptosis and promoting cell growth (e.g., cyclin D1 and c-Myc) (572)
and inhibition of NF-KB is associated with increased sensitivity to cisplatin in both in vitro
and in vivo ovarian cancer models (431). Pommier et al. (572) provide a detailed review of
AKT and NF-KB regulation and their roles in apoptotic pathways. In addition, AKT acts
upstream of MAPK pathways as discussed below. While the P13-kinase/AKT cascade
triggers pro-survival events, inhibition of this signaling cascade may sensitize ovarian cancer
cells to cisplatin (591).
Mismatch repair in cisplatin-induced apoptosis
Cisplatin resistance has been associated with MMR status, where cells deficient in
MMR exhibit a higher tolerance to drug treatment compared to their MMR-proficient
counterparts (3,4,177,213,216,751). The level of cisplatin resistance afforded by MMR
deficiency, though relatively small (up to 2-fold) in in vitro systems, is sufficient to produce a
large difference in drug responsiveness in vivo in tumor model systems (13,212). The
available preclinical and clinical data also suggest that tumors with a significant fraction of
MMR-deficient cells will exhibit reduced responsiveness to specific drugs including cisplatin
(4,112,212,441). In addition to its association to cisplatin resistance, MMR status has also
been implicated in the etiology of hereditary nonpolyposis colon cancer (HNPCC); a high
proportion of HNPCC patients carry mutations in the MMR genes hMSH2 and hMLH1 (82).
The influence of MMR deficiency on drug resistance as well as its pathogenetic role in
HNPCC may both arise from a role of MMR in triggering apoptosis'. Several studies have
shown that MMR status correlates with the ability of cells to undergo apoptosis, with MMR-
deficient cells failing to undergo apoptosis following exposure to certain DNA-damaging
agents (177,251,311,685). Furthermore, in testicular tissues, where cisplatin-based
treatment is most effective, mismatch repair proteins are expressed in high levels (473).
Alterations in MMR function may therefore have profound consequences in clinical
* Lin et al. recently demonstrated that an Msh2G 6 7 4 A mutation in mice caused DNA repair
deficiency that resulted in a strong cancer predisposition while it did not affect the DNA damage
response function of Msh2. Although MEFs with this point mutation remained sensitive to cisplatin
compared to Msh2 null MEFs (413), suggesting that mismatch repair function in mutation avoidance
rather than DNA damage signaling is involved in tumorigenesis, the growth advantage of the point
mutants due to a deficient apoptotic response may have also contributed to tumorigenesis.
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resistance to chemotherapeutic agents, and the signaling properties of MMR are discussed
in detail elsewhere (38,666).
The mismatch repair proteins MSH2 and MLH1 bind to cisplatin damage
(179,213,473) and have also been implicated in the DNA damage response regulatory
network. While MMR plays a critical role in mutation avoidance, the mismatch repair
proteins MSH2, MSH6, and MLH1 were shown to interact with other DNA damage response
proteins, including BRCA1, ATM (a member of the P13K family), BLM, and the RAD50-
MRE11-NBS1 protein complex, to form the complex BASC (BRCAl-associated genome
surveillance complex) (736). Potential roles for MMR in DNA damage-induced signaling
have been shown by studies demonstrating that p53 phosphorylation on serine residues 15
and 392 following DNA methylation damage is dependent on functional hMutSa and hMutLa
(178) and that induction of p53 and apoptosis by MNNG each require functional MutSa in
human cells (285). In addition, Brown et al. demonstrated that human tumor cell lines
deficient in MSH2 or MLH1 are defective in S-phase checkpoint activation following ionizing
radiation (IR)., which resulted from deficient ATM phosphorylation of CHK2 (on threonine 68)
and subsequent deficiency in CDC25A phosphorylation and degradation; furthermore,
MLH1 and MSH2 may directly associate with ATM and CHK2 kinases, respectively,
establishing a molecular scaffold for the two kinases that allows ATM to phosphorylate and
activate CHK2 in response to IR (76) (Fig. 1.3).
MMR is also implicated in the DNA damage signaling response following cisplatin
treatment, and several molecular determinants of MMR-provoked apoptosis in response to
cisplatin have been identified. Cisplatin treatment was shown to activate the JNK1 kinase
more efficiently in MMR- proficient cells than in -deficient (hMLH1-) cells (512,513), and
MMR has been shown to be required for the activation of the nuclear non-receptor tyrosine
kinase c-Abl in response to cisplatin treatment (251,512,513). Recently it was shown that c-
Abl, following MLH 1-dependent activation in cisplatin-treated cells, stabilizes the p53-related
protein p73; Gong et al. demonstrated the requirement for MLH1 in the activation of c-Abl,
which in turn was required for the induction of p73 (251). While this study demonstrated the
requirement for MLH1 in activating an apoptotic response involving c-Abl- p73, the authors
showed that MLH1 did not affect the accumulation of p53 in response to cisplatin, although
both p53 and p73 pathways contributed to cisplatin toxicity (251). Furthermore, interaction
of the mismatch repair protein PMS2 with p73 is enhanced following cisplatin treatment, and
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stimulation of p73 apoptotic functions following cisplatin damage requires PMS2 (637). It
has also been shown that overexpression of hMSH2 or hMLH1, but not of any of the other
MMR proteins, can induce apoptosis in repair proficient and deficient human cell lines
(553,785), thus implicating a direct role of these repair proteins in triggering programmed
cell death. c-Abl activation in response to another form of DNA damage, ionizing radiation,
is dependent on the activation of ATM and ATM phosphorylation of c-Abl (30,628), and
although MMR proteins were shown to interact in protein complexes including ATM (736),
neither MSH2 nor MLH1 were required for c-Abl activation in response to IR (76). In
contrast, MMR is required for c-Abl activation following cisplatin treatment (512,513). While
the latter result suggests c-Abl acts downstream in cisplatin-induced signaling, it is also
worth noting that the c-Abl DNA-binding domain shows sequence similarity to HMG-box
proteins (632,714) and like HMG-box proteins, it recognizes non-canonical DNA structures
such as four-way junctions and single-strand loops (714). Therefore c-Abl may recognize
cisplatin-modified DNA and may be involved signaling directly, although such binding activity
of c-Abl to cisplatin-DNA adducts has not been reported. It is also worth noting that in testis,
the tumors of which are extremely sensitive to cisplatin treatment, c-Abl phosphorylation of
p73 increases following IR damage (264).
MMR deficiency affords low-level resistance to cisplatin treatment
(177,213,216,251,512). Indeed, the effect of acquired resistance due to loss of MMR is
more pronounced towards alkylating damage than towards cisplatin damage (up to 100-fold
versus -2-fold difference) (4,311,685). Therefore other mediators of cell death in addition to
MMR must be contributing to cisplatin-induced toxicity. Gong et al. (251) showed that both
p53 and p73 pathways contribute to cisplatin toxicity. While MutSoa may mediate alkylation-
induced toxicity in part by a p53-dependent pathway (178,285,685,751), such p53
dependence for MMR-mediated toxicity has not been observed for cisplatin damage.
Branch et al. demonstrated in ovarian carcinoma cells that the effects of MMR and p53 on
cisplatin cytotoxicity are independent and additive, with p53 status being the major
determinant of toxicity (68). In addition, one study has shown that MMR does not mediate
cisplatin-induced toxicity in MEFs (119), and MMR did not play a significant role in the
acquired drug resistance of A2780 cells (449). Therefore other "sensors" of cisplatin
damage, or secondary lesions resulting from ineffective repair of platinated DNA, may
trigger programmed cell death following drug treatment. Based on the results of several
studies, the role of p53 in apoptosis and toxicity in response to DNA damaging agents varies
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greatly depending on the cell type studied ((285,774) and references therein). Zamble et al.
demonstrated p53-dependent apoptosis in mouse testicular teratocarcinoma cell lines
exposed to cisplatin, although p53 deficiency did not confer resistance to cisplatin treatment
as measured by colony formation assays (774). From the evidence available, it is clear that
cisplatin treatment induces a complex apoptotic response involving the activation of parallel
death response pathways, a MMR-dependent pathway activating p73 and a MMR-
independent pathway (via p53). A diagram of the signaling events following DNA damage is
shown in Fig. 1.4.
MAPK signaling cascades
As mentioned above, cisplatin induces activation of c-Abl tyrosine kinase, which in
turn stabilizes p73 and enhances cisplatin-induced apoptosis. C-Abl is also required for the
cisplatin-induced activation of both p38 mitogen-activated protein (MAP) kinase (539) and
stress-activated c-Jun N-terminal protein kinase (275,373). These kinases are members of
the mitogen-activated protein kinase (MAPK) signaling cascades, of which there are three
major groups-extracellular signal-regulated kinases (ERKs), c-Jun N-terminal
kinases/stress-activated protein kinases (JNKs/SAPKs), and p38-, that regulate cell
growth, differentiation, survival, and cell death. C-Abl mediates activation of JNK/SAPK in
response to cisplatin damage through its phosphorylation of MEK kinase 1 (MEKK-1), an
upstream effector of the SEK1 to JNK/SAPK pathway (372). Cisplatin, but not transplatin,
was shown to activate JNK and ERK cascades in both the cisplatin-resistant Caov-3 and the
cisplatin-sensitive A2780 human ovarian cancer cell lines (275), and cisplatin provoked the
activation of SAPK/JNK and p38 kinase dose-dependently in HeLa cells, with significantly
lower activation in resistant subclones than in the sensitive parental line (78). Furthermore,
one study showed that the differential duration of the activation of MAPK pathways,
specifically of JNK and p38, in sensitive and resistant ovarian cancer cells correlated with
cisplatin-induced apoptosis, thus demonstrating the important role of the MAPK signaling
cascades in cisplatin-induced toxicity (438). Activation of JNK and p38 was associated with
the phosphorylation and subsequent activation of c-Jun and induction of an immediate
downstream target of c-Jun transcriptional activation and an inducer of apoptosis, the Fas
ligand (FasL, Fig. 1.5), as well as with caspase activity and apoptosis. FasL induction was a
critical event for cisplatin-induced apoptosis as pre-treatment with a neutralizing anti-FasL
antibody inhibited cisplatin-induced apoptosis and resistance to cisplatin correlated with a
failure to up-regulate FasL (438). FasL is also regulated by the Forkhead family
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transcription factor FKHRL1 in response to cisplatin damage (591). While FKHRL1 induces
apoptosis in its unphosphorylated state, cisplatin-induced phosphorylation of FKHRL1 was
observed in cisplatin-resistant ovarian cancer cells but not in cisplatin-sensitive cells, and
the unphosphorylated form of FKHRL1 was shown to bind the FasL promoter and induce
apoptosis. Phosphorylation of FKHRL1 following cisplatin treatment in resistant cells was
achieved by AKT kinase, a substrate of P13-kinase that acts upstream of p53 in promoting
survival as described above. The data summarized here thus support an important role of
the JNK > c-Jun > FasL > Fas pathway in mediating cisplatin-induced apoptosis.
As mentioned above, in addition to the JNK/SAPK cascade, activation of p38 has
been implicated in mediating cisplatin toxicity. P38 activation by cisplatin was shown in
Rat1 cells in which expression of c-Myc was deregulated, and c-Myc potentiation of
cisplatin-induced p38 activation was associated with Bax activation and the mitochondrial
pathway of apoptosis (162,163). Cisplatin also induced c-Myc-dependent activation of
mitogen-activated protein kinase kinase (MKK) 3/6 and apoptosis signal-regulating kinase 1
(Ask1), and inhibition of Ask1 blocked cisplatin-induced p38 activation and downstream
apoptotic features (162). Another study showed that p38 activity is a major determinant of
cisplatin-induced apoptosis in NIH3T3 cells (332), and using specific kinase inhibitors
another group showed that cisplatin induced apoptosis through the p38 but not the ERK
MAPK pathway (752). The role of p38 in cisplatin sensitivity was shown to be modulated by
the AKT2 kinase in ovarian cancer cells; constitutively active AKT2 conferred cisplatin
resistance to the cisplatin-sensitive A2780S ovarian cancer cells, whereas P13K inhibitor or
dominant negative AKT2 sensitized A2780S and cisplatin-resistant A2780CP cells to
cisplatin-induced apoptosis through regulation of the ASK1/JNK/p38 pathway (771). AKT2
phosphorylates ASK1 at Ser-83 resulting in inhibition of its kinase activity, and accordingly
activated AKT2 blocks signaling downstream of ASK1, including activation of JNK and p38
and the conversion of Bax to its active conformation. Thus AKT2 inhibits cisplatin-induced
JNK/p38 and Bax activation through phosphorylation of ASK1 and may play an important
role in chemoresistance (771). Furthermore, cisplatin-induced Bax conformation change
was inhibited by dominant negative forms of JNK and p38, supporting the important role of
these kinases in cisplatin-induced apoptosis.
Although the aforementioned studies suggest that p38 and JNK kinases play critical
roles in cisplatin-induced signaling pathways and apoptosis, other studies show that the
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third MAPK pathway, extracellular signal-regulated kinases (ERKs), also plays an important
role in mediating apoptosis in response to cisplatin treatment. Wang et al. (732)
demonstrated that cisplatin induced dose- and time-dependent activation of ERK and that
this activation was necessary for cisplatin-induced cell death in HeLa cells. Cisplatin-
induced apoptosis was associated with cytochrome c release and subsequent caspase-3
activation in HeLa cells, both of which could be prevented by treatment with MEK inhibitors
(MEK is upstream of ERK) (732). Another study showed that suppression of the MEK-ERK
transduction pathway by a selective inhibitor, 2'-amino-3'-methoxyflavone (PD98059),
increased drug resistance of human cervical carcinoma SiHa cells to cisplatin (764). This
study also demonstrated the negative regulation of ERK on NF-KB) activation, and NF-KB
activation has been shown to inhibit apoptosis (348,709) (although this transcription factor
may be involved in positive regulation of human testicular apoptosis (552)). While cisplatin
activated nuclear ERK2 and NF-KB in SiHa cells, suppression of the MEK-ERK2 pathway by
PD98059 resulted in a further enhancement of cisplatin-induced NF-KB activation. These
results suggest that the MEK-ERK signaling pathway plays a role in the chemosensitivity of
SiHa cells, and suppression of this pathway increases cisplatin resistance partly via an
increase of NF kappa B activation (764). Although p38 was also activated by cisplatin, p38
did not have an effect on NF kappa B activation in this cell type. Another study showed that
cisplatin treatment of mice caused phosphorylation of JNK and ERK kinases but not the
phosphorylation of p38 in liver tissue (299). Moreover, Arany et al. (17) showed that the
three members of the MAPKs-ERK, JNK, and p38-are all activated in cisplatin-treated
mice and in an immortalized mouse proximal tubule cell line; however, only inhibition of ERK
abolished caspase-3 activation and apoptotic death. This study also showed that cisplatin-
induced ERK and caspase-3 activation were epidermal growth factor receptor (EGFR) and
c-src dependent as inhibition of these genes inhibited ERK and caspase-3 activation and
attenuated apoptotic death.
While activation of the MAP kinases is required for apoptosis in some cell types, one
study showed that the MAP kinases may be involved in promoting cell survival following
cisplatin treatment. Hayakawa et al. (274) showed that cisplatin, but not transplatin,
activated JNK, p38 and ERK and strongly increased ATF2-dependent transcriptional activity
in a breast cancer cell line. Activation of JNK but not p38 kinase or ERK kinase was
required for the phosphorylation and transcriptional activation of ATF2, and increased ATF2
activity was associated with cisplatin resistance whereas inhibition of JNK and ATF2
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sensitized cells to cisplatin. Moreover, the wild-type ATF2-expressing clones exhibited rapid
DNA repair after treatment with cisplatin but not transplatin. Conversely, expression of
dominant negative ATF2 quantitatively blocked DNA repair. These results indicate that JNK-
dependent phosphorylation of ATF2 plays an important role in the drug resistance
phenotype likely by mediating enhanced DNA repair (by a p53-independent mechanism).
Based on the results presented here, it is clear that the MAPK signaling cascades play an
important role in the cellular response to cisplatin (also see sectionl.4.4).
DNA-PK -dependent signaling in response to cisplatin damage
As mentioned above, mismatch repair proteins, perhaps along with other proteins in
the BASC complex, bind to cisplatin-DNA adducts and mediate pathways leading to
apoptosis. Another upstream effector of cisplatin-induced apoptosis that binds to cisplatin-
damaged DNA is DNA-dependent protein kinase (DNA-PK). DNA-PK is composed of two
DNA-binding Ku polypeptides, which are the units that bind both cisplatin-modified DNA as
well as double-strand breaks in vitro (695,696), and a serine/threonine kinase catalytic
subunit, DNA-PKc$, which is a member of the P13-kinase related family. DNA-PK is
essential in recombination and participates in nonhomologous end joining (NHEJ) and V[D]J
(variable [division] joining) recombination (202,203) and may also play a role in regulating
NER (92,504). The complex is also proposed to have a role in cell signaling after DNA
damage and interestingly DNA-PK, like ATM, phosphorylates and activates c-Abl in
response to IR (371). Although cisplatin damage has been shown to inhibit DNA-PK activity
on duplex DNA in vitro (697,699), recent data indicate that this complex may play an
important role in intercellular signaling following cisplatin damage. Jensen and Glazer (331)
demonstrated that cells deficient in Ku80 or in DNA-PKcs are significantly more resistant to
cisplatin compared with their wild-type counterparts. However this resistant phenotype was
only observed when the cells were grown at high density (i.e., 70-100% confluency at time
of cisplatin exposure, 30,000 cells per cm2 ); at relatively low cell densities (500 cells per
cm2 ), DNA-PK had no effect on cisplatin sensitivity. Both the kinase activity of DNA-PK and
direct cell-to cell contact were required for mediating cisplatin sensitivity. While the
presence of Ku80+'+ cells in contact with Ku80-'- cells during cisplatin exposure decreased
the survival of the Ku80-'- cells, this study indicates that DNA-PK is involved in the
transmission of a death signal to neighboring cells, and other experiments on gap junction
expression and function revealed that this signal is sent via gap junction intercellular
communication (GJIC) following cisplatin treatment. The role of DNA-PK in transmitting
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death signals is not a general response to DNA damage, as Jensen and Glazer found no
differences between Ku80- and GJIC-proficient and -deficient cells treated with UV,
mitomycin C, or 1-methyl-3-nitro-l-nitrosoguanidine (MNNG) at high cell density (331).
Furthermore, while the cisplatin resistance of MMR-deficient cells occurred at both low and
high cell densities, the authors conclude that the MMR-associated damage response
pathway is distinct from the density-dependent, DNA-PK- and GJIC-mediated pathway.
Earlier in vitro work showing that the presence of cisplatin adducts inhibits DNA-PK
kinase activity (697,699) is not consistent with the Jensen and Glazer study where DNA-
PKcs activity is required to transmit the death signal to neighboring cells. Furthermore,
DNA-PK mutants were previously shown to be more sensitive to cisplatin (3-4-fold)
compared to the wild-type cell line (504) and acquired cisplatin resistance and associated
IR-cross resistance was shown to be due to overexpression of the Ku80 subunit resulting in
increased Ku-binding activity in resistant cells (227). The discrepancies between the
aforementioned studies may be due to cell type-specific effects and/or culture and treatment
conditions. However it is of interest to note that in addition to its role in DNA binding, Ku
heterodimer is also expressed at the cell surface and may play a direct role in cell-cell
adhesion (505). In addition, one study on the cisplatin-sensitive ovarian cell line A2780 and
two resistant subclones revealed that the sensitive cell line showed a 20-30% decrease in
DNA-PK phosphorylation activity when cells underwent apoptosis whereas the resistant
clones displayed 80-90% decrease in activity, with decreased kinase activity associated with
proteolytic degradation of DNA-PKcs (280). Therefore the role of Ku and DNA-PK in
mediating cisplatin sensitivity requires further study.
Repair shielding and transcription factor hijacking revisited
Proteins involved in DNA repair and the DNA damage signaling network that bind
cisplatin-DNA adducts may be inhibited by other adduct-binding proteins that block access
to the adduct. For example, in vitro purified replication protein A (RPA), a protein involved
DNA damage recognition in NER, binds a cisplatin-modified substrate; however addition of
HMGB1 inhibits the cisplatin-DNA binding activity of RPA (548) and may inhibit both repair
and regulatory/signaling activities of RPA. Furthermore, while testicular cancer cells are
naturally nucleotide excision repair (NER) deficient (380,381,739), repair shielding by HMG-
box protein binding to cisplatin adducts may make these cells especially sensitive to the
drug. It is of interest to note that in addition to repair shielding by blocking access to the
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adducts and to the hijacking of transcription factors of essential growth genes, HMGB1
binding to cisplatin adducts may also interfere directly with the transcription of genes
involved in cell cycle regulation, DNA repair, and apoptosis. HMGB1 interacts in vitro with
p53 and p73 and has been shown to be capable of either enhancing or inhibiting the p73-
and p53-dependent transactivation of p53-responsive promoters, including Bax, Mdm2, and
p21 gene promoters (329,668). Whether HMGB1 stimulated or suppressed transcriptional
activity was dependent on the cell type studied. Thus HMGB1 binding to cisplatin-DNA
adducts may also contribute to cisplatin sensitivity via p53- and p73-dependent mechanisms
as HMGB1 interactions with both p53 and p73 influence the transactivation activity of the
latter proteins. However while the interaction of HMGB1 with p53 and p73 may lead to
either induction or suppression of apoptotic pathways, it is not clear whether transcription
factor hijacking of HMGB1 by cisplatin adducts would contribute to increased or decreased
sensitivity to the drug by this mechanism, and more work is necessary to determine if
hijacking of HMGB1 alters p53 and/or p73-dependent transcription. The role of HMG-box
proteins in repair shielding and hijacking were discussed previously (Sections 1.3.1 and
1.3.3)
1.3.5 Cisplatin-induced mutagenesis
Polymerase beta
As mentioned above, cisplatin adducts are effective inhibitors of DNA polymerase
progression; the replicative enzymes pol (x, pol 8, and pol £ have been shown to be
incapable of replicating past a cisplatin adduct in vitro (288,717). However cells have
evolved error-prone polymerases than can bypass damage, albeit with low fidelity, in order
to cope with and tolerate DNA damage. The cost of this tolerance is the generation of
mutations, as these polymerases lack proof-reading activity and can incorporate incorrect
nucleotides opposite the damaged template. Both E. coli and eukaryotes have different
bypass polymerases capable of synthesis past specific lesions (reviewed in Goodman
(252)). For example, human DNA polymerase P can bypass cisplatin adducts efficiently
and can elongate the product of a stalled polymerase at the site of a cisplatin adduct in vitro
(288,704). However bypass of cisplatin-adducts by pol results in mutations, with dTTP
being incorporated opposite the 3' platinated guanine residue in the 1,2-d(GpG) intrastrand
crosslink at 15-25-fold greater frequency than on an undamaged template (704).
Experiments in vivo support the in vitro data by showing that overexpression of pol may
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contribute to increased spontaneous as well as cisplatin-induced mutagenesis (93,94), the
latter which may result from pol P gap filling of excision repair patches (95,534). The effects
of pol 3, however, have not been tested in vivo at normal expression levels.
Polymerase eta
Another DNA polymerase with the ability to perform translesion synthesis of a
cisplatin-damaged substrate is pol l. Pol q is a member of the Y family of bypass
polymerases that can temporarily replace the processive replicative polymerase at the site
of the adduct and perform efficient translesion synthesis passed the adduct (566). Pol q is
encoded by the yeast Rad30 and the human XPV (also called POLH) genes and is
important in tolerating UV-induced DNA damage (456). Pol , like pol , is capable of
bypassing cisplatin-DNA adducts in vitro (455,707). However pol 11 is -150 times more error
prone than pol P on an undamaged template, and misincorporation of dTTP opposite the 3'
guanine in the 1,2-d(GpG) intrastrand crosslink is 5-10 times greater for pol rq than for pol P
(31,704,707). Because error-prone bypass of some adducts may require two
polymerases-one polymerase for dNTP misinsertion and a second polymerase for
extension of the mismatched primer termini-Bassett et al. (31) determined the efficiency of
extension for both pol qr and pol of mismatched primer termini opposite the 1,2-d(GpG)
adduct. This study found that for pol r, the efficiency of extension of a 3' G:T mismatch for
the next two steps is 2.1-2.3 x 10-3 on platinum-damaged DNA relative to extension of fully
complementary primers on undamaged DNA, while the efficiency of extension of the adduct-
containing 5'G:T mismatch is 0.7-1.1 x 10-2. The efficiency of extension of the 3' G:T
mismatch for pol P was found to be 1.3-7.2 x 10-4 on platinum-damaged DNA. The authors
estimate that the overall probability of damage-induced mutations is higher for pol q-
catalyzed translesion synthesis (1.8-2.5 x 104) than for pol P-catalyzed translesion synthesis
(1-10 x 10-6) but concede that an overall error rate of 10 -4 may be sufficient for accurate
bypass of the lesion since a translesion polymerase is only required to insert two
nucleotides opposite the adduct and perhaps extend those nucleotides by a single base
(31). In addition to base mutations, pol Tq is more error-prone than pol with respect to
other polymerase errors, namely frameshifts, and has been shown to generate deletions 18-
fold more frequently than pol P when replicating an undamaged DNA template (457). Pol 
was shown to catalyze -1 frameshift deletions when replicating past the 1,2-d(GpG) adduct
in vitro with at least 2-fold higher frequency than pol (32). Taken together, the data show
36
that both polymerases and q may play a role in cisplatin-induced mutagenesis, though pol
q may be more mutagenic.
Polymerase mu
It has recently been demonstrated that pol gp can efficiently perform translesion
synthesis of damaged templates including 8-oxoguanine, an abasic site, 1,N(6)-
ethenoadenine, and a cis-syn thymine-thymine dimer (787). Pol gp is a member of the X
family of polymerases, which also includes pol P and two recently identified polymerases X
and G (87). Pol p has been implicated in nonhomologous end-joining DSB repair (433,788)
and was shown to generate a high frequency of -1 deletion products from undamaged DNA
templates (788) and -1 and -2 deletion products from damaged templates (787). Pol p. was
shown to bypass the 1,2-d(GpG) adduct with an efficiency of 14-35% compared to
undamaged DNA, which makes pol pt less efficient than pol rq but more efficient than pol P at
performing translesion synthesis of cisplatin-adducts under similar reaction conditions (271).
Similar to pol rq and , pol p also displayed misincorporation of dTTP opposite the platinated
guanines. Interestingly, pol p performs better on gapped duplex templates than on primed
single-stranded templates, and when tested on gapped DNA templates, bypass of the 1,2-
d(GpG) adduct was highly error-prone and resulted in 2, 3, and 4 nucleotide deletions (271).
Therefore, in addition to pol ¢ and pol Tq, pol represents another DNA polymerase that may
contribute to cisplatin-induced mutagenesis. It is important to note, however, that the above
studies were all performed in vitro, and the relative contributions of these polymerases to
cisplatin-induced mutagenesis in vivo have not yet been reported. The DNA polymerases
pol K, which is the human homologue of E. coil dinB (pol IV) (242), pol t, encoded by
Rad30B, and pol A are all unable to bypass cisplatin-DNA adducts in vitro
(432,463,527,705).
Replicative bypass and cisplatin-induced mutations in cells
The mutagenetic effects of cisplatin have been extensively characterized in E. coil.
Cisplatin-induced mutations in E. coil require SOS induction and are therefore most likely
dependent on the SOS-inducible bypass polymerases Pol II, Pol IV, and Pol V, encoded by
the SOS-inducible genes polB, dinB, and umuDC, respectively. Cisplatin induces a 1-6%
mutation frequency in SOS-induced cells (89,761). Most of the mutations (>80-90%) are
targeted to the 5'-platinated base of the major d(GpG) and d(ApG) adducts (66,89,761),
although no sequence-dependent mutational hotspots were detected in the M13mp18 lacZ'
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gene fragment (762). The mutational spectra reported following cisplatin treatment in SOS
induced E. coli show that the majority of mutations are G-->T (66,761,762) and A-->T
(89,761) tranversions for the d(GpG) and d(ApG) adducts, respectively, while G-->A and
A--G transitions were also detected (761,762). Low levels (-10%) of tandem base-pair
substitutions occurring at the 5' modified base and the adjacent 5' base were also reported
in SOS-induced E. coli (89,761). Although the d(GpG) adduct is the most abundant adduct
in cisplatin-treated DNA, several studies have shown that the d(ApG) is more mutagenic
than the d(GpG) adduct. Yarema et al. showed that the d(ApG) adduct, with a mutation
frequency of 6%, is 4-5 fold more mutagenic than the d(GpG) adduct, which displays a
mutation frequency of 1.4% in the same experimental system using ssDNA (761). Other
studies using adducts in duplex DNA reported lower mutation frequencies, with 0.2 and 1-
2% for the d(GpG) and d(ApG) adducts, respectively (66,89). Interestingly, transplatin was
shown to be an ineffective mutagen in E. coli (34).
Cisplatin-induced mutations have also been reported in Chinese hamster ovary cells,
where platinum drugs cause 15-23% deletion mutations as well as base substitutions in the
Aprt gene (155,156), and in the SUP4-o gene of S. cerevisiae, where all possible types of
base pair substitutions as well as deletions, insertions and double mutations were identified
(479). These varied types of mutations may result from other mechanisms of mutagenesis
in addition to the error-prone bypass described above. For example, cisplatin-induced
strand breaks could result in double-strand break misrejoining and non-homologous repair
events leading to large deletions. Indeed, cisplatin resistant ovarian cell lines displayed
increased DSB misrejoining activity and deletions of between 134 and 444 base pairs that
arose through illegitimate recombination at short repetitive sequences (73). Furthermore,
defects in DNA repair, which lead to hypersensitivity to cisplatin, can also lead to increased
cisplatin-induced mutations; when a cisplatin-damaged plasmid was transfected into XPC
cells, which are defective in the XPC gene, and normal human fibroblasts, an increased
mutation frequency was observed in the XPC cells, with most of the mutations consisting of
large deletions (106). This result suggests that less repair and the persistence of cisplatin-
DNA adducts can lead to a higher mutation frequency, which is not surprising as DNA error-
prone polymerases will then have more opportunities to perform translesion synthesis and
as the misrepair of secondary damage (i.e., strand breaks) may also result in deletion
events. On the flip side, the presence of other cisplatin adduct binding proteins such as
HMG-box proteins, may prevent bypass and mutation fixation. For example, HMGB1
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binding to cisplatin adducts was shown to inhibit translesion bypass (287,706), which may
prevent mutations at the cost of eliciting toxicity. Consistent with the notion that adduct-
binding proteins may inhibit bypass and prevent mutation fixation, defects in hMLH1 or
hMSH6 (the MMR proteins that bind cisplatin-DNA adducts) were shown to result 2.5-6-fold
increased replicative bypass of cisplatin adducts (708), although this observation may result
from decreased attempts at mismatch correction as well as from an increased ability to
bypass adducts in the absence of MMR adduct-binding proteins. Cisplatin-induced
mutagenesis may also be enhanced by the activity of DNA repair proteins. For example in
E. coli, cisplatin-induced mutagenesis as measured by rifampicin resistance is suppressed
in cells that are deficient in the mismatch DNA glycosylase MutY, with mutY mutant cells
displaying a mutation frequency 25-fold lower than the mutation frequency observed in wild-
type cells (Kartalou et al., unpublished results). While the major 1,2-d(GpG) adduct induces
mainly SOS-dependent G to T transversions at the 5'-platinated G (66,761,762), both the
bacterial and human MutY proteins bind to the major intrastrand crosslink when an A is
opposite the 5'-platinated G, and both proteins displayed catalytic activity and introduced
incisions on the compound lesion substrate in vitro (Kartalou et al., unpublished results).
Therefore processing of cisplatin adducts by certain DNA repair proteins designed to protect
the genome against mutations may in fact enhance cisplatin-induced mutagenesis.
1.3.6 Other consequences of cisplatin damage
In addition to inhibition of replication and transcription, and the induction of DNA
damage signaling and mutagenesis, cisplatin-DNA adducts affect other DNA metabolic
processes. For example, telomeres carry potential cisplatin reaction sites in their tandem G-
rich repeats (in humans, 5'-TTAGGG-3' (501)). Telomeres play important roles in protecting
chromosome ends from DNA degradation and rearrangements, and telomere length, which
shortens with every cell division until it reaches a critical length, is a determinant for the
number of divisions a cell undergoes before it reaches senescence and dies. One
mechanism for the stabilization of telomere length is the synthesis of the tandem repeats by
the ribonucleoprotein telomerase (53,205), and thus telomerase activity may be important
for the tumorigenic potential (and immortalization) of cells (255). Telomere length was
shown to be degraded in HeLa cells following cisplatin treatment, including with low doses of
drug (320). In addition to reacting with telomeric DNA and possibly causing its degradation,
cisplatin may also bind to the RNA and/or protein regions of telomerase, and cisplatin, but
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not transplatin, was shown to inhibit telomerase activity in testicular cancer cells (83). Thus
while cell proliferation depends on telomere length, the effects of cisplatin on telomere
maintenance may contribute to drug toxicity.
Cisplatin may also alter chromatin structure by affecting interactions between DNA
and nucleosomal proteins including histones, the structural proteins around which DNA is
wrapped to form condensed chromatin. Cisplatin treatment may induce crosslinking
between nucleosomal proteins and between nucleosomal proteins and DNA
(25,210,276,416). Furthermore, an intrastrand crosslink in DNA may itself affect chromatin
structure as the 1,3-d(GpTpG) intrastrand crosslink of cis-{Pt(NH3) 2} 2 + alters the translational
positioning of DNA and forces opposite rotational settings around the histone octamer core,
resulting in asymmetric arrangement of DNA with respect to the core histones (149). As
mentioned previously, the linker histone H1 strongly binds cisplatin-modified DNA over
transplatin-modified or undamaged DNA in vitro (758), and thus interactions between
histone proteins and cisplatin-DNA crosslinks may also affect chromatin organization.
Studies have also shown that cisplatin treatment affects the post-translational modification
of histones. Cisplatin induces phosphorylation of histone H3 at Ser-10 by p38 kinase as
well as the hyperacetylation of histone H4 (727). Some of these modifications may be
mediated by effectors of apoptosis and may be important for the DNA fragmentation
associated with programmed cell death. For example, as mentioned in Section 1.3.1,
cisplatin induces poly(ADP-ribosyl)ation of nuclear proteins, and one protein shown to
undergo significant poly(ADP-ribosyl)ation is histone H1 (530,602); it has been shown that
the poly(ADP.-ribosyl)ation of histone H1 correlates with internucleosomal DNA
fragmentation during apoptosis (765)..
1.4 Cellular mechanisms of resistance to cisplatin
One of the major limitations of cisplatin chemotherapy is acquired or intrinsic
resistance. As mentioned in Section 1.1, certain cancers are inherently resistant to the
effects of cisplatin damage, while other cancers acquire drug resistance after an initial
response. This acquired resistance may result from the selection of cells during initial drug
treatment that carry or develop mechanisms of overcoming or tolerating cisplatin-induced
damage; cancers that exhibit intrinsic resistance may already possess such mechanisms.
There are several known mechanisms of cellular resistance to cisplatin, which include
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reduced intracellular accumulation of cisplatin owing to either decreased uptake or
increased efflux of the drug, detoxification of cisplatin by thiol-containing biological
molecules, increased tolerance of cisplatin adducts, and enhanced repair of cisplatin-
induced genomic damage by DNA repair systems. Cisplatin sensitivity and resistance are
also determined by the balance of pro- and anti-apoptotic signals (517,728). Although
resistance to cisplatin is multi-factorial in the sense that multiple mechanisms contributing to
resistance may be operative within the same tumor (228,458,638), many studies have tried
to determine key cellular players in cisplatin resistance in efforts to modulate these
resistance mechanisms or in the pursuit of developing new drugs that overcome these
mechanisms (see Section 1.5).
1.4.1 Reduced intracellular accumulation of cisplatin
Reduced uptake or increased export of cisplatin may reduce the intracellular
concentration of the drug, and intracellular levels of cisplatin have been shown to correlate
with cisplatin sensitivity in ovarian cancer cell lines (410,423,482,545) and a human
hepatoma cell line (339). Although the mechanism of cisplatin entry into cells is not fully
known, recent studies suggest a role for copper transporters in cisplatin transport. The
copper transporter Ctrl, for example, was shown to affect intracellular levels of cisplatin in
yeast and mouse cells while deletion of Ctrl results in reduced intracellular accumulation of
cisplatin and decreases cellular sensitivity to the drug (321). Furthermore, increased
expression of Ctrl in human ovarian cancer cells leads to increased intracellular
accumulation of cisplatin (297). In addition to Ctrl, the copper exporters ATP7A and ATP7B
may also modulate sensitivity to cisplatin. These copper exporters exhibit a negative
association with cisplatin sensitivity, with increased expression correlating with decreased
sensitivity to drug treatment (360,604). Recent data suggests that ATP7A may contribute to
cisplatin resistance by sequestering the drug into vesicles (610), thus making potential
cellular targets such as DNA inaccessible to the drug. Studies have also shown that cell
lines exhibiting resistance to copper also show cross-resistance to cisplatin and visa versa
(360,605).
Other membrane proteins may also affect cisplatin uptake and/or efflux. For
example, a 48kDa membrane protein is expressed at lower levels in drug resistant human
squamous carcinomas cell lines that also exhibit decreased intracellular accumulation of the
drug, implicating this protein in cisplatin uptake (43). Conversely, cisplatin resistant murine
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lymphoma cells that showed reduced drug accumulation were shown to overexpress a 200
kDa plasma membrane glycoprotein, different from the multidrug resistance-associated P-
glycoprotein (1170 kDa), suggesting that this larger protein may be involved in cisplatin
export (362). In addition to membrane proteins, some evidence suggests that cisplatin
accumulation may depend on membrane potential; although cisplatin is not transported by
the sodium-potassium pump, the sodium-potassium ATPase inhibitor ouabain inhibits drug
uptake (16). Furthermore, because cisplatin uptake cannot be inhibited by structural
analogues and cannot be saturated, it has been suggested that drug entry into cells most
likely occurs to some extent by passive diffusion (237,306,436). Therefore, although the
primary mechanisms of cisplatin uptake and efflux are not known, multiple factors affect the
intracellular accumulation of cisplatin and may accordingly mediate sensitivity to the drug.
1.4.2 Inactivation of cisplatin
In addition to reduced uptake or increased efflux, the effective intracellular
concentration of cisplatin may also be modulated by cellular proteins that react with and
inactivate the drug. Once cisplatin enters cells and undergoes hydrolysis, it can covalently
react with thiol-containing compounds, which essentially chelate/quench the drug and
reduce the effective intracellular concentration of drug that can react with DNA. The most
abundant cellular thiol is the tripeptide glutathione (y-glutamylcysteinylglycine, GSH), which
is present at concentrations 0.5-10 mM inside cells (112). GSH is synthesized in a two-step
pathway involving the enzymes y-glutamylcysteine synthetase (also known as glutamate
cysteine ligase), which completes the first and rate-limiting step of peptide bond formation
between cysteine and glutamic acid to form y-glutamylcysteine (y-GC), and glutathione
synthetase, which couples y-GC with glycine and completes the second step of tripeptide
synthesis. The enzyme y-glutamylcysteine synthetase can be inhibited by D,L-buthionine-
S,R,-sulfoximine (BSO), and this feature of enzyme inhibition has been exploited to
determine the effects of limited GSH on cisplatin sensitivity. For example, a cisplatin-
resistant murine leukemia L1210 subline has elevated GSH levels compared to its sensitive
parent cell line and exposure to BSO reduces GSH levels in the resistant subline to nearly
the levels observed in the parent line and abrogates resistance to cisplatin (305). GSH may
contribute to cisplatin resistance by facilitating the export of cisplatin once reacting with and
inactivating the drug (322). In addition to reducing the intracellular concentration of drug,
GSH can react with cisplatin monoadducts in DNA, preventing formation of the crosslink and
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thereby reducing the cytotoxic potential of the drug (181). Whether GSH facilitates the
export of cisplatin or prevents formation of cytotoxic crosslinks, increased GSH levels have
been associated with cisplatin resistance. In studies of ovarian cancer cell lines, GSH levels
were shown to be increased in resistant cells (35,248,746,747), with one study showing that
a selection for human ovarian drug-resistant cells in vitro led to the development of cell lines
that showed 30- to 1000-fold increased resistance as well as 13-15-fold increased levels of
glutathione as compared with the drug-sensitive parental cells (248). A different study
measured intracellular glutathione concentration in human ovarian cell lines and showed
that IC50 values for cisplatin and carboplatin correlated with GSH levels (481); however
BSO had differential effects on the cell lines, with cellular GSH depletion by BSO increasing
cisplatin cytotoxicity in only one of two resistant cell lines. Another study using in vitro
selection of cisplatin-resistant sublines of human ovarian carcinoma cells showed that GSH
levels were only elevated in cells exhibiting high levels of resistance (9-fold and 13-fold) and
not in cells that displayed low levels of resistance (2-3-fold) (15). The resistance of both
low- and high-resistant sublines, however, could be partially reversed by extended depletion
of GSH by BSO treatment. Despite the aforementioned correlative results on GSH levels
and cisplatin resistance, other studies have revealed that increased GSH levels is not a
consistent characteristic of cisplatin resistant cells. One study showed that GSH levels did
not differ between a sensitive human testicular tumor cell line and an in vitro derived 5.6-fold
drug-resistant subline (364). Another more recent study determined the correlations
between intracellular GSH content and drug sensitivity in 14 human cancer cell lines (from
non-treated patients) and showed that there was no correlation between GSH content and
the growth inhibitory effects of cisplatin and its analogues carboplatin and oxaliplatin (59).
Therefore while intracellular glutathione can play a major role in determining cisplatin
sensitivity, other factors are clearly involved.
Metallothionein (MT) represents another thiol that may play a role in cisplatin
resistance. While one-third of MT's amino acid residues are cysteines that can bind metal
ions, this thiol compound plays an important role in the detoxification of heavy metal ions in
cells and accordingly confers resistance to cadmium (376). MT reacts with cisplatin at a
ratio of 10 +/- 2 Pt(ll) per mol of protein (550) and can therefore have a major impact on the
concentration of cisplatin available to react with DNA. Human ovarian carcinoma cells that
are 3-4-fold resistant to cisplatin showed 9-23-fold elevated levels of MTs (14). However
these resistant cells were selected in vitro by chronic exposure to CdCI 2 and ZnCI2, and
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selection with cisplatin did not generate cell lines with elevated MT levels. In another study,
tumor cell lines with acquired resistance to cisplatin overexpressed MT, and human
carcinoma cells that were chronically exposed to heavy metals maintained high levels of MT
and displayed resistance to cisplatin, and cisplatin resistance could be conferred by
expression of a vector encoding human metallothionein-llA (367). MT-conferred drug-
resistance is also supported by a recent study that examined the effect of MT on cisplatin
resistance in C3H mice inoculated with MBT-2 murine bladder tumor cells. This study
showed that reduced MT levels in tumors increased the levels of cisplatin accumulation and
the antitumor activity of cisplatin in the tumors (606). Furthermore, overexpression of MT in
the ovarian cancer cell line A2780 by stable gene transfection resulted in a protection from
the growth-inhibitory effects of cisplatin (7-fold) (289), and a moderate increase in MT
content was observed in an in vitro derived resistant (5.6-fold) human testicular tumor cell
line (364). However as with GSH, higher levels of MT do not always correlate with
increased resistance to cisplatin. One study showed that cisplatin resistant human ovarian
carcinoma cell lines displayed varying levels of cross-resistance to cadmium and varied
expression of MT; furthermore, cisplatin resistance could not be conferred by expression of
a metallothionein gene construct in mouse C127 cells, and thus no causal relationship
between MT expression and cisplatin resistance could be established (621). In addition, MT
content was not a major determinant of tumor sensitivity in a study of ovarian tumor samples
from untreated patients and from patients who had undergone chemotherapy (506). Thus
although the intracellular levels of thiols such as GSH and MT do not universally correlate
with cisplatin sensitivity, they can play a role in cellular sensitivity to cisplatin. Indeed, both
GSH and MT may be useful as predictive indicators for clinical response to cisplatin-based
chemotherapy in ovarian cancer patients (677).
1.4.3 Repair and bypass of cisplatin-DNA adducts
If cisplatin is not inactivated by thiols, it can react with DNA to form cytotoxic lesions.
These lesions can induce apoptosis, as discussed above, if they are not removed by DNA
repair proteins, and accordingly DNA repair is a critical determinant of sensitivity to cisplatin.
Numerous studies have demonstrated increased removal of cisplatin adducts in cisplatin-
resistant ovarian cancer cell lines (35,208,338,340,396,453,454,545,790,790). In addition,
Ferry et al. showed that certain NER genes, specifically ERCC1, XPB, XPC, and XPF, are
over-expressed in an in vitro selected human resistant ovarian cancer cell line. Cisplatin
resistance in this subline and other resistant sublines was associated with cross-resistance
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to UV as well as increased repair activity (208). Over-expression of the NER genes XPA
and XPE, in addition to ERCC1, and associated cisplatin resistance have been shown in
other studies of ovarian and other tumor cell lines (75,114,146,147,596,663). While repair
capacity is a determinant of cisplatin sensitivity, and while biopsies from untreated ovarian
carcinomas reveal as much as a 10-fold difference in the repair efficiency of cisplatin-
modified DNA (344), repair capacity may prove useful as predictive marker of clinical
response to platinum-based therapy. In support of this idea, patients who were clinically
resistant to platinum-based therapy had a 2.6-fold higher expression level of ERCC1 in their
tumor tissue (harvested before treatment began) than did patients who responded to that
therapy (145). Another study determined the mRNA levels of XPA and ERCC1 in malignant
ovarian cancer tissues from patients before administration of platinum-based chemotherapy
and correlated the expression level of these NER genes with clinical outcome; this study
revealed that greater levels of ERCC1 and XPA mRNA were found in tissues from patients
whose tumors were clinically resistant to therapy as compared with tumor tissues from those
individuals clinically sensitive to therapy (147). Although alternative splicing of mRNA may
inhibit the function of full length gene products, this study also showed that alternative
splicing of ERCC1 among the samples was highly variable, with no difference observed
between responders and non-responders. However another study showed an inverse
correlation between alternative splicing of ERCC1 in a series of human cell lines and tissues
and cellular capability to repair cisplatin-modified DNA (767). It is clear from these studies,
however, that another mechanism for cisplatin resistance is increased DNA repair capacity,
as high expression levels of repair proteins and higher repair capabilities confer resistance
to cisplatin and correspond to poor response to cisplatin therapy. Conversely, a deficiency
in repair leads to hypersensitivity to cisplatin (168,403,569) and accordingly testicular cancer
cells, which are inherently NER deficient (380,381,739), are especially sensitive to cisplatin.
Studies have also shown that cisplatin-resistant cells exhibit increased repair of
coding regions of the genome. Repair of damage in the coding strands of actively
transcribed genes is accomplished by a subpathway of NER called transcription-coupled
repair (TCR) (reviewed in Hanawalt, (265)). Several studies have shown that cisplatin
adducts are removed more efficiently from specific genes-namely dihydrofolate reductase
(DHFR), ribosomal RNA (rRNA), multidrug resistance (MDR1), c-myc, and delta-globin
genes-compared to non-active genomic regions, although at high levels of damage the
differential repair between active and non-coding regions is eliminated
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(342,399,580,789,790). One study demonstrated increased gene-specific repair in resistant
ovarian cancer cell lines compared to the sensitive parental cells, although this increased
repair was limited to interstrand crosslinks and no differential repair of the intrastrand
adducts was observed (790).
As with other mechanisms of drug resistance, increased repair is not a universal
factor in drug resistance and is not found in all cisplatin-resistant models. Although the case
was made above that repair capacity could be a prognostic indicator of clinical response to
platinum chemotherapy, one study showed that the DNA repair capacity of protein extracts
from different tissues varied significantly but did not directly correlate with the organotrophic
toxicity profile of cisplatin (343). In addition, a study of three pairs of cisplatin-sensitive and -
resistant cell lines, two derived from TGCT and one from bladder cancer, found no
correlation between DNA repair capacity and cisplatin resistance as well as no major
differences between the repair of cisplatin damage in transcribed and non-transcribed genes
(382). Furthermore, in a study of twelve unrelated human ovarian cancer cell lines derived
from patients who were either untreated or treated with platinum-based chemotherapy, only
platinum-DNA tolerance correlated strongly with cisplatin sensitivity; intracellular platinum
accumulation, glutathione levels, DNA-adduct formation, and DNA-adduct removal did not
correlate significantly (337). Adduct tolerance may be achieved by increased bypass of
cisplatin-DNA adducts. As discussed above, DNA replicative polymerases stall at cisplatin
adducts. The arrested replication complex requires the aid of error-prone translesion
polymerases than can synthesize DNA past the damaged template in order to avoid
potentially severe consequences such as replication fork collapse and strand-break
formation, and such polymerases capable of translesion synthesis past cisplatin adducts
include polymerases P, T, and p (see Section 1.3.5). Therefore increased bypass tolerance
of cisplatin-damaged DNA may be a possible mechanism for cisplatin resistance.
Overexpression of pol 3 in CHO cells, for example, was shown to confer resistance to
cisplatin (93), and pol 3 gene amplification has been detected in tumors that are refractory to
cisplatin therapy (354,618) and human colon carcinoma cells selected for cisplatin
resistance exhibited a 4-5-fold increase in pol ¢ activity (388). In addition, mouse 3T3 cells
expressing pol P antisense RNA showed increased sensitivity to cisplatin (300), and down-
regulation of pol P by siRNA resulted in increased sensitivity to cisplatin in both HeLa and
the relatively resistant ovarian cancer SKOV-3 cell lines (7); however pol 3 null and siRNA
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knock-down mouse embryonic fibroblast cell lines did not exhibit increased sensitivity to
cisplatin (525,570,655). Because pol D is involved in repair patch synthesis in BER
(222,655), increased expression of pol P may be associated with increased repair rather
than increased translesion bypass. Interestingly, extracts from cells overexpressing DNA
polymerase D demonstrated a five- to six-fold increase of repair synthesis involving pol 3 on
cisplatin-modified templates compared with control extracts (95). Although dRP lyase
activity of pol P was shown to be the rate-determining step in the multi-step BER pathway in
vitro (661), it has not been shown that overexpression of pol P alone leads to increased
repair in vivo. Furthermore, decreased expression of pol P leads to increased sensitivity to
cisplatin but not to the nucleic acid antagonist 5-fluorouracil (5-FU) (570); 5-FU, when
incorporated into DNA, is a substrate for the base excision repair enzyme, uracil
glycosylase, whereas cisplatin has not been shown to be a substrate for glycosylase
incision. Therefore the effects of pol , the major BER polymerase, on cisplatin sensitivity is
most likely related to translesion bypass by pol P rather than to excision repair pathways
involving pol 13. In support of polymerase bypass contributing to cisplatin resistance, yeast
strains deficient in polymerase , which has been shown to be capable of bypassing UV
thymine-thymine dimmers (401,514), are hypersensitive to cisplatin (750). In addition,
platinum-resistant murine leukemia cell lines show a 3-4-fold increase in bypass of platinum-
DNA adducts (243) and cisplatin-resistant human ovarian cancer cell lines displayed a 2.3-
4.8-fold increase in bypass ability as measured by chain elongation compared to the
cisplatin-sensitive parent cell lines (434). The importance of replicative bypass in cisplatin
resistance is also demonstrated in a study showing that hMLH1 or hMSH6 defects result in
1.5-4.8-fold increased cisplatin resistance and 2.5-6-fold increased replicative bypass of
cisplatin adducts (708).
While tolerance of cisplatin damage by translesion synthesis represents one
mechanism of bypass, cells can also tolerate adducts by recombination-dependent bypass.
A replication complex arrested at the site of an adduct will collapse, leading to a single-
strand gap, if it is not aided by bypass mechanisms such as translesion synthesis. If
unrepaired this single gap could result in a more detrimental DSB when the cell undergoes
another cycle of replication. This gap, however, can also be "bypassed" and repaired by
recombination-dependent pathways of replication fork recovery. The process of fork
regression at DNA damage sites in E. coli is thought not only to prevent replication fork
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degradation, but also to allow other repair mechanisms access to the replication-blocking
damage (134). Thus increased strand break repair or recombinational bypass may
contribute to cisplatin resistance (refer to Fig. 2.1 in Chapter 2 for strand-break repair
pathways in E. col). If the replication fork is not recovered by recombination-dependent
pathways, a DSB can occur (B in Fig. 2.1). Thus lethal secondary cisplatin-induced damage
requires repair by other DNA repair pathways such as recombination and DSB end-joining
pathways. In E. coil, DSB repair is accomplished by the RecBCD pathway of recombination
repair whereas in mammalian cells, DSB repair requires the Rad family of proteins and may
occur by either homologous recombinational repair or by non-homologous end joining
(discussed in detail in Chapter 2). S. cerevisiae deficient in RAD51 and RAD52 are more
sensitive to cisplatin compared to wild-type cells (259). In addition, overexpression of the
Rad51 paralog XRCC3 in MCF-7 cells leads to a 2-6-fold increase in cisplatin resistance.
While in mammalian cells break repair pathways may be either conservative and relatively
error-free or non-conservative, resulting in genomic instability, the use of non-conservative
(i.e., low fidelity) pathways may increase sensitivity to the original genotoxic insult; and
consequently the use of conservative over non-conservative pathways may contribute to
resistance. The importance of DSB repair in determining cisplatin sensitivity is
demonstrated by studies showing that the induction of cisplatin resistance is frequently,
though not invariably, associated with cross-radioresistance in human cancer cell lines
(35,286,428,700), and DSBs are a predominant form of lethal damage induced by irradiation
(508). Furthermore, Britten et al. (74) showed that radiation-sensitive and radiation-resistant
tumor cells exhibit a differential level of DSB misrejoining activity, with high DSB misrejoining
in radiosensitive cells being a result of an increase in non-conservative DSB rejoining
activity (perhaps via illegitimate recombination) that results in losses of between 40 and 440
base pairs. A decrease in the fidelity of DSB rejoining may also play a role in cisplatin
sensitivity, and in support of this idea, Britten et al. (73) found a significantly lower level of
DSB misrejoining activity within nuclear protein extracts from cisplatin-resistant (and radio-
resistant) ovarian tumor cell lines than in the nuclear extracts from the cisplatin-sensitive
(and radio-sensitive) parental cell lines, with acquired cisplatin resistance associated with a
2-3 fold decrease in the activity of non-conservative DSB rejoining. The mis-rejoining
events detected in this study generated deletions between 134 and 444 base pairs, all of
which involved recombination at distant short sequence repeats (i.e., micro-homologies).
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1.4.4 Regulatory proteins and cellular determinants of apoptosis
p53-mediated apoptosis
Adduct tolerance may result from increased bypass, as described above, or from a
defect in damage processing and/or a failure to activate cell death pathways. Such defects
may arise from alterations in the expression or function of tumor suppressor genes and
oncogenes. The tumor suppressor gene p53, for example, plays an important role in
delaying cell cycle progression in response DNA damage, thus allowing time for repair; if the
level of genomic damage is beyond the repair capacity of the cell or is irreparable, p53 may
also initiate apoptosis (reviewed in (562,719)). P53 elicits these effects by acting as a
transcription factor for genes involved in DNA damage response signaling including
p2 1 cIP1/WAF1 (188), which encodes the cyclin-dependent kinase inhibitor p21 with anti-
proliferative and anti-apoptotic properties (236,719), gadd45 (358), which plays a role in the
G2 checkpoint response by inhibiting the Cdc2/Cyclin B1 complex (735,783), Mdm2 (27),
which encodes an antagonist of p53 that complexes with p53 to inhibit p53-mediated
transactivation (102,493) and to target p53 for ubiquitin degradation (270,298,392), and Bax
(488), which encodes a Bcl2-related protein that serves as a pro-apoptotic factor by
facilitating the release of AIF and cytochrome c from the mitochondria, thereby activating the
caspase cascade (647). Thus inactive p53 may result in defective cell cycle arrest and DNA
repair or failure to activate apoptosis, and likewise alterations in the signaling events
upstream in the p53 pathway (e.g., the PI3K/AKT signaling cascade) may also contribute to
drug resistance.
Human lymphoma and ovarian carcinoma cell lines expressing mutant p53 are more
resistant to cisplatin compared to cell lines expressing wildtype p53 and show reduced
activation of cell cycle arrest and pro-apoptotic signals (189,196,554). Furthermore,
introduction of wildtype p53 in resistant human ovarian and lung cancer cells expressing the
mutant protein can sensitize these cells to drug, both in vitro (230,657) and in mouse
xenograft models (229,375,634,656). Mutations in p53 have also been found in a proportion
of testicular germ cell (302) and ovarian tumor samples (375,615) that failed to respond to
cisplatin-based therapy, suggesting that defective p53 contributes to cisplatin resistance in
vivo and that treatment may select for resistant p53 mutant cells. One study showed that in
addition to a slightly higher level of mutated p53 transcripts, a resistant human ovarian
carcinoma cell line also displayed higher levels of Mdm2 protein, and thus this study
demonstrated two possible mechanisms of p53 inactivation in resistant cells (194).
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Furthermore, an in vitro study comparing various human cell lines of the National Cancer
Institute drug screen, 18 of which express wild-type p53 and 39 of which harbor p53
mutations, the mutant cell lines were significantly more resistant to cisplatin, bleomycin, and
5-fluorouracil than the wild-type cell lines (523). Similarly, gene expression profiling of the
NCI's 60 cell lines demonstrated that wild-type p53 positively correlates with sensitivity to
cisplatin (712).
As with the other modes of drug resistance, mutated and/or inactivated p53 is neither
necessary nor sufficient for a resistant phenotype. Studies measuring drug-induced
apoptosis levels and p53 status in cell lines derived from human ovarian and testicular
cancers-the cancers for which cisplatin is most effective-did not show a correlation
between p53 status and apoptosis following cisplatin treatment (84-86,157). One study
compared p53 expression and p53 mutations in 17 drug-responsive and 18 unresponsive
TGCTs; p53 was detected in 59% of the responsive samples and in 83% of the non-
responsive tumors (370). P53 mutations were detected in only 1 of the 17 responsive
tumors, while there were no mutations detected in the 18 resistant tumors. In addition,
human foreskin fibroblasts with inactivated p53 and p53 null (p53-1-) mouse embryonal
fibroblasts are hypersensitive compared to their p53 wildtype counterparts (273), and
likewise sublines of the breast cancer cell line MCF-7 in which p53 function was disrupted
exhibited increased sensitivity to cisplatin, which was attributed to their reduced ability to
repair cisplatin DNA damage and/or defects in cell cycle checkpoint control (197).
Importantly, although MCF-7 cells display normal p53 function, these cells do not readily
undergo p53-dependent apoptosis. Thus, perhaps only in cells in which p53 functions in
initiating apoptosis does mutated p53 confer resistance. Moreover, because p53 serves
multiple functions and acts upstream of other genes and proteins in the DNA damage
response and apoptotic network (it is estimated that p53 activates transcription of 200-300
genes (688)), other proteins in these DNA damage response pathways may be capable of
compensating for defective p53. For example, overexpression of BRCA1 may compensate
for loss of p53 in maintaining global genomic NER through up-regulation of XPC, DDB2, and
GADD45 (269). Additionally, as discussed above, data on p53 expression and function in
TGCTs and other cell types do not support a consistent role for p53-pro-survival or pro-cell
death-in the response to cisplatin.
The role of p73 in cisplatin-induced cell death
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Another protein in the p53 family, p73, has also been implicated in cisplatin
resistance. p73-deficient mouse embryo fibroblasts exhibit increased resistance to cisplatin
(251) and loss of p73 induction and p73-mediated apoptosis was demonstrated in a
cisplatin-resistant bladder cancer cell line (533). Contrary to the latter data and the
demonstrated role of p73 in cisplatin-induced apoptosis (see Section 1.3.4), overexpression
of p73 in human ovarian cancer cells was shown to confer cisplatin resistance and to lead to
higher expression of the DNA repair and damage response genes DNA-PK, ATM, XRCC6,
XPD, XPG, XPB, XRCC1, MGMT, and hMLH1 as well as increased repair capability of a
cisplatin-damaged substrate (716). The conflicting data on the effects of deficient- and over-
expression of p73 may in part be due to the mutual and competing influence of p53 and p73
on gene transactivation and apoptosis. The two closely related proteins p53 and p73 share
similar transcriptional activation, DNA binding, and oligomerization domains (346,349);
indeed, p53 and p73 can both activate transcription from promoters containing p53-
response elements (346,349,510,716) (which may explain why overexpression of p73 leads
to increased DNA repair) and these proteins have been shown to compete for DNA binding
as p73 can reduce the transactivational activity of p53 (702,715). Furthermore, both
proteins are negatively regulated by MDM2 (24,270,361,532,721,781). Both p53 and p73
can activate apoptosis in several cell lines and both proteins are induced following cisplatin
treatment (211,251). The similarities between these two proteins can lead to important
consequences in the clinical responses to cisplatin. For example, mutant p53 can abrogate
p73-mediated sensitivity to cisplatin; p53 polymorphisms found in advanced head and neck
cancers influence p73 function and the inhibition of p73 by specific p53 mutations correlates
with clinical drug resistance (42). In addition, Strano et al. demonstrated that human tumor-
derived p53 mutants associate with p73 in vitro and in vivo, and these the p53 mutants also
inhibit the transcriptional activity of p73 (667). Conversely, overexpression of a tumor-
derived truncated transcript of p73, which lacks the acidic N-terminus corresponding to the
transactivation domain of p53 and which was found in 46% of breast cancer cell lines
surveyed, was shown to partially protect lymphoblastoid cells against cisplatin-induced
apoptosis and was shown to reduce the ability of wildtype p53 to promote apoptosis by
acting as a dominant negative inhibitor to p53 (211). Thus mutant forms of p53 and p73
may result in the dual inhibition of apoptosis leading to increased drug resistance.
The c-Abl and mitogen-activated protein kinase (MAPK) pathways
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Despite the similarities between p53 and p73, the mechanism of activation of these
two proteins in response to cisplatin damage is different; p73 is a tyrosine phoshoprotein-
unlike p53 which is a serine/threonine phosphoprotein-and p73 but not p53 is
phosphorylated and stabilized by c-Abl, a non-receptor tyrosine kinase (5,694,770).
Furthermore, c-Abl-dependent induction of p73 and p73-mediated apoptosis following
cisplatin treatment is dependent on mismatch repair, whereas p53 induction and p53-
mediated apoptosis following cisplatin damage is not dependent on MMR (251,637),
Although p53 is not a known phosphorylation target of c-abl, c-abl regulates p53 by
preventing the nuclear export of p53 by Mdm2 and by inhibiting both Mdm-2- and E6-E6-AP-
mediated p53 ubiquitination within the nucleus (249,646,648). Therefore c-Abl, acting
upstream of p73 as well as regulating p53 levels (although only the former mechanism was
shown to contribute to cisplatin sensitivity (251)), may also contribute to cisplatin resistance.
Accordingly cells deficient in c-Abl are more resistant to cisplatin and cells deficient in MMR,
which is required to activate c-Abl in response to cisplatin (512,513), are consequently
resistant to the drug (251,513).
In addition to c-Abl, a member of the activator protein-1 (AP-1) transcription factors,
c-Jun, has also been shown to stabilize p73 in response to cisplatin treatment, and c-jun (-/-)
mouse fibroblasts are resistant to cisplatin-induced apoptosis while reintroduction of c-Jun
restores p73 induction and cisplatin sensitivity (612,686). The effect of c-Jun on cisplatin
sensitivity may be linked to c-Abl activation; c-Abl acts upstream of stress-activated protein
kinase/c-Jun NH2-terminal Jun kinase (SAPK/JNK) (373,374), and JNK activation mediates
the expression of c-jun (140,386,612,616). Cisplatin activates JNK in a dose-dependent
manner while transplatin fails to activate the kinase (78,274,275,556,576). In addition,
inhibition of JNK activation correlates with cisplatin resistance; cisplatin-induced apoptosis
involves JNK activation whereas acquired cisplatin-resistance is associated with reduced
apoptosis and attenuation of JNK activation (78,238). Consequently activation of JNK is
associated with better survival in the clinic (244), although several studies showed that JNK-
mediated activation of c-Jun (576) and ATF2 (274) may facilitate repair of cisplatin damage
and subsequently lead to increased cellular viability following cisplatin treatment. Consistent
with the latter observation, another study showed that expression of a non-phosphorylatable
dominant negative c-Jun in human glioblastoma cells inhibits AP-1-driven transcription and
in turn increases apoptosis induced by a variety of DNA-damaging agents including cisplatin
(575). Furthermore, it was shown that c-Jun expression is elevated in cisplatin resistant
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human ovarian cancer cells, and elevated c-Jun expression may induce increased levels of
GSH (760). Conflicting data on whether mitogen-activated protein kinase activation
enhances cisplatin-induced apoptosis or affords protection against cell death following
cisplatin treatment is also demonstrated by two studies in drug-resistant and sensitive
ovarian cancer cell lines; one study showed that exogenous expression of dominant
negative c-Jun or treatment with an inhibitor of MAPK (PD98059) caused increased
sensitivity to cisplatin (275), whereas the other study showed that expression of a dominant
negative c-Jun or use of a different MAPK inhibitor (SB202190, inhibitor of p38 kinase)
reduced apoptosis following cisplatin treatment (438).
The MAPK kinases JNK and p38 were shown to be regulated by the serine/threonine
kinase AKT2; constitutively active AKT2 renders cisplatin-sensitive A2780S ovarian cancer
cells resistant to cisplatin, whereas inhibition of AKT2 sensitizes A2780S and cisplatin-
resistant A2780CP cells to cisplatin-induced apoptosis through regulation of the
ASK1/JNK/p38 pathway (771). While AKT2 phosphorylates ASK1 resulting in inhibition of
its kinase activity, activated AKT2 blocked ASK1-mediated signaling, including activation of
JNK and p38 and the conversion of Bax to its active conformation. Moreover, inhibitors of
JNK and p38 or dominant negative forms of the proteins inhibited cisplatin-induced Bax
conformation change (771). Another member of the MAPK family, extracellular signal-
regulated protein kinase (ERK), also plays a role in cisplatin resistance as HeLa cell variants
selected for cisplatin resistance showed reduced activation of ERK following cisplatin
treatment, and ERK activation contributed to cell death in this cell type (732).
c-Fos, c-Myc
The activation of other proto-oncogenes may also confer drug resistance by
activating pro-survival pathways. For example, higher expression of the oncogene c-fos is
associated with cisplatin resistance both in vitro (354,369,619) and in the clinic (618), and a
reduction in c-fos expression can reverse cisplatin resistance (232,233,496,617). C-Fos, is a
nuclear transcription factor that induces transcription of a number of genes involved in the
regulation of cell replication, cell cycle progression, and differentiation through its
interactions with members of the c-Jun (described above) and ATF/CREB families to form
AP-1 transcription factor (108,186). AP-1 has also been linked to chemotherapeutic
resistance (760), and an adenovirus expressing a dominant negative inhibitor of AP-1 DNA
binding can sensitize cisplatin-resistant ovarian cancer cells (57). Fos RNA is induced
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following treatment with various DNA-damaging agents including cisplatin (293), and genes
whose expression levels are modulated by c-Fos/AP-1 and that may affect sensitivity to
cisplatin include genes involved in proliferation and apoptosis, metallothionein, DNA
polymerase j, and c-myc (186,233). Like AP-1, the expression of c-Myc protein is higher in
cisplatin resistant cells (354,518) and resistance can be reversed by c-myc down-regulation
(51,118,379,406). c-Myc is another transcription factor and it regulates the cell cycle by
modulating the expression of genes such as cyclin D1, cyclin A, and elF4E (150,624); c-
Myc, like c-fos, is induced following genotoxic insult including cisplatin damage (542,710)
and c-Myc may protect against cell death through the regulation of GSH levels (50,51) and
ornithine decarboxylase (ODC) induction (542)'. Protection against cisplatin by c-Myc was
shown to involve the pro-survival NF-KB transcription factor discussed in Section 1.3.4;
cisplatin activates NF-KB, which in turn induces c-Myc and results in reduced apoptosis
(542).
H-Ras
In addition to c-fos and c-myc, the oncogene H-ras has been implicated in playing a
role in cisplatin resistance. Ras protein is involved in the activation of the mitogen-activated
protein kinases, which have been shown to mediate cisplatin-induced apoptosis (see section
1.3.4 and above). Ras alleles are frequently mutated in cisplatin resistant tumors, whereas
tumors for which cisplatin exhibits the most effectiveness (i.e., testicular and ovarian tumors)
typically have a low frequency of mutated ras alleles (710). Similar to c-Fos, H-Ras can
increase expression of metallothionein and DNA polymerase P and increased ras
expression results in cisplatin resistance (323,354,619). While studies have associated
cisplatin resistance induced by h-Ras with increased repair (195,408), a recent study
showed that the NER protein ERCC1 is markedly up-regulated by activated H-Ras, and H-
Ras-mediated induction of ERCC1 is dependent on an increase in AP-1 transcriptional
activity; accordingly, ERCC1 small interfering RNA expression was shown to reduce the
oncogenic H-Ras-mediated increase in DNA repair activity as well as to suppress the
oncogenic H-Ras-mediated resistance of NIH3T3 cells to cisplatin (766). Although
* ODC is a critical enzyme in polyamine biosynthesis and intracellular polyamines
are essential for cell proliferation and differentiation; consequently ODC can protect cells
against cisplatin-, H202 -, and radiation-induced apoptosis (542).
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expression of activated H-Ras results in cisplatin resistance in human breast cancer and
mammary epithelial cells (195,408), a study of 16 human ovarian carcinoma cell lines, both
untreated cell lines as well as cell lines with acquired cisplatin resistance, showed that ras
overexpression or mutation did not correlate with cisplatin sensitivity (291).
The Bcl-2 family
The aforementioned signaling proteins and transcription factors mediate cisplatin
resistance by acting upstream of resistance mechanisms described previously. These
transcription factors can induce expression of intracellular thiols to inactivate the drug,
bypass polymerases for translesion synthesis past adducts, and DNA repair proteins to
increase removal of the adducts. However the proteins discussed above also regulate
downstream effectors of apoptosis, including caspase activation and the Bcl-2 family of pro-
and anti-apoptotic factors. For example, p53 activates transcription of the pro-apoptotic
protein Bax, whereas it suppresses transcription of Bcl-2, a factor that inhibits apoptosis
through its interaction with Bax (218,487,531). Bax is reduced in cisplatin resistant ovarian
cancer cells (554) and expression of Bax in MCF-7 breast cancer cells can sensitize the
cells to cisplatin (608). Alternatively, higher expression of pro-survival or anti-apoptotic
factors can confer drug resistance, and overexpression of Bcl-2 or Bcl-XL leads to cisplatin
resistance (170,171,189,235,281,485,486,555). Furthermore, the susceptibility of testicular
tumors cells to cisplatin may be due to the relative proportions of pro- versus anti-apoptotic
factors (e.g. Bax: Bcl-2 ratio) that favor apoptosis, with high levels of Bax and low levels of
Bcl-2 (111,430,439), although some reports indicate no correlation between endogenous
levels of Bcl-2 and Bax expression and cisplatin-induced apoptosis in TGCT cell lines
(84,85). Increased expression of another factor of apoptosis, X-linked inhibitor of apoptosis
protein (XIAP, Section....), a direct inhibitor of caspase-3, -7, and -9, was also associated
with cisplatin resistance in an ovarian resistant subline, alongside with reduced expression
of Fas-ligand, an inducer of apoptosis (439). Fas-ligand receptor-mediated apoptosis is
achieved through the Fas-associated death domain protein (FADD), and basal level of
FADD expression was shown to be higher in the cisplatin sensitive ovarian cancer cell line
A2780 compared to resistant subclones (281). Furthermore, cisplatin treatment induced
expression of FADD in the sensitive cells whereas it suppressed FADD expression in the
resistant clones (281).
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Based on the numerous studies on cisplatin resistance, it is clear that multiple factors
play a role in both intrinsic and acquired drug resistance. Cells may be inherently resistant
to cisplatin due to high repair capacity or a deficiency in triggering apoptosis in response to
DNA damage. Alternatively, cisplatin treatment may select cells that develop mechanisms
of resistance, such as mutations in signaling proteins (e.g., MMR proteins, p53, and p73)
resulting in an inability to induce apoptosis. Investigators continue to probe mechanisms of
resistance in order to understand how best to treat cancer and hopefully achieve the clinical
success observed with testicular germ cell cancer. However cisplatin resistance even
occurs, albeit with lower frequency, in TGCTs, and this resistance may be due to differential
thresholds of apoptosis and may be overcome by high doses of cisplatin-based
chemotherapy (502). To circumvent the limitation of resistance associated with cisplatin
therapy in the treatment of other cancers, new platinum derivatives have been developed. A
few of these compounds are discussed below.
1.5 Cisplatin analogs and second generation compounds
The major disadvantages of cisplatin-based therapies, namely dose-limiting toxicity
and clinical resistance, have inspired the development of new compounds that retain the
potent anticancer effects of cisplatin while circumventing such limitations. Over the past
three decades, thousands of platinum derivatives have been investigated for their ability to
overcome dose-limiting toxicity and drug resistance associated with cisplatin. Two prevalent
cisplatin analogues that have proved effective in cancer chemotherapy are carboplatin (cis-
diammine(cyclobutane-1 ,1 -dicarboxylato)-platinum(l I)) and oxaliplatin (1,2-
diaminecyclohexaneoxalato platinum (II)) (Fig. 1.6). Carboplatin exhibits reduced toxicity
but tumors resistant to cisplatin may be cross-resistant to carboplatin (402). However
compounds containing a 1,2-diaminocyclohexane (DACH) carrier ligand (e.g., oxalipatin) are
non-cross-resistant with cisplatin in cell lines with acquired cisplatin resistance and show
clinical activity in tumors intrinsically resistant to cisplatin (592). In addition, DACH
compounds such as oxaliplatin lack the nephrotoxicity of cisplatin and the myelosuppression
of carboplatin (480). The DACH structure is believed to result in the different spectrum of
clinical activity and toxicity of oxaliplatin compared to cisplatin and carboplatin, as the DACH
ligand forms bulkier and more hydrophobic DNA adducts. Indeed, the solution structure of
the oxaliplatin-GG adduct is significantly different from the cisplatin-GG intrastrand adduct
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(98). As a result of their different adduct structures, cisplatin and oxaliplatin adducts are
differentially processed by DNA metabolic proteins. For example, the major diguanyl
intrastrand crosslinks formed by cisplatin and oxaliplatin are differentially bypassed by
polymerases 3 and rq, with the oxaliplatin 1,2-d(GpG) adduct undergoing more efficient
translesion synthesis (with respect to both kinetics and fidelity) than the cisplatin 1,2-d(GpG)
adduct (98). The different adduct structures also result in differential recognition by cellular
proteins, including excision repair (536) and mismatch repair proteins (778). Such
differential cellular processing of the adducts leads to different mechanisms of resistance for
the two platinum drugs, and hence resistance mechanisms such as mismatch repair
deficiency and enhanced replication bypass have reproducibly been shown to discriminate
between cisplatin and oxaliplatin (99,435,708). In August 2002, the FDA approved
oxaliplatin for the treatment of recurring metastatic colon and rectum carcinomas, where the
drug has been shown to improve response rates and progression-free survival when given
with 5-fluorouracil.
To mimic the potency of the major 1,2-d(GpG) cisplatin adduct, second generation
platinum compounds are modeled on cisplatin and possess certain common characteristics.
For example, these compounds are "electroneutral" so that they may pass through non-
polar substances such as cell membranes. To form crosslinks, the compounds must also
have two good leaving groups (preferably in the cis conformation as the trans isomer of
cisplatin is clinically inactive). Additionally, inert carrier ligands, usually tertiary amine
groups, increase adduct stabilization through hydrogen bonding with nearby bases. Second
generation platinum compounds may also include modifications designed to circumvent the
resistance mechanisms associated with cisplatin. In addition to carboplatin and oxaliplatin,
numerous other platinum compounds have entered clinical trials during recent years. These
compounds include JM335 (trans-ammine (cyclohexylaminedichlorodihydroxo)
platinum(IV)), an active trans platinum complex, and AMD473 (previously ZD0473, cis-
amminedichloro(2-methylpyridine) platinum(ll)), a sterically hindered complex shown to be
less reactive towards thiol-containing molecules than cisplatin (289,290). JM335 exhibited
antitumor activity in vitro and reduced cross-resistance in tumor cell lines with acquired
cisplatin resistance (363,365). AMD473 also demonstrated low levels of cross-resistance
with cisplatin as well as a broad-spectrum of antitumor effects (289,292,365,472,582), and
this drug has undergone initial Phase I and Phase II clinical testing for various tumor types
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(219,240,241,347). Other platinum analogues that have undergone various levels of
preclinical and clinical testing include nedaplatin (cis-diammine-glycolato-0,0'platinum I,
254-S, CDGP), cycloplatam (ammine cyclopentylamine malato platinum (II)), SKI 2053 R
(methyl, isopropyl, dimethylamino, dioxelane malonato platinum (II)), satraplatin
(bis(acetato)amminedichloro(cyclohexylamine) platinum (IV), JM216, an orally bioavailable
platinum analog that shows activity in prostate cancer (664)), BBR3464 (a trinuclear
platinum agent exhibiting differential recognition and processing by cellular proteins
compared to cisplatin (64,356,357,467,780)), and the carboplatin analogue lobaplatin
(diamminomethyl cyclobutane lactate platinum 11, D-19466 (reviewed in (402,468)) (Fig. 1.6).
These compounds were designed to improve potency and organospecificity while reducing
the side effects of platinum-based chemotherapy.
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Chapter 2: DNA repair pathways that mediate sensitivity to
cisplatin: recombination and mismatch repair
2.1 Recombination pathways help cells tolerate cisplatin-induced
dama-ge
2.1.1 Recombination pathways in E. coli mediate sensitivity to cisplatin
It has long been established that NER is a major pathway for repairing cisplatin-DNA
adducts. However as early as 1973, Beck and Brubaker reported that a recA E. coli mutant
was significantly more sensitive to cisplatin damage compared to wild-type while recB and
recC mutants exhibited intermediate levels of sensitivity (33). Furthermore, their study
showed that a lexl mutant incapable of inducing recombinational repair was hypersensitive
to cisplatin, and the effect of a double mutation in LexA and NER (lexl uvrA6) was
cumulative. Husain et al. later also showed that in addition to NER, a RecA-dependent
pathway contributed to survival following cisplatin treatment (313). More recent evidence
supports an important role for recombination in tolerating cisplatin-induced damage.
The two major pathways of recombination in E. coli are depicted in Fig. 2.1 which is
based in part on models of S. West and J. Szostak ((680,742) and reviewed in Lusetti and
Cox (429)). The first pathway, daughter-strand gap (DSG) repair, involves the RecFOR
proteins and is employed when replication fork progression is blocked by DNA lesions. In
the DSG pathway (A in Fig. 2.1), persistent cisplatin-DNA adducts (perhaps due to poor
nucleotide excision repair of the 1,2 intrastrand crosslink) are encountered by the replication
complex (Step 1). Stalled replication results in the formation of a DSG opposite the adduct.
The presence of an adduct-binding protein (ABP) may present an even stronger block to
replication than the adduct alone. Interactions between the proteins of the RecFOR
pathway and the replication fork initiate RecA nucleation and strand exchange (Step 2). The
ensuing RecA-catalyzed strand exchange (with the aid of the RecFOR accessory proteins)
results in the formation of a Holliday junction (Step 3). Branch migration of the Holliday
junction catalyzed by RecA, RuvAB or RecG proteins results in the repair of the DSG and
restoration of the replication fork (Step 4). Resolution of the Holliday junction by RuvC
restores two double stranded DNA molecules (Step 5). The DSG pathway may serve as a
mechanism of damage tolerance because the cisplatin adduct is bypassed by
recombinational "repair" and persists in the DNA. The second recombination pathway,
double strand break (DSB) repair (B in Fig. 2.1), employs the RecBCD proteins. In the DSB
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pathway, the replication complex encounters an unrepaired DSG or a nick opposite the
adduct (Step 6). Collapse of the replication fork forms a DSB (bottom) and a DSG (top); the
DSG portion of the collapsed replication fork is processed by the DSG pathway (A). Other
mechanisms by which the DSB could arise include incisions made by DNA repair proteins
(e.g., MutH, MutY); if two adducts are in close proximity on opposite strands, abortive repair
activity may result in strand breakage. Alternatively, a single incision made by a DNA repair
protein and encountered by the replication complex could lead to replication fork collapse as
shown in Fig B Step 6. By the proposed scheme, repair of the DSB requires an intact
homologue of the damaged duplex, which would be present in E. coil if multiple replication
forks are operative (in mammalian cells, the sister chromatid could serve this role). The
RecBCD complex (pac-man object) binds the DSB free end (Step 7) and generates ss DNA
that is a substrate for RecA nucleation. RecA nucleoprotein filaments catalyze the invasion
of the RecBCD generated ss tail into the homologous duplex (Step 8). RecA catalyzed
strand exchange and branch migration results in the formation of a Holliday junction and
restoration of the replication fork (Step 9). Resolution of the Holliday junction by RuvC yields
two intact duplexes (only one molecule is shown; Step 10).
Recent results show that E. coli use both DSG and DSB recombination pathways to
defend against cisplatin treatment (779). While the formation of DSGs is consistent with
previous studies showing that cisplatin adducts inhibit DNA polymerases and cause frequent
replication blocks (80,123,266,333,475), the finding that cisplatin induces, in addition, lethal
DSBs had not been previously reported. The formation of DSBs has been confirmed
biochemically in the recent study described in Chapter 4 using neutral single-cell
electrophoresis and by work of Nowosielska and Marinus (522). These recent data thus
support the earlier genetic findings by Zdraveski et al. and provide direct evidence that
cisplatin-DNA damage leads to the formation of double-strand breaks, and thus as
Zdraveski et al. have shown, both DSG and DSB pathways of recombinational repair are
required in tolerating cisplatin-induced damage. Work by Courcelle et al. suggests that Rec
proteins may not be involved in recombination repair pathways per se but may be critical in
avoiding replication fork collapse and in promoting replication fork recovery in the face of
DNA damage (132-136). Courcelle et al. propose that RecA, rather than promoting
recombination to overcome DNA lesions, is required to maintain replication forks that are
blocked by DNA lesions until those lesions are removed by excision repair (135). In support
of this view, several studies have shown that Rec function-specifically the function of recA,
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recF, and recR genes-and nucleotide excision repair exhibit a synergistic effect on the
recovery of replication following UV irradiation, suggesting that both Rec proteins and
excision repair proteins are involved in a common pathway (132,133,136,234,601).
However recent work using a drug-induced recombination lacZ assay to directly visualize
recombination events shows that cisplatin induces recombination in a dose-dependent
manner (521,779), which is consistent with the DSB formation analysis showing that
cisplatin induces DSBs in a dose-dependent fashion. In addition, while recBC and recD
mutant cells recover replication while recF and recR mutants do not recover following UV
irradiation (132), both recBCD and recFOR mutants are highly sensitive to cisplatin damage,
implying that cisplatin damage requires additional Rec function than the replication recovery
function following UV irradiation. Taken together, the data summarized above show that
although nucleotide excision repair (NER) has been assigned the central role in modulating
the sensitivity of eukaryotic and prokaryotic cells to cisplatin, double-strand break repair by
recombination is equally as important as NER in determining cell survival following cisplatin
damage.
2.1.2 DSB repair and recombination in eukaryotic cells
Eukaryotic cells also possess several pathways to deal with DNA strand breaks. The
primary pathways for the repair of DSBs are homologous recombination (HR), single-strand
annealing (SSA), and nonhomologous end-joining (NHEJ), which are reviewed in detail
elsewhere (20)1,262,350,450,520,541,675). Unlike NHEJ, HR and SSA pathways require
homology. HR is the most conservative (i.e., the most error-free) pathway and is important
for the recovery of collapsed replication forks. In Saccharomyces cerevisiae, HR relies on
the RAD52 epistasis group of genes, which includes RAD50, RAD51 (encoding the E. coli
RecA homologue), RAD52, RAD54, RAD57, RAD59, MREI 11, and XRS2. Similarly,
numerous mammalian genes have been implicated in HR (based on their sequence
similarity to the yeast RAD52 epistatis group genes) and the mammalian genes include
Rad50, Rad51, Rad52, Rad54, Rad54B, and Mre11. Human cells express other Rad51-
related proteins including Rad51B, Rad51C, Rad51D, XRCC2 and XRCC3, and numerous
interactions among these Rad51 paralogs have been reported
(70,419,450,451,620,639,743); for example, both XRCC2 and XRCC3 interact with Rad51
and participate in DSB repair by HR (336,418,561). Like the E. coli paradigm, eukaryotic
recombination involves strand invasion, branch migration, and Holliday junction formation
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and resolution. Rad50, Mrel 1 (the E. coli SbcC and SbcD homologs respectively) and Xrs2
in yeast, and in humans the analogous proteins Rad50, Mrel 1, and Nbsl (or nibrin, the
protein defected in the ataxia telangiectasia-like disorder, Nijmegen breakage syndrome
(200)), otherwise known as the MRN complex, may process the termini of the DSB before
Rad51-mediated strand invasion. Rad51-mediated homologous pairing and joint molecule
formation is facilitated by Rad54 and RPA (328,559,639,640,711). The products of the
genes disrupted in the hereditary breast cancer syndromes, BRCA1 and BRCA2, also
interact with the Rad51 protein and are involved in human HR (45,466,498,500,626,630),
though the exact function of these proteins is still unclear. Holliday junctions or four-strand
intermediates arising from replication fork regression are resolved by the Mus81-
Emel/Mms4 heterodimer (1,117,125,469). In SSA, the ends of a DSB are digested by 5' to
3' exonucleases (perhaps by MRN) until regions of homology on the two sides of the break
are exposed. The homologous regions are annealed and the nonhomologous ends are
trimmed off and the duplex ends ligated. SSA may create deletions as well as expansions
between repetitive sequences and thus entail information loss (588,589). Several proteins
involved in DSB repair by HR also participate in SSA; these proteins include Rad52, RPA
and the Rad50/Mrel 1/Xrs2 protein complex in yeast or the MRN complex in human cells.
Digestion of the ssDNA tails may be achieved by Rad1/Rad10 in yeast and XPF-ERCC1
endonuclease in human cells. The third DSB repair pathway, NHEJ, is essential for V(D)J
(variable [division] joining) recombination and is mediated by DNA-PK. In NHEJ, the Ku
heterodimer binds to the ends of a DSB and activates DNA-PKcs and the DNA ligase
IV/XRCC4 (X-ray cross-complementing 4) heterodimer, which then ligates the two duplex
ends regardless of whether the two ends are from the same chromosome. Although NHEJ
was thought to be the major repair pathway for DSBs in mammalian cells, recent studies
have demonstrated that homology-directed repair is also a major DSB repair pathway, with
up to 50% of observed repair at a specific genomic locus occurring by recombination
(131,334,335,412). Furthermore, homologous recombination is stimulated 2-3 fold by a
chromosomal DSB (335,499). The relative contributions of HR versus NHEJ may be cell-
cycle dependent, as HR was shown to be the predominant recombination pathway in human
cells in S phase but not in M or G 1/Go phases of the cell cycle (609). Interestingly, NHEJ
and homologous repair were shown to both participate in the repair of a single DSB,
indicating that the two pathways are not completely separable (590).
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Following treatment with DNA damaging agents such as ionizing radiation, alkylating
agents and cisplatin, Rad51 forms discrete nuclear foci that are believed to be the sites of
DNA damage and DSBs (52,247). Homologous recombination requires the recombinase
RAD51 and in vertebrate cells, all five RAD51 paralogs. The paralogs form two complexes in
solution, a XRCC3/RAD51 C heterodimer and a RAD51 B/RAD51 C/RAD51 D/XRCC2
heterotetramer (419,450,451,620,743). Disruption of any one of the five paralog genes
prevents subnuclear assembly of the Rad51 recombinase at damaged sites and renders
cells 30-100 fold more sensitive to DNA cross-linking agents including cisplatin
(52,246,418,682,683). Regulation of Rad51 may be achieved in part by the c-Abl tyrosine
kinase, which interacts constitutively with Rad51 and which phosphorylates Rad51 on Tyr-
54 in vitro (769). Furthermore, treatment of cells with ionizing radiation induces c-Abl-
dependent phosphorylation of Rad51, although studies have revealed conflicting roles for
this event. One study, for example, showed that c-Abl phosphorylation of Rad51 serves to
negatively regulate Rad51 as it inhibits Rad51 DNA binding as well as Rad51-catalyzed
strand exchange (769). By contrast, other studies have shown that c-Abl phosphorylation of
Rad51 (via formation of a complex with ATM) promotes interaction between Rad51 and
Rad52 and is required for IR-induced Rad51 foci formation (103,768).
Like in E. coil, recombination in eukaryotic cells protects against cisplatin-induced
damage. S. cerevisiae deficient in RAD51 and RAD52 are more sensitive to cisplatin
compared to wild-type cells, and importantly rad51l cells are much more sensitive to
cisplatin than to UV (259), suggesting that cisplatin repair requires RAD51 function in
recombination. In addition, overexpression of the Rad51 paralog Xrcc3 in MCF-7 cells leads
to a 2-6-fold increase in cisplatin resistance. This resistance is accompanied by a 2-fold
increase in drug-induced Rad51 foci, an increase in cisplatin-induced S-phase arrest, and
decreased cisplatin-induced apoptosis (755). Furthermore, Xrcc3 overexpression is
associated with increased Rad51C protein levels, which is consistent with the known
interaction of these two proteins (450,451). Along the same lines, an inhibitory synthetic
peptide specific for Rad51C inhibits assembly of the Rad51 recombinase and sensitizes
CHO cells to cisplatin when it is added to growth medium (124). Another protein involved in
DSB repair, the Brcal protein, was shown to promote subnuclear Rad51 foci formation
following cisplatin treatment, and Brcal(-I-) mutants are 5-fold more sensitive to cisplatin
compared with wild-type cells (45). Interestingly, Rad51 and the TFIIH subunit XPD
involved in NER may cooperate to tolerate cisplatin damage via recombination repair.
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Overexpression of XPD was shown to result in cisplatin resistance, which was associated
with increased Rad51-related homologous recombination and increased sister chromatid
exchanges whereas no change in NER activity was observed (9). Furthermore, XPD and
Rad51 colocalize and coimmunoprecipitate in a human glioma cell line (9). Rad51 is also
important for cisplatin resistance in cells expressing the BCR/ABL oncogenic tyrosine
kinase, which is a fusion tyrosine kinase (FTK) that arises from reciprocal chromosomal
translocations (see Skorski (649,650) for a review on BCR/ABL). FTK-transformed cells
display cisplatin resistance as well as increased expression of Rad51, which is dependent
on STAT5-dependent transcription and inhibition of caspase-3-dependent cleavage
(652,653). In addition, phosphorylation of Rad51 by BCR/ABL is required for enhanced
DSB repair and cisplatin resistance. Importantly, cisplatin-induces DSBs in HI-60 cells that
are independent of the DNA fragmentation associated with apoptosis (309). Thus
recombination mechanisms, in both prokaryotic and mammalian models, help cells tolerate
cisplatin-induced damage.
2.2 Mismatch repair mediates cisplatin-induced toxicity
Mismatch repair proteins act on nucleotide mismatches as well as insertion-deletion
loops. These proteins are also important for the recognition of homeologous (similar but
nonidentical) DNA sequences and can prevent the recombination of two DNA molecules
when the sequences exhibit non-homology. Although MMR is critical in maintaining
genomic integrity, this pathway paradoxically sensitizes cells to DNA damage by alkylating
agents and cisplatin. The possible mechanisms of MMR-mediated sensitivity to cisplatin in
both bacterial and mammalian cells are discussed below.
2.2.1 The E. coli paradigm of mismatch repair
Methyl-directed mismatch repair in mutation avoidance
During DNA replication, the DNA pol III holoenzyme, its proofreading activity, and the
aid of accessory proteins such as ssb result in a cumulative error frequency of - 10-7 (226).
The correction of these misincorporation errors requires post-replicative mismatch repair
(Fig. 2.2). Mismatch repair discriminates between template and the newly synthesized
daughter strands by the methylation status of d(GATC) sites; in E. coli, the DNA adenine
methyltransferase (Dam) protein methylates the N6 position of adenine in the sequence
d(GATC). While the number of Dam molecules is only -130 per cell (62), the enzyme
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cannot keep pace with the replication fork and consequently the duplex is transiently
hemimethylated, thus allowing MMR to distinguish template (methylated) from daughter
(unmethylated) strands. MMR is initiated by recognition of a distorted structure arising from
mismatched bases; this recognition requires the MutS homodimer, in which the two
monomer subunits hold different conformations and form a structural heterodimer
(267,397,670). Following MutS binding to the mismatch and ADP to ATP exchange, a
MutS/MutL complex is formed and in a process that has still not entirely been elucidated, the
complex translocates along DNA (2,8) and forms a tertianary complex with the latent
endonuclease MutH. MutL activates MutH in an ATP-dependent reaction (20,257,263) and
activated MutH makes an incision 5' to the dG of an unmethylated d(GATC) site located
either 5' or 3' to the mismatch (256,490). Incision on the unmethylated strand may occur
several kilobases from the mismatch (669,722), and hence MMR is also referred to as long-
patch repair. DNA unwinding from the incision site to a point beyond the mismatch error is
achieved by helicase II (UvrD) (151,757), and DNA is chewed from the incision site back to
the site of the mismatch by one of several exonucleases depending on the directionality of
the reaction (e.g., Exo VII or RecJ for 5' to 3', and Exo I, Exo X, or Exo VII for 3' to 5'
activity). In the presence of ssDNA-binding protein, DNA polymerase III holoenzyme
performs DNA resynthesis and DNA ligase finally seals the nick. The Dam protein then
methylates the new strand, completing the MMR reaction.
Mutation avoidance by E. coli mismatch repair, as it is described above and reviewed
elsewhere in detail (267,394,490,491), relies on hemi-adenine methylation to distinguish
between the nascent strand containing the error and the template strand. Indeed, both
reduced expression and overexpression of Dam result in hypermutability in E. coil
(282,447,759). Of relevance to the models of MMR-mediated sensitivity to DNA damaging
agents described below, in the case where Dam is absent and the genome is unmethylated
at d(GATC) sites, MutH cannot distinguish between the new and template strands. In vitro
experiments show that in this situation MutH aimlessly makes an incision on either strand,
although the endonuclease shows reduced activity on unmethylated compared to
hemimethylated substrates (20,740). Furthermore, Au et al. (20) have shown in a
reconstituted in vitro system that in the absence of d(GATC) methylation MutH can make
incisions on both DNA strands and form a double-strand break (DSB). When both strands
are methylated, the duplex is resistant to MutH incision. Interestingly, preexisting internal
nicks can substitute for MutH function in vitro (395), which sheds light on how eukaryotic
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MMR, for which there is no known MutH homologue, may discriminate between template
and daughter strands.
Anti-recombination function of mismatch repair
In addition to recognizing and correcting post-replicative mismatches, MMR also
recognizes mismatches between two DNA molecules undergoing recombination and can
abort recombination mid-reaction. In this way, MMR prevents recombination between
divergent DNA sequences and performs "anti-recombination", and even low divergence (1 %
or less) can substantially inhibit homologous recombination in bacteria, yeast, and
mammalian cells (152,153,158,720,772,773). Several early studies in E. coli showed that
mutants deficient in MMR exhibit increased frequencies of intragenic recombination
(204,791), and in conjugational crosses between E. coli and Salmonella typhimurium, the
genomes of which exhibit -16% sequence divergence, elimination of the recipient MMR
system was associated with up to a 1000-fold increase in conjugational recombination
frequencies (583). Radman (578) suggested that MMR may serve in anti-recombination to
ensure the fidelity of recombination events. According to Radman's proposal, mismatches
in regions of heteroduplex lead to MMR-dependent excision of the invading strand within a
recombination intermediate, resulting in abortion of the strand-exchange reaction. More
recent work has demonstrated that the inactivation of MMR leads to a -6-fold increase in the
frequency of intergenic recombination exchanges (398), and biochemical studies using the
closely related bacteriophages M13 and fd show that MutS and MutL block RecA-catalyzed
strand transfer of M13-fd but not of M13-M13 (homologous) DNA substrates (748,749).
Stambuk and Radman proposed two models of MMR-mediated anti-recombination: a
MutH-independent mechanism involving an abortion of the recombination reaction that
requires free ends and the UvrD helicase, and a MutH-dependent pathway requiring
unmethylated d(GATC) sites and de novo DNA synthesis (662) (Fig. 2.3). In their study of
interspecies recombination between the linear Hfr DNA from Salmonella typhimurium and
the E. coli circular chromosome, recombination between these two divergent (16% on
average) sequences involved DNA synthesis requiring the PriA primosome and RecF
functions. This DNA synthesis may be promoted by the inherent instability of the
heteroduplex and may provide the unmethylated d(GATC) sites required for the MutH-
dependent pathway of anti-recombination; recombination-dependent DNA replication also
occurs following DNA damage in E. coli (383-385), making the MutH-dependent pathway
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relevant for damaged recombination substrates. This MutH-dependent pathway occurs
relatively late-stage in the recombination reaction, following DNA synthesis, and also
requires MutS and MutL in addition to PriA and RecF. During this late-stage
antirecombination, editing occurs on the DNA strand that contains the mismatch in the
heteroduplex region derived from the parental sequences, and MutH incision occurs at an
unmethylated d(GATC) site in the newly synthesized extension of the mismatch-containing
strand (Fig. 2.3B). Unwinding and excision from the unmethylated d(GATC) site to the
Holliday junction would interrupt recombination and separate the two parental DNA
molecules. The MutH-independent pathway of anti-recombination corresponds to the
dissociation of the earliest RecA-catalyzed heteroduplex due to mismatch formation, and
hence it is an early-stage editing pathway of the recombination substrates. This early-stage
pathway requires MutS, MutL, the UvrD helicase, and RecBCD nuclease for the digestion of
the dissociated single-stranded end and may occur prior to the initiation of DNA synthesis
(Fig. 9A).
Mismatch repair in cisplatin sensitivity
It was originally established by Fram et al. (224) that mismatch repair proteins
potently sensitize cells to specific DNA damaging agents including cisplatin; E. coli dam
mutant strains, which have decreased adenine methylase activity and are thus unable to
distinguish between parental and newly synthesized DNA strands, are hypersensitive to
cisplatin. However dam mutants with an additional mutation in any of the mismatch repair
genes mutS mutL, or mutH show reduced sensitivity and near wild-type levels of resistance
(224,522). Unlike cisplatin, the therapeutically inactive platinum compound, transplatin,
does not elicit differential sensitivity in E. coli dam- and wild-type strains.
The effect of MMR on cisplatin sensitivity is most likely direct, as MutS recognizes
cisplatin-DNA lesions in vitro ((778) and Chapter 4). One prevalent model to explain the
influence of MMR on cellular sensitivity to DNA damage is the futile repair model. Futile
cycling was originally proposed to explain the effect of MMR on cellular sensitivity to
methylating agents (351) and has been extended to explain MMR effects on cisplatin
sensitivity (a discussion of this model is also presented in Chapter 4). According to this
model, MMR initiates repair on the strand opposite the adduct. While the adduct remains
following repair synthesis, another cycle of repair is initiated, again on the strand opposite
the adduct. Because the adduct is not removed in these repair cycles, the continual and
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"futile" repair results in a persistent strand gap, and if encountered by a replication fork this
single-strand gap may be converted to a lethal double-strand break (Fig. 5.10). Futile
cycling may be more prevalent in cells lacking adenine methylation because of the
increased level of MutH substrates (i.e., unmethylated d(GATC) sites). Thus in a Dam-
deficient cell, MMR recognition of a cisplatin adduct may result in MutH incision and
digestion of either strand, and coupled with replication such repair activity may lead to a
double-strand break. Furthermore, in Dam-deficient cells MutH may introduce nicks on both
strands, thus forming a double-strand break independent of replication.
An alternative model to futile cycling is MMR-mediated inhibition of recombinational
bypass of cisplatin adducts. According to this model, MMR, serving its role in anti-
recombination, may recognize cisplatin adducts as heterologies within a recombination
intermediate and may abort the recombination reaction. Recent work by Calmann and
Marinus show that in vitro MutS blocks RecA-catalyzed strand exchange of two
recombination substrates when one substrate is modified with cisplatin (90). While the
inhibitory effects of MutS were not enhanced by the addition of MutL, the lack of an
observed effect of MutL may have been the result of low "divergence" generated by 4-8
adducts versus the high level of divergency (e.g., close to 200 mismatches) in previous
studies demonstrating a role of MutL in anti-recombination (749). While MMR-mediated
anti-recombination is expected to occur in both Dam-proficient and-deficient cells, the
effects of anti-recombination may be more detrimental to cells lacking Dam due to the
decreased availability of recombination proteins in these cells; because of the high level of
endogenous damage in dam mutant cells ((731) and Chapter 3), recombinational proteins in
these cells may be operating close to maximal capacity. Thus the cells cannot afford any
further damage burden, and inhibition of recombinational repair of cisplatin adducts confers
such additional damage burden. This model is discussed in more detail in Chapter 4.
Both models of MMR-mediated sensitivity to cisplatin-futile cycling and inhibition of
recombination-are consistent with genetic data showing that in dam mutant cells, an
additional mutation in mutS, mutL, or mutH abrogates sensitivity to drug. The futile cycling
model requires the complete MMR repair reaction involving MutS recognition and MutH
incision, and thus mutations in each of the MMR mut genes is expected to abrogate
sensitivity. Inhibition of recombination, if occurring by the late-stage model proposed by
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Stambuk and Radman, also requires MutH function*. Furthermore, both futile repair and
anti-recombination models support the hypothesis that MMR leads to strand break formation
following cisplatin damage; in futile cycling, MMR may be introducing single nicks after
recognition of cisplatin adducts in an attempt to initiate repair. These single nicks may be
converted to lethal DSBs if encountered by a replication fork. In anti-recombination, MutS
binding to a cisplatin adduct may prevent recombinational bypass of the adduct and
consequently lead to strand break formation. Additionally, strand break formation occurring
by either mechanism would be increased in a Dam-deficient background, as MutH incisions
require unmethylated d(GATC) sites and as the high level of basal damage in dam mutants
renders these cells more susceptible to the effects of anti-recombination.
2.2.2 Mismatch repair in mammalian cells
Since the initial discovery in E. coil, it has been shown in numerous studies that
mammalian cells deficient in mismatch repair also exhibit increased survival and tolerance to
drug treatment (3,4,177,213,251,497,512,540,567,751). Although the influence of MMR on
sensitivity to DNA-damaging agents is more pronounced for alkylating agents than it is for
cisplatin damage in in vitro systems (up to 100-fold versus -2-fold) (4,46,47,311,685), the
level of cisplatin resistance afforded by MMR deficiency is sufficient to produce a large
difference in drug responsiveness in vivo in tumor model systems (13,212,216). The
available preclinical and clinical data also suggest that tumors with a significant fraction of
MMR-deficient cells will exhibit reduced responsiveness to specific drugs including cisplatin
(4,212,441,568). The importance of acquired drug resistance by loss of MMR is
underscored by studies demonstrating that treatment with cisplatin can lead to an
enrichment of MMR-deficient, and thus drug-resistant, cells in vitro and in tumor xenograft
models (214,215). Furthermore, paired ovarian tumor samples from patients before and
after platinum-based chemotherapy showed a reduction in MLH1 staining in 66% of the
cases (215), thus demonstrating a model of acquired clinical resistance whereby drug
treatment selects for MMR-deficient and consequently drug-resistant cells.
Eukaryotic homologs to E. coil MMR proteins
' This late-stage anti-recombination model also requires PriA function. Interestingly, PriA is
required for replication restart following the stalling of the fork at sites of DNA lesions (139,614) and
for recombinational bypass of cisplatin adducts (521), and consequently priA mutant E. coli are
hypersensitive to cisplatin treatment (522).
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Eukaryotic mismatch repair is functionally homologous to the E. coil MMR system,
and the yeast and mammalian homologs to the MutS and MutL proteins are shown in Table
2.1. While there are no identified MutH homologs to date, eukaryotic MMR is not thought to
be methyl-directed as in E. coli. Different mechanisms have been proposed for strand
discrimination in eukaryotes. These mechanisms include nick-directed repair
(198,296,489,684), where the nicks at the 5' and 3' ends of Okazaki fragments during
lagging strand synthesis and the growing 3' end of the leading strand provide the strand
discrimination signals. Interestingly, the human MSH2-MSH6 complex translocates away
from the mismatch in an ATP-dependent manner in vitro (253) and the human pathway of
mismatch correction may possess a bidirectional excision capability similar to that of E. coil
(198). In addition, while human MSH2, MLH1, and PMS2 interact with proliferating cell
nuclear antigen (PCNA) and while PCNA is required for the repair initiation step of MMR
(260,489,703), it has been proposed that PCNA might confer information on daughter vs.
template strands to the MMR machinery based on the position of the replication complex.
Alternatively, PCNA might trigger the 3' to 5' exonuclease activities of DNA polymerases in
mismatch removal (253). The final stage of MMR, repair synthesis, may be achieved
primarily by DNA polymerase 6 in human cells (425).
Table 2.1: Eukarytoic homologs to the E. coli MutS and MutL proteins*
Organisms Eukaryotic protein function
E. coli Yeast Mammals
MutS MSH1 --nd--- Mutation avoidance in mitochondria
MSH2 MSH2 Forms heterodimers with MSH6 (to form MutSo) and
MSH3 (to form MutSP) to repair replication errors,
recognize mismatches in recombination intermediates,
remove nonhomologous tails (MutS only), inhibit
recombination between heterologous sequences, and in
mammals participates in DNA damage-induced signaling
MSH3 MSH3 Forms complex with MSH2 to form MutSP; repairs small
insertion/deletion mismatches
MSH4 MSH4 Forms heterodimer with MSH5 to promote crossing-over
in meiosis
MSH5 MSH5 Forms heterodimer with MSH4 to promote crossing-over
in meiosis
MSH6 MSH6 Forms complex with MSH2 to form MutSo; repairs both
base-base and insertion/deletion mismatches
MutL PSM1 PSM2 Forms heterodimers with MLH1 to repair replication
errors and mismatches in recombination intermediates,
inhibits recombination between heterologous sequences,
________ ______ __________ and in mammals participates in DNA damage-induced
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signaling
MLH1 MLH1 Forms heterodimers with the other MutL homologs
MLH2 PMS1 Forms heterodimers with MLH1 to repair replication
errors and mismatches in recombination intermediates
MLH3 MLH3 Forms heterodimers with MLH1 to repair replication
errors and to promote crossing-over in meiosis
*Adapted from Harfe and Jinks-Robertson (267). nd, not determined
Eukaryotic MMR in mutation avoidance and in anti-recombination
The importance of mammalian MMR in mutation avoidance is underscored by
studies demonstrating that mutations in the MutS and MutL homologs may be linked to
tumorigenesis. For example, mouse knockouts of MSH2, MSH3, MSH6, PMS1, PMS2, and
MLH1 have all been constructed, and all, with the exception of PMS1 and MSH3 knockouts,
show an increased incidence of various types of internal organ tumors
(22,158,159,185,577). In addition, MMR is linked to tumorigenesis in humans, as mutations
in human MLH1 and MSH2 are associated with 60% and 70% respectively of the cases of
hereditary non-polyposis colon cancer (HNPCC) (reviewed in Buermayer (82)), and
individuals heterozygous for MLH1 are predisposed to HNPCC as loss of heterozygosity
(i.e., loss of function of the wild-type, functional allele) results in highly elevated mutation
rates and subsequent tumor development (278). Although MMR deficiency is associated
with a reduced ability to trigger apoptosis as well as with hypermutability, Lin et al. recently
demonstrated that an Msh2G67 4A mutation in mice caused DNA repair deficiency that
resulted in a strong cancer predisposition while it did not affect the DNA damage response
function of Msh2 (413).
Like in E. coli, MMR in eukaryotes recognizes mismatches in recombination
intermediates. Such mismatch recognition may trigger either mismatch correction or
complete abortion of the recombination event (678). The repair of mismatches in
recombination intermediates results in gene conversion, whereby information on one
chromosome is replaced with information from the homologous chromosome ((191,268,680)
and reviewed in 1025, 1026, 1027, 1008, 1031}). Studies in yeast have supported a role of
MMR in limiting heteroduplex formation (via blockage or reversal of strand-exchange) in a
mismatch-dependent manner (104,105,511,516,679). Furthermore, MMR was also shown
to inhibit single-strand annealing between non-homologous sequences in yeast (671,672).
Although few studies have examined the role of MMR in anti-recombination in mammalian
cells, the data available suggest that recombination between divergent sequences is
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increased in MMR-deficient cells (190,718), although according to one study the effects of
MMR are only observed for spontaneous recombination as the efficiency of double-strand
break-induced recombination was not affected by sequence divergence in mismatch repair
proficient or deficient backgrounds (718).
Roles of mammalian MMR in mediating cisplatin sensitivity
As mentioned previously, the presence of an intact MMR system in mammalian cells
confers sensitivity to cisplatin, as is observed with E. coil. Like the E. coil MutS damage
recognition protein, the mammalian MutS homologs bind cisplatin-modified DNA in vitro.
Human MutSa specifically recognizes the major 1,2-instrastrand crosslink but fails to
recognize the major 1,3-intrastrand crosslink produced by tansplatin (179,473), and thus
MutS recognition of the different adducts correlates with the toxicity profile of the agents as
transplatin is clinically inactive (see Chapter 1, Section 1.2). MutScX binding to cisplatin-
DNA adducts is enhanced when the complementary strand contains T opposite the 3' and C
opposite the 5' guanine in the crosslink while binding to an adduct opposite correct bases is
much lower (756), suggesting that replicative bypass may enhance MutSuo interactions with
cisplatin adducts. Importantly, however, Duckett et al. showed that the major 1,2-d(GpG)
adduct effectively competes with a G:T mismatch substrate for human MutS(o binding in
vitro, with the binding constant for the cisplatin crosslink estimated to be about an order of
magnitude less than the binding constant for the G:T mismatch (179). Such binding affinity
of MutSoa for the major cisplatin crosslink is consistent with a significant effect in vivo and is
of particular significance as human MSH2 is highly expressed in testis and ovary (473);
cancers arising in these organs are the cancers best treated by cisplatin therapy. Thus the
two models of MMR-mediated sensitivity in E. co/i-futile cycling and the inhibition of
recombinational bypass of cisplatin adducts-are also applicable in mammalian cells. The
mammalian MutS homologs may recognize a cisplatin adduct and initiate repair; if repair is
initiated on the strand opposite the adduct, the lesion remains leading to additional cycles of
repair and a persistent strand gap, which may in turn lead to more lethal DNA damage and
cell death. This model, as mentioned above, has been proposed for alkylation damage,
where sensitivity to methylating agents such as N-methyl-N'-nitro-N-nitrosoguanidine
(MNNG) and N-methyl-N-nitrosourea (MNU) is abrogated in cells deficient in MMR
(47,67,97,250,311,359). Interestingly, cytotoxicity and steady-state chain elongation assays
indicate that hMLH1 or hMSH6 defects result in 1.5-4.8-fold increased cisplatin resistance
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and 2.5-6-fold increased replicative bypass of cisplatin adducts (708). Thus defects in
hMutLo and hMutSx may contribute to increased net replicative bypass of cisplatin adducts
and therefore to drug resistance by preventing futile cycles of translesion synthesis and
mismatch correction. Supporting this hypothesis is the finding that extracts from cells
lacking hMLH1 and hMSH2 showed -3-fold reduction in cisplatin damage-specific DNA
synthesis (207). While MMR status had no effect on NER activity, such MMR-dependent
repair synthesis may reflect a reduction in DNA synthesis associated with adverse
processes (egg., futile cycling) rather than productive repair activity. In addition, while
mammalian MMR, like E. coli MMR, also serves to monitor recombination events and to
prevent recombination between divergent DNA sequences, it may also prevent the
recombinational bypass of cisplatin adducts. The aforementioned study showing that
hMLH1 or hMSH6 defects result in 1.5-4.8-fold increased cisplatin resistance and 2.5-6-fold
increased replicative bypass of cisplatin adducts is also consistent with the notion that MMR
may prevent the recombinational bypass of cisplatin adducts during replication.
Although the futile repair and anti-recombination hypotheses are operable in
mammalian cells, recent data suggests that MMR in mammalian cells may serve as a
"sensor" of DNA damage (217,666). In support of this view, the human mismatch repair
proteins MSH2, MSH6, and MLH1 were found to be associated with other DNA damage
response proteins, including BRCA1, ATM, BLM, and the RAD50-MRE1 1-NBS1 protein
complex, to form a DNA damage surveillance complex (736). Furthermore, cisplatin is
reported to activate signaling kinases such as the c-Jun NH2-terminal kinase (JNK/stress-
activated protein kinase) (512,513) and c-Abl tyrosine kinase (251,637) in a MMR-
dependent manner (refer to Chapter 1, Section 1.3.4 for a detailed discussion of MMR-
mediated apoptosis in response to cisplatin). Thus while MMR may serve upstream in DNA
damage signaling, conferring signals of damage level to effectors in apoptosis, the effects of
MMR deficiency in cisplatin toxicity may also be linked to an inability to trigger apoptosis in
mammalian cells.
Taken together, the results on MMR and recombination show that recombination is a
critical means for tolerating cisplatin-induced damage and that MMR, acting either by futile
cycling or by an abortive repair mechanism, enhances the cytotoxic effects of cisplatin.
However further work is required to determine if MMR is acting primarily as a block to
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recombinational repair or as an enzymatic pathway leading to the production of additional
strand breaks.
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Chapter 3: Materials and methods
3.1 Bacterial strains
The strains used in this study are derivatives of AB1 157 and the complete genotypes
are listed in Table 3.1. We used the dam-16::Kan strain (GM3819) which carries a deletion
of a large part of the dam gene. The auxotrophic phenotype of each mutant used in this
work was confirmed by growth on the appropriate supplemented minimal medium. The
strains used for the sulA::lacZ reporter assay are lambda ind sulA::lacZ lysogens of AB1157
(GM4352), GM3819 (GM4355) and GM5556 (GM5878).
The dam mutH mutant strain was constructed by P1 transduction. Briefly, the Tn10
marker, which encodes TetR_N and TetR_C, was amplified from GM5555 genomic DNA
using the primers; 5' - CAC TTG TCG GGC TGG TTA CGC CAG AGA ATT TAA AAC GCG
ATA AAG CTC GAC ATC TTG GTT ACC GTG AAG - 3' and 5' - ATG GCT TCG GTA AGC
GCT TTC GCA TTC GCT GCT TTC GGT CGT ATC CGC GGA ATA ACA TCA TTT GGT
GAC - 3'. These primers contain 24 bases at their 3' ends to anneal to Tn10 for PCR
amplification, and 45 bases at the 5' end to target the resulting PCR fragment for
recombination with the mutH gene (see below). The 2 kb product, identified by separating a
fraction of the reaction products on a 1% agarose gel, was purified using the QlAquick PCR
Purification kit. This DNA fragment was used for mutH gene replacement in KM22 cells as
previously described by Murphy et al. (507) and as described briefly below.
KM22 cells (obtained from M. Marinus, UMass Worcester) were prepared for
transformation by diluting 100 pL of an overnight culture in 10 mL LB plus 1 mM IPTG,
growing (37°C, 250 rpm) until OD 600 = 0.6, washing the cells twice with 15 mL cold water,
and resuspending the final cell pellet in 75 pL 1 mM MOPS/20% glycerol. Approximately
100 p L of cells and 500 ng of DNA was combined in a chilled electroporation cuvette and a
2.5 kV pulse at 129 Ohms was applied using a Electro Cell Manipulator 600 electroporation
system (Bantex). Immediately after electroporation, cells were transferred to a culture tube
containing 3 mL LB and 1 mM IPTG and grown at 37°C as above. After three hours, cells
were harvested by centrifugation, resuspended in 100 pL LB, plated on LB containing 4
pg/mL Tetracycline, and incubated over night at 37°C. The next day, successful
transductants were picked and grown over night in liquid culture with 12 pg/mL Tetracycline.
Cultures were then analyzed individually for the correct genotype by performing PCR using
primers to amplify mutH. The primers used for mutH analysis were 5'- ATG TCC CAA CCT
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CGC CCA CT -3' and 5'- ACT GGC CCG TCA TTT TCT GAT CCA GTA G -3'. Because the
45 base sequences used to target the Tn10 insertion were located 100 bases from each end
of the mutH gene (690 bp), insertion of Tn10 into mutH would replace the central 400 bases
of mutH with -2 kb. Therefore the mutH insertion deletion product would have an expected
size of -2.2 kb. Gel analysis on a fraction of the PCR products from all transformants
analyzed showed a -2.2 kb fragment, confirming insertion of Tn10. The KM22 mutH::Tn10O
allele was then used to construct the mutH derivative of GM3819 by P1 transduction,
essentially as described by Miller.
TABLE 3.1 Genotypes of E. coli K-12 strains used in this study
Strain Genotype Source
AB1157 F- thr-I araC14 leuB6(Am)A (gpt-proA)62 lacYl tsx-33 DeWitt and
supE44(AS) galK2(0c) hisG4(0c) rfbD1 mgl-51
rpoS396(Am) rpsL31(StrR) kdgK51 xylA5 mtl-I argE3(0c)
thi-1
GM3819 dam-16::Kan thr-1 leuB6 thi-I argE3 hisG4 proA2 lacYl Parker and
galK2 mtl-1 xyl-5 ara-14 rpsL31 tsx-33 supE44 rfbD1 Marinus (543)
kdgK51
GM5555 As AB1157 but mutS215::Tn 10 Lab. stock
GM5556 As GM3819 dam-16::Kan but mutS215::TnlO10 Lab. stock
As GM3819 dam-16::Kan but mutH::Tn10 This work (P.
Rye)
3.2 Chemicals
Cisplatin was obtained from Sigma-Aldrich and dissolved in ddH20 at 37°C. The
concentration of drug was determined by UV/Visible scan (165,417,737). The chemicals
used as part of the Affymetrix GeneChip protocol were obtained from the suggested
vendors.
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3.3 Cytotoxicity Analysis
Overnight cultures were diluted 1000-fold and grown in Luria-Bertani medium until
the cells reached exponential growth as determined by OD600. The exponentially growing
cells were resuspended in M9 minimal medium at a cell density of 2 X 108 cells/ml and
treated with drug at the indicated doses for 2 hours at 37°C. Following treatment
appropriate dilutions in M9 medium were plated on LB plates and incubated at 37°C until
visible colonies could be counted. Results from three independent experiments plated in
duplicate were averaged and plotted against drug concentration, +SEM (standard error of
the mean).
3.4 Array analysis
3.4.1 RNA preparation
Total RNA isolation and purification
Overnight cultures were diluted 1000-fold with fresh LB medium and cultured further.
Log phase cultures were diluted to a cell density of 2 X 108 cells/ml in M9 salts and
incubated at 37°C for two hours with or without drug, after which they were resuspended in
LB broth for 90 minutes. OD600 were measured and total RNA was isolated from cells by
extraction using the MasterPure RNA Purification Kit (Epicentre Technologies) followed by
DNAse digestion according to the manufacturer's protocol. The isolated total RNA was
quantitated by absorption at 260 nm (typical yield from a 15 ml culture was 250-500 pg of
total RNA), and the purity was determined by the ratio of absorption values at 260/280nm.
RNA quality was determined by formaldehyde agarose gel electrophoresis (1.2% agarose in
FA Buffer pH 7.0 (20 mM 3-[N-morpholino]propanesulfonic acid, 5 mM sodium acetate, 1
mM ethylenediaminetetraacetic acid (EDTA))) or by analysis on an Agilent 2100
Bioanalyzer. All samples visualized by gel electrophoresis or by the bioanalyzer
electropherogram showed clear distinct bands correlating to 16S and 23S ribosomal RNA,
indicating that no detectable RNA degradation occurred and that RNA integrity was
maintained throughout the RNA isolation procedure (data not shown).
mRNA enrichment, fragmentation, and labeling for arrays
mRNA was enriched from total RNA as described in the Affymetrix GeneChip
Expression Analysis Technical Manual for GeneChip E. coli Sense Genome Arrays. In
brief, reverse transcriptase and primers specific to 16S and 23S rRNA were used to
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synthesize complementary cDNAs. Then rRNA was removed by treatment with RNase H
(Epicentre Technologies), which specifically digests RNA within an RNA:DNA hybrid. The
cDNA molecules were removed by DNase I (Amersham Biosciences) digestion and the
enriched mRNA was purified on Qiagen RNeasy columns according to the manufacturer's
protocol. Enriched mRNA was then fragmented by heat and ion-mediated hydrolysis. The
5'-end RNA termini were then modified by T4 polynucleotide kinase (New England Biolabs)
and y-S-ATP (Boehringer Mannheim). Next a biotin group (PEO-iodeacetyl-Biotin, Pierce
Chemical) was conjugated to 5'-ends of the RNA. The conjugated product was purified
using RNA/DNA Mini Column Kit (Qiagen) and the efficiency of the labeling procedure was
determined by a gel-shift assay on a 4-20% TBE Gel (Invitrogen, data not shown). Target
hybridization and probe array washing, staining, and scanning were performed as described
in the Affymetrix Manual.
3.4.2 Data analysis
Basal comparisons between mutant strains and wild-type
Experiments for array analysis were performed in biological replicates with three
independent experiments for each strain. Signal intensities of each array were normalized
by Robust Multi-array Average (RMA) version 0.1 release (55,319) and normalized signal
intensities for each gene were averaged across the three biological replicates for each
strain. Changes in gene expression are given as signal log ratios (base 2), and analysis of
variance (ANOVA) was used to compare gene expression values in each mutant strain
using wildtype E. coli as the baseline for comparison. All microarray data analysis (i.e.,
RMA normalization and ANOVA) was performed using the Array Analyzer module version
1.1 in S-Plus (Insightful) version 6.0. Transcripts were filtered based on a p-value threshold
of 0.05 as well as a fold change threshold of two (signal log ratio 1< x < -1). Differentially
regulated genes were annotated and categorized according to general function by the NCBI
Clusters of Orthologous Groups database. We determined the number of d(GATC) sites in
the promoter/regulatory regions of genes differentially expressed in our analysis by
searching the upstream sequence regions (-400 base pairs from the transcriptional start
site) of each gene. Sequences searched were provided on colibase
(http://colibase.bham.ac.uk/), and the number of expected GATC sites occurring by chance
in 400 bp was taken from Oshima et al. (535) and estimated to be one GATC site every 256
base pairs (or between one and two sites in the searched regions). Raw microarray data
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and RMA-normalized data is available at the NCBI Gene Expression Omnibus (GEO)
repository under the accession number GSE2928.
Pairwise comparisons between drug-treated and mock-treated cultures
Signal intensities of each array were normalized by a variation of Robust Multi-array
Average (RMA) (55,319) called GCRMA (753) and normalized signal intensities for each
gene were averaged across the replicates for each strain. Probe sets that were designated
as absent for all chips were filtered out of the data set. Pairwise comparisons were made for
each gene to determine cisplatin-induced fold changes within each strain, and changes in
gene expression are given as signal log ratios (treated/untreated, base 2). To compare
gene expression values of treated versus mock treated samples, a value of significance was
determined using the Local Pooled Error test (LPE) (324), and p-values were adjusted by
the Benjamini and Hochberg method (40) to allow a false discovery rate of 0.10. Signal log
ratios for each gene having a p-value < 0.10 are listed in Chapter 5, Tables 5.3-5.6. To
include basal gene expression changes (e.g., gene expression values measured in a dam
mutant compared to the wild-type strain), signal log ratios and LPE p-values for a mutant
(mock-treated) versus wild-type (mock-treated) were also calculated for each gene. All data
analysis, including RMA normalization and LPE, was performed using the Array Analyzer
module version 2.0.2 in S-Plus version 6.2 (Insightful), and GCRMA-normalized data is
available at the Gene Expression Omnibus repository under accession number GSE2999.
Differentially expressed genes were grouped according to general function categories
provided by NBCI Clusters of Orthologous Groups (COGs).
3.5 Semi-quantitative real-time RT-PCR
Total RNA was isolated from cultures and quality of RNA was determined as
described above. DNAse digestion for total RNA was performed using amplification grade
Deoxyribonuclease I (Invitrogen). Briefly, total RNA was incubated with 1 U DNase I per
microgram RNA in 200 mM Tris-HCI pH 8.4, 20 mM MgCI2, 500 mM KCI for 15 minutes at
room temperature. The reaction was terminated by the addition EDTA (2 mM final
concentration) and by heating for 10 minutes at 650 C. cDNA synthesis was performed
using random hexamer primers (Invitrogen) and the Omniscript Reverse Transcriptase Kit
(Qiagen) according to the manufacturer's protocol. In order to ensure that the amplification
observed in the PCR reactions was due to cDNA template made from mRNA and not from
contaminating genomic DNA, controls were carried out for each sample using the same
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conditions except that reverse transcriptase was not added to the reactions.
Semiquantitative real-time PCR reactions were performed with QuantiTect SYBR Green
(Qiagen) according to the manufacturer's protocol on a DNA Engine Opticon thermal cycler
(MJ Research). Primers specific to each target gene were designed using Primer3 software
(http://www-genome.wi.mit.edu/cqi-bin/primer/primer3.cgi/)) and are listed in Table 3.2.:
Optimal melting temperatures for each primer pair were determined by performing real time
analysis with a temperature gradient ranging over 10 degrees ( 5°C from the optimal
calculated Tm for each primer pair) and negative controls with no template cDNA were
performed to ensure that primers alone did not yield an amplification product. Relative gene
expression values for the samples were measured by including a standard curve analysis
for each gene assay; a separate batch of wildtype cDNA template was used to make a
series dilution, and amplified product from this dilution series was used to make a standard
curve by which to quantify the relative amount of product in each experimental sample. To
account for variation in the efficiency of the reverse transcription reaction between samples,
we performed RT-PCR for the constitutively expressed gapA (D-glyceraldehyde 3-
phosphate dehydrogenase) gene and normalized the gene expression values detected in
each sample to the value determined for gapA. Each experiment was carried out in
triplicate so each relative gene expression value reported for each strain represents the
average of three independent biological replicates. The student t-test (two sample, two
tailed) was used to determine if the expression values of a given gene were significantly
different between strains.
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Table 3.2 Primer sequences for real-time RT-PCR
Gene Left primer Right primer
recA 5'-TACAGCTACAAAGGTGAGAAGATCG-3' 5'-TTCGCTATCATCTACAGAGAAATCC-3'
lex,4 5'-GCATATTGAAGG TCATTATCAGGTC-3' 5'-ACCGTTACGTACATCCTGAGTTTT-3'
rec.N 5'-GTACAGCTGTTCCTCTGTCA CAAC-3' 5'-GTCATTTCCTGCAG TAGAGAGGTT-3'
su14 5'-CAACTTCTACTGTTGCCATTGTTAC-3' 5'-AGAGCTGGCTAATCTGCATTA CTT-3'
yebG 5'-CGAAGAGAAAATGTCGTTT ACCAG-3' 5'-CTCAGCACATCTTTTTGTTCTGC-3'
Idinl 5'-AGTA TGCGTTTCCTGATAATGAAGG-3' 5'-TATTCGCTGACAAACCAGTCAT-3'
u-vrA 5'-ATAAAGTGGTGTTGTACGGTTCTG-3' 5'-CACGGAC GATTACTGATAAACTTG-3'
,uvrB 5'- GTTTCCACTATTCCACGTTTTACC -3' 5'-GTAGTTTTCAATCCCCGAACAGTA-3'
,cho 5'-GTGGTACGGCGTT TAACTTCTC-3' 5'-GTTAACGCTTTTGCCGATATAGAG-3'
,rvA 5'-CCTGTTTTTATGAACTCCCTGAAG-3' 5'-CTCAACGGCATTAACG AACTG-3'
,rulvB 5'-GTTCGTTCACAGATGGAGATTTTC-3' 5'-GA TCTCATCAATAAACAGCACGTC-3'
priA 5'-GTGTGATTTAGCAAGTGAAACACC-3' 5'-TTTCCAGT ACGCTGAGATAAACCT-3'
PriB 5'-GAAAGGTCAGTCCATCAGGAAT-3' 5'-CCGACCGTTATACTGTGAGTAATG-3'
gapA 5'-TATGACTGGTCC GTCTAAAGACAA-3' 5'-GGTTTTCTGAGTAGCGGTAGTAGC-3'
r-l/(G 5'-GAATCAGTGTGTGTGTTAGTGGAAG-3' 5'-CACTATCGGTCAGTCAGGAGTATTT-3'
3.6 Neutral single cell gel electrophoresis
Cultures were grown as described above. Microgel electrophoresis was performed
as described in detail by Singh (641,643,644). Briefly, small aliquots (0.25 pII) of cells were
mixed with 50 pI of 0.5% agarose (biotechnology grade 3:1, Amresco). Agarose containing
cells was then immediately transferred to an MGE microscope slide (Erie Scientific,
Portsmouth, NH) pre-coated with 50 p1 agarose, and after cooling another layer of agarose
(200 plI) containing 5g/ml RNAse A (Amresco), 0.25% sodium N-lauroyl sarcosine, and 0.5
mg/ml lysozyme (Amresco) was added with a coverglass. Slides were incubated at 4°C for
10 minutes, after which they were transferred to a humidified chamber at 37°C and
incubated for 30 minutes. Coverglasses were then removed and the slides immersed in
lysis buffer (2.5 M NaCI, 100 mM EDTA tetra sodium salt, 10 mM Tris pH 10, 1% sodium N-
lauroyl sarcosine, 0.1% Triton X-100) and incubated for 8 hours. Slides were then
immersed in buffer for protein digestion (2.5 M NaCI, 10 mM EDTA, 10 mM Tris pH 7.4)
containing 1 mg/ml Proteinase K for 2 hours at 37°C. After protein digestion, the slides were
placed in a modified electrophoresis unit (TECA 2222, Ellard Instrumentation, Monroe, WA)
with buffer (300 mM sodium acetate, 100 mM Tris pH 9) and allowed to equilibrate for 20
minutes, after which electrophoresis was performed for 1 hour at 12 V (0.4 V/cm) with buffer
recirculation at 100 ml/min. Following electrophoresis slides were incubated in solution
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containing 1:1 ethanol: 20 mM Tris pH 7.4 containing 1 mg/ml spermine for 30 minutes, and
slides were then transferred to fresh solution for another 30 minutes. Slides were allowed to
air dry until analysis. Dried slides were stained with 50 p1 of 0.25 pM YOYO-1 iodide
(Molecular Probes) in 2.5% dimethyl sulfoxide and 0.5% sucrose and immediately viewed
on a Nikon Eclipse E600 fluorescence microscope equipped with a 100X/1.25 oil-immersion
Fluor lens and a B-2A filter set (exciter, 490 nm; emitter, 515 nm). Three to four
independent experiments were performed for each strain, and each experiment consisted of
two slides per strain with at least 50 observations taken per slide, giving a total of at least
400-600 observations per strain. Pictures were analyzed by Komet analysis software
version 4.0.2 (Kinetic Imaging Ltd.) and by visually counting individual strand breaks or tails
for each cell. The frequency at which no DSBs occurred, one DSB occurred, and so on was
determined for each strain. We assume that one tail corresponds to one double-strand
break (54). To determine if the frequency at which DSBs occurred between mutant and
wildtype was different, we performed the Mann-Whitney U test to compare the frequency of
DSBs in each mutant strain to the frequency observed in wildtype. For drug-treated
cultures, pictures were analyzed by Komet image analysis software or by visually counting
strand breaks where counting was feasible. To determine if the frequency at which DSBs
occurred in each group was different, we performed the Mann-Whitney U test to compare
the frequency of DSBs upon increasing drug dose within strains as well as between mutant
strain and wild-type at each drug dose.
3.7 Electrophoretic mobility shift assay
3.7.1 Preparation of platinum-modified DNA probes.
Platinum-modified DNA probes were prepared as previously described (473,563).
Briefly, oligonucleotides were purchased from Integrated DNA Technologies and purified by
gel electrophoresis. The platination reaction was carried out in 5 mM Na3 PO4 buffer, pH 7.4,
at 37 C for 18-21 h, and the platinated DNA was purified by high performance liquid
chromatography on a C18 column (reverse-phase) and the presence of the adduct was
confirmed by MADLI-TOF (data not shown). The complementary strands (bottom strands in
Fig. 5.1) were radiolabeled with [7_32p] dATP and the DNA strands were hybridized by
heating the top and bottom strands for 5 min at 80 °C and then letting the mixture cool for
14-20 h. The sequences of the DNA duplexes are shown in Fig. 5.1. Concentrations were
determined by measuring A2 60.
91
3.7.2 Binding assay
MutS was purchased from USB and provided in 50% glycerol. Before the binding
assay glycercol was removed by dialysis against 20 mM KPO 4, pH 7.4, 0.1 mM EDTA, 1mM
PMSF and 10 mM beta-mercaptoethanol. Binding assays contained the radiolabeled DNA
duplex probes (1-20 nM), either unmodified or modified with cisplatin, and MutS present at
0-200 nM or 0-20 pmoles. Binding reactions were carried out in 10 l solutions containing
20 mM Tris pH 7.6, 5 mM MgCI2, 0.1 mM DDT, 0.01 mM EDTA, and 50 ng of nonspecific
salmon sperm (Stratagene) or chicken erythrocyte competitor DNA for 30 minutes on ice.
Samples were then loaded onto 6% (29:1) acrylamide:bis) native polyacrulamide gels
containing TAE buffer (90 mM Tris (pH 8.0), 2.0 mM EDTA, 90 mM boric acid) and 5%
sucrose, and separated by electrophoresis at room temperature in TAE buffer at - 25 mA
(140V) for 2 h. Quantitative analysis was determined by Molecular Dynamics Storm system
and ImageQuant software.
3.8 SulA::lacZ reporter assay
Overnight cultures in LB broth were diluted ten-fold in minimal salts and 3 ml portions
placed on MacConkey agar plates for 10 min and the residual liquid removed by aspiration.
The plates were allowed to dry at room temperature and filter paper disks were placed on
the surface. Cisplatin (1.2 mg/ml) was added to the disks in 5, 10, and 20 l volumes. Water
was used on the control disk. The plates were incubated overnight at 370C.
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Abstract
DNA adenine methylation by DNA adenine methyltransferase (Dam) in Escherichia coli
plays an important role in processes such as DNA replication initiation, gene expression
regulation, and mismatch repair. In addition, E. coli deficient in Dam are hypersensitive to
DNA-damaging agents. We used genome microarrays to compare the transcriptional
profiles of E. coli strains deficient in Dam and mismatch repair (dam, dam mutS, and mutS
mutants). Our results show that >200 genes are expressed at a higher level in the dam
strain while an additional mutation in mutS suppresses the induction of many of these same
genes. We also show by microarray and semiquantitative real-time RT-PCR that both dam
and dam mutS strains show de-repression of LexA-regulated SOS genes as well as the up-
regulation of other non-SOS genes involved in DNA repair. To correlate the level of SOS
induction and the up-regulation of genes involved in recombinational repair with the level of
DNA damage, we used neutral single-cell electrophoresis to determine the number of
double-strand breaks per cell in each of the strains. We find that dam mutant E. coli have a
significantly higher level of double-strand breaks compared to the other strains. We also
observe a broad range in the number of double-strand breaks in dam mutant cells with a
minority of cells showing as many as ten or more double-strand breaks. We propose that
the up-regulation of recombinational repair in dam mutants allows for the efficient repair of
double-strand breaks whose formation is dependent on functional mismatch repair.
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4.1 Introduction
The DNA adenine methyltransferase (Dam) protein methylates the N6 position of the
adenine residue at d(GATC) sites of the E. coil genome. Dam methylation is a
postreplicative process (444), and consequently the newly synthesized daughter strand is
unmethylated for a short time after passage of the replication fork. This transient
hemimethylated state following DNA replication plays a crucial role in processes such as the
regulation of gene expression (130,442,538), DNA mismatch repair (37,538,622), and the
timing of chromosome replication initiation (23,420,526,603). By altering the recognition
sequences of transcriptional regulators and RNA polymerases, Dam methylation may affect
the ability of proteins to bind the upstream regions of genes and in such a way may serve to
regulate gene expression. Because d(GATC) sites are not randomly distributed in the E.
coil genome (279,535), Dam deficiency may therefore have a direct effect on gene
expression patterns.
In methyl-directed mismatch repair, hemimethylated d(GATC) sites serve as the
strand discrimination signal so that mismatch repair can differentiate between parent
(methylated) and daughter (unmethylated) strands (490). The mismatch repair system relies
on three unique proteins: MutS, MutL, and MutH. If there is a misincorporation error
following the replication fork, MutS recognizes the mismatch and a protein-DNA complex is
formed with MutS, MutL and the latent endonuclease MutH. Activated MutH then makes an
incision on the unmethylated, or newly synthesized, strand at a d(GATC) site located either
5' or 3' to the mismatch (20,126,256). Methylation status therefore allows mismatch repair
to act on the new strand while preserving the sequence of the template strand, and in this
way mismatch repair helps protect the genome against mutations arising from
misincorporated deoxynucleotides. In the case where Dam is absent and the genome is
unmethylated at d(GATC) sites, MutH cannot distinguish between the new and template
strands; in vitro experiments show that in this situation MutH aimlessly makes an incision on
either strand, although the endonuclease shows reduced activity on unmethylated compared
to hemimethylated substrates (20,740). Furthermore, Au et al. (20) have shown in a
reconstituted in vitro system that in the absence of d(GATC) methylation MutH can make
incisions on both DNA strands and form a double-strand break (DSB).
E. coil deficient in Dam exhibit pleiotropic changes that have helped uncover many
functions of adenine methylation. Dam-deficient strains display a mutator phenotype (447),
94
which most likely results from mismatch repair activity on template rather than daughter
strands following replication errors. Interestingly, a mutator phenotype is also conferred by
the overexpression of Dam (282,759), which may result in fully methylated DNA following
the replication fork that is resistant to MutH incision. Other studies have shown that the
SOS response is constitutively induced (sub-induced) in the absence of Dam (524,558,607).
The induction of SOS response genes in dam mutant strains may be due to the presence of
single-stranded DNA resulting from errant MutH incisions. However dam mutS/L/H strains
in which mismatch repair is inactivated also show SOS sub-induction (557). Dam-deficient
E. coli are also hyper-recombinogenic (445,446) and double mutants deficient in both Dam
and recombinational repair (dam recA, -B, -C, and dam ruvA, -B, -C) are inviable
(443,447,557,731). Wang and Smith (731) have shown that the requirement for
recombination in dam E. coli is correlated to the mismatch repair-dependent production of
double-strand breaks (DSBs), and accordingly mutations in mismatch repair (mutL or mutS)
allow the recovery of dam rec mutants.
Wang and Smith (731) determined the relative levels of DSBs in dam, recB
(temperature sensitive mutant, Ts), dam recB(Ts) and dam recB(Ts) mutS/L cells; they
could only detect DSBs in the dam recB(Ts) strain and not in the dam- only cells. However
we expect dam mutant cells to exhibit a higher level of DSBs compared to wildtype because
dam mutants deficient in DSB repair are inviable (443,447,558). Furthermore, dam mutants
are hypersensitive to exogenous DNA-damaging agents and this hypersensitivity is
abrogated by an additional mutation in mismatch repair (224); this hypersensitivity may be
due to basal differences in dam mutants that, like DSB formation, are dependent on
mismatch repair. In order to help elucidate the global changes resulting from Dam
deficiency and the role of mismatch repair in producing these changes, we determined the
global gene expression profiles of wildtype, dam, dam mutS, and mutS E. coli strains by
microarray analysis of -4,200 open reading frames. We also measured the number of
DSBs in each of the strains and correlate the level of basal DNA damage with the induction
of genes involved in recombination and DSB repair. Our findings show that many genes
involved in carbohydrate metabolism and transport, energy production and conversion, cell
motility, and translation are up-regulated in dam mutant E. coil, whereas an additional
mutation in mutS suppresses gene induction. We also see up-regulation of several SOS-
response genes in both dam and dam mutS mutants. However only the dam mutant cells
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show a higher level of DNA DSBs compared to wildtype, and double-strand break formation
in dam mutant E. coli is dependent on functional mismatch repair.
4.2 Results
4.2.1 Dam-deficient strains show a higher number of basal gene expression
changes compared to the mutS strain
We measured the global gene expression patterns in four E. coli strains using the
Affymetrix microarray platform. We isolated mRNA from three independent biological
replicate cultures for wildtype, dam, dam mutS, and mutS strains, and the gene expression
values from the replicates were averaged. Gene expression changes in mutant strains are
given as signal log ratios (mutant/wildtype, log base 2) and analysis of variance (ANOVA)
was performed to compare gene expression levels in each of the mutant strains to the gene
expression levels measured in wildtype E. coli. Figures 4.1A-C show the log p-value versus
signal log ratio for all transcripts, and the bold lines mark the boundaries by which the data
were filtered; the bold horizontal line represents the p-value threshold while the two bold
vertical lines mark the signal log ratio threshold applied to the data. Genes whose
expression show at least a + 2-fold change compared to wildtype (signal log ratio + 1) with a
p-value < 0.05 are represented in Figs. 4.1 D and 4.1E and are listed in Tables 4.2-4.4.
When we compare the basal gene expression differences between each of the mutant
strains and wildtype, the results show that while the mutS strain does not display many
differences from wildtype at the transcriptional level, both dam and dam mutS strains show
differential expression of 206 and 114 genes, respectively. The majority of genes
differentially expressed are expressed at higher levels (induced) in the mutant strains
compared to wildtype (Fig. 4.1 D). Among the most prominent groups of up-regulated genes
are those encoding ribosomal subunit proteins and products involved in carbohydrate
transport and metabolism (Fig. 4.1 E). In particular, several genes encoding proteins in the
sugar phosphotransferase system (PTS) and maltose transport are up-regulated in the
Dam-deficient strains. Dam E. coli also show up-regulation ( 2-fold induction, p < 0.05) of
many genes involved in energy production and conversion (24 genes), cell motility (17
genes) including flagellar biosynthesis, amino acid transport and metabolism (9 genes),
transcription (8 genes) as well as genes of unknown function (12 genes). Dam mutS E. coli
also show up-regulation of genes involved in cell motility (5 genes) and genes of
unclassified or unknown function (24 genes).
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The higher level of global transcription in the Dam-deficient strains may be due to
genes whose regulation is directly controlled by adenine methylation. While some
transcriptional activators bind unmethylated DNA (63), the absence of Dam methylation may
lead to the up-regulation of genes whose promoters/regulatory regions are normally
methylated and therefore whose transcriptional activators are usually bound only following
replication when the DNA is transiently unmethylated. Alternatively, genes whose
repressors require adenine methylation for DNA binding affinity may also be up-regulated in
the absence of Dam. Under such scenarios, Dam deficiency would directly affect the
transcription of genes and would lead to increased gene expression. Although we were
unable to find a correlation between gene expression level and the presence of d(GATC)
sites in upstream sequence regions (-400 base pairs from the transcriptional start sites) in
dam or dam mutS strains (Supplementary Tables 1 and 2), we do see expression changes
of certain genes known to be regulated in a Dam-methylation-dependent manner. For
example, dnaA expression is reduced in both dam and dam mutS strains (signal log ratio = -
.368, p = .035 and -.412, p = .025, respectively) as shown previously in dam mutant strains
(69,421). Methylation of d(GATC) sites in the dnaAp2 promoter, two of which are in the -35
and -10 sequences, may affect the affinity of DNA binding proteins that regulate the
expression of dnaA (69,143). In addition, we find expression of the phase variation flu gene
(agn43) to be slightly down-regulated (signal log ratio = -.383, p = .016) in dam E. coil.
While agn43 transcription is controlled in a methylation-dependent manner, it is DNA
methylation of three d(GATC) sites in the regulatory region that prevents binding of the
repressor OxyR and that therefore leads to agn43 expression and the ON phase (130,725).
L0bner-Olesen et al. (421) have shown that a 10-fold overproduction of Dam leads to a 20-
fold induction of flu expression.
4.2.2 The effects of MutS on gene expression in a dam mutant background:
differences between dam and dam mutS strains
Both dam and dam mutS strains show a high level of gene induction compared to
wildtype (Fig. 4.1A and B). The dam mutS strain, however, shows higher variability among
some of these induced genes (Fig. 4.1 B); specifically, 39 genes that show 2-fold higher
expression in dam mutS compared to wildtype are filtered out of the data set due to their
high variability (i.e., they do not meet the p-value threshold), and of these 39 genes 15
encode ribosomal proteins. The remaining genes are mostly involved in protein and
carbohydrate metabolism. Data in Fig. 4.1 D and 4.1 E show the filtered data set that
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includes genes showing at least + 2-fold change and p <0.05. Fig. 4.1 E shows that many of
the expression changes in dam and dam mutS strains fall under common categories, with
carbohydrate transport/metabolism and translation accounting for close to 50 % of the
transcriptional changes in these strains. Many of the genes induced in dam mutS are also
induced in the dam strain; that is, the genes induced in dam include the majority of the
genes induced in dam mutS, and it is the case that the dam strain appears to show up-
regulation of more genes rather than induction of a distinct set of genes within the
categories shown in Fig. 4.1 E (refer to Tables 4.2-4.4 for a complete list of genes). There is
a striking difference between these two strains, however, in the number of induced genes
encoding for products in energy production and conversion. The dam strain displays a high
number of induced genes falling under this category whereas the dam mutS strain does not
(Fig. 4.1 E). Therefore it appears that MutS deficiency in a dam mutant background reduces
the number of induced genes in this category as well as decreases the overall number of
transcriptional changes. This effect of MutS is only observed in the dam background, as
mutS E. co/i closely resemble wildtype and show transcriptional changes for only 17 genes.
The transcriptional changes observed in the mutant strains are not attributable to different
growth stages, as all four strains showed similar growth rates in culture at the time RNA was
isolated (data not shown).
4.2.3 Dam and dam mutS strains display constitutive SOS and up-regulation of
genes involved in DNA recombination and repair
The SOS response is induced when RecA is activated in the presence of single-
stranded DNA (723). Activated RecA then facilitates the autocleavage of the LexA
repressor and the transcriptional activation of those genes whose operons are normally
bound and repressed by LexA. Our microarray data show that several LexA-regulated
genes are induced in dam and to a lesser extent in dam mutS E. coli. The analysis shows
that the genes lexA, recA, and yebG are all induced at least two-fold in the dam strain
compared to wildtype (p < .001, Table 4.1). The LexA-regulated genes sulA and recN also
show induction in the dam strain, with signal log ratios (dam/WT) of 0.95 (p = .004) and
0.762 (p = .022) respectively. Many of these genes (lexA, recN, sulA, and yebG) are also
induced in the dam mutS strain (Table 4. 1). The SOS genes involved in nucleotide excision
repair (uvrA, uvrB, and the recently characterized gene cho (494)) do not show induction in
the dam and dam mutS strains by microarray analysis, although our RT-PCR results show
98
that the cho gene is expressed at a significantly higher level in the dam strain compared to
wildtype (see below and Table 4.1).
RecN, a protein known to be involved in DSB repair (387,560), is not required for
dam mutant survival as dam recN mutants are viable (557). However we find that recN is
significantly induced in the dam and dam mutS strains. We also see a moderate but
significant (p < 0.05) induction of a non-SOS gene recG in the dam strain (signal log ratio =
.300, p = .013). The RecG helicase catalyzes branch migration of three- and four-stranded
DNA junctions in vitro and is proposed to catalyze fork regression in vivo (464,465,594);
RecG has been shown to be important for tolerating DSBs (387,471) and may be required
for dam mutant viability (443).
Several other genes involved in recombinational repair show unique up-regulation in
dam and dam mutS E. coil. The primosomal gene priB shows up-regulation in these strains.
PriB is a structural protein of the primosome, which allows replication restart at
recombination intermediates including sites of template damage where the replication fork
collapses (515,613). The genes encoding for the subunits of the E. coli histone-like protein
(HU), hupA and hupB, are also induced in Dam-deficient E. coli. HU is involved in
recombinational repair (174,411), and hupAB double mutants are hypersensitive to both y-
irradiation (60) and UV-induced damage (411).
We performed semi-quantitative real time PCR to confirm the gene expression
changes we observed by microarray analysis. For the RT-PCR studies, we isolated total
RNA from three independent replicates using the same procedure we used for the
microarray experiments. After DNAse digestion, cDNA for each sample of isolated total
RNA was made using random hexamer primers and reverse transcriptase, and controls with
no reverse transcriptase were performed for each sample to ensure that genomic DNA was
removed by digestion. To determine the relative expression levels for a particular gene, all
cDNA samples and no reverse transcriptase controls were run in the same assay along with
samples for a standard curve. We accounted for variation between samples by normalizing
the expression level of each gene in a sample to the amount of housekeeping gene
message (gapA) in that sample. After normalization to gapA level, we set the expression
level for each gene detected in wildtype to a value of one and adjusted the expression levels
in the other strains accordingly (Fig. 4.2). We performed the student t-test to compare the
amount of transcript measured in a mutant strain to the amount in wildtype, and
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comparisons for which p < 0.05 are designated in Figure 4.2 by an asterisk. Our RT-PCR
results confirm the microarray data and show that the SOS response genes recA, lexA,
sulA, dinl, and yebG, are all expressed at higher levels in dam compared to wildtype, while
the genes lexA and yebG are also expressed at a significantly higher level in dam mutS
compared to wildtype E. coli (Fig. 4.2A). We also used real-time RT-PCR to measure the
levels of other SOS genes involved in recombinational repair and show that the genes recN,
ruvA, and ruvB are highly expressed in dam and dam mutS strains compared to wildtype
(Fig. 4.2B). The uvrC homologue, cho, which has been shown to be up-regulated as part of
the SOS response (206), is also significantly induced in the dam strain (Fig. 4.2C). The
SOS response genes are not induced in mutS E. coli.
The relative expression changes determined by array and RT-PCR correlate as to
the direction of change for the LexA-regulated genes discussed. Expression changes
measured by these methods however do not always show the same absolute magnitudes of
change. In most cases RT-PCR detected slightly lower magnitudes of change. For
example, in dam E. coli, the SOS gene displaying the highest level of induction by
microarray analysis is recA (4-fold induction), while RT-PCR detected a two fold induction of
recA in dam compared to wildtype (Table 4.1). In general, however, our levels of SOS
response gene induction in dam cells compared to wildtype are consistent with those
determined by Peterson et al. (558) using the beta-galactosidase reporter assay. The RT-
PCR data also confirm the microarray data in showing that the non-SOS genes priB and
hupB are moderately induced in dam E. coli.
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TABLE 4.1 Differential basal gene expression (mutant/WT) of several SOS response
genes and other genes involved in DNA maintenance determined by microarray
analysis and RT-PCR
lexA-regulated SOS Array RT-PCR
response gene Signal log ratio* Signal log ratio*
(ANOVA p-value) (t-test p-value)
Gene Blattner damNVT dam mutSNVT damNVT dam mutSNV/WT
name Number mutSNVWT mutSNVT
lexA b4043 1.56 .914 .223 .970 .997 .283
(.001) (.051) (.498) (.009) (.023) (.238)
recA b2699 2.02 1.69 .348 1.19 .986 -.009
(.000) (.000) (.278) (.001) (.088) (.491)
recN b2616 .752 .835 .269 1.66 1.53 -.593
(.022) (.008) (.350) (.013) (.015) (.278)
sulA b0958 .950 .784 .232 1.47 .870 -.086
(.004) (.010) (.427) (.004) (.068) (.424)
yebG b1848 1.60 1.14 .049 1.72 1.59 .314
(.001 .001) (.856) (.046) (.012) (.305)
ruvA b1861 .240 .182 .227 1.21 1.09 .317
(.541) (.784) (.553) (.002) (.073) (.147)
ruvB b1860 .094 -. 159 .107 1.12 1.07 .584
(.843) (.569) (.802) (.003) (.005) (.113)
dinl b1061 .652 .448 .360 1.32 .420 -.832
(.091) (.232) (.446) (.002) (.256) (.135)
uvrA b4058 -.277 -.308 -.121 .637 .669 .441
(.240) (.195) (.584) (.041) (.060) (.166)
uvrB b0779 -.155 -.095 .273 .966 .821 .327
(.468) (.671) (.283) (.047) (.064) (.231)
chol ydjQ b1741 -.150 -.156 -.133 1.52 .974 .275
(.520) (.331) (.414) (.014) (.050) (.210)
Genes involved in Array RT-PCR
DNA Signal log ratio* Signal log ratio*
repair/replication (ANOVA p-value) (t-test p-value)
restart (non-SOS)
Gene Blattner damNVT dam mutS/WT damNVT dam mutSNVT
name Number mutS/WT mutSNVT
priA b3935 .026 -.317 -. 197 .071 -.283 -.264
(.872) (.162) (.332) (.300) (.290) (.319)
priB b4201 2.19 1.63 .356 .874 .813 .509
(.001) (.018) (.502) (.055) (.073) (.218)
hupA b4000 1.04 .209 0.100 -.219 .269 -.034
(.015) (.555) (.859) (.355) (.324) (.474)
hupB b0440 1.89 1.60 .523 .556 .283 .114
(.001) (.003) (.176) (.023) (.296) (.314)
Table 4.1: *Signal log ratios represent the log of expression ratios (mutant/WT), base 2. Therefore a
signal log ratio of 1 is the equivalent to a 2-fold change in expression level. Genes listed were tested by
both array and RT-PCR. ANOVA values were determined using the array analyzer module in SPlus and
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represent the significance for expression differences between mutant and WT. The student t-test was
performed to compare the expression values of a given gene measured by RT-PCR in mutant versus wild-
type strains.
4.2.4 Dam-deficient E. coli exhibit a higher level of DSBs
We performed neutral single cell microgel electrophoresis to determine the level of
DSBs in the genomes of wildtype, dam, dam mutS, and mutS mutant cells. Using the single
cell electrophoresis method developed by Singh (643,644), we were able to detect a single
double strand break in the genome of a cell. We assume that one linear tail corresponds to
a single double-strand break (54) as shown in Fig. 4.3A; an individual cell with no DSBs
appears as a head with no tail, whereas a cell with DSBs appears as a head followed by
linear tails indicative of the number of breaks in the genome. For these experiments,
cultures were grown as described above for the gene expression studies and three
independent experiments were performed. A total of 600 to 1000 single cells for each strain
were analyzed by Komet analysis software (Kinetic Imaging Ltd.) and by the visual counting
of the number of DSBs. Our data show that Dam-deficient E. coli have a significantly higher
level of basal DSBs (Mann-Whitney U test, P < .02) compared to the level of DSBs in the
wildtype strain, with dam cells having on average 1.2 breaks per cell (Fig. 4.3B). The dam
mutS and mutS strains do not show a significantly higher level of double strand breaks
compared to wildtype.
Although the average number of DSBs detected in the dam strain is 1.2 breaks per
cell, we observe a broad range of breaks per cell. A small percentage of the dam cells (6
%) show levels of double strand breaks between 5 and 12, while 42% of the cells show no
DSBs and the majority of cells display between 1 and 4 DSBs. We expect that this broad
range in the number of DSBs is due to differences in the cell population with respect to the
number of active DNA replication forks and the stages of recombination substrates in each
cell. In other words, DSBs are lethal lesions and most likely do not persist for long in the
cells, and therefore we were able to capture relatively few cells with a high level of damage
that had not yet completed recombinational repair. The short persistence of DSBs in the cell
would explain why previous studies could only detect DSBs in dam rec double mutant
strains deficient in recombinational repair and were unable to detect DSBs in dam only
mutant cells (522,544). The other strains did not show a broad range of DSB formation; 80-
90% of the cells showed no DSBs while 1-3 DSBs were detected in the remaining cells.
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Komet image analysis software analyzes photometric data and quantifies the
fluorescence of the head and tail. The software provides measurements such as the mean
intensities of the head and tail and the tail length. Percent DNA in the head or tail
represents a percentage of the total measured intensity (head and tail), and cells with a
higher level of DNA damage will display a higher percentage of tail DNA. Figure 12C shows
a box plot of the distribution of cells for each strain according to the percentage of tail DNA.
The horizontal line in each box represents the median of the data, while the box represents
the inter-quartile range, or the range including 50% of the data. The lines extending from
the top and bottom of each box mark the minimum and maximum values within the data set
that fall within an acceptable range, and any values outside of this range (outliers) are
displayed as individual points. The dam cells display the broadest range of data, with many
cells showing a very high percentage of DNA in the tail. The distribution of cells by percent
tail DNA is similar for wildtype, dam mutS, and mutS strains, although dam mutS E. coli
show a few outliers with a high level of damage. The data support the idea that mismatch
repair induces DSBs in dam cells and causes a high level of damage; while only a subset of
dam mutant cells exhibit very high levels of damage, we speculate that the lethal damage is
repaired efficiently and does not persist for long in the cells, resulting in a majority of the
cells showing lower levels of damage.
4.3 Discussion
Dam-deficient E. coli exhibit pleiotropic changes including an increased mutation
rate, uncoordinated DNA replication initiation, and transcriptional alterations (420,448,538).
Many of these phenotypes result from the absence of hemimethylated DNA following
passage of the replication fork. Dam-deficient E. coli also exhibit a hypersensitivity to DNA
damage and a dependence on recombinational repair, and both phenotypes can be
suppressed by inactivating mismatch repair (224,466,731). In the present study, we
determined the global transcriptional changes in dam, dam mutS and mutS E. coli. Our data
show that dam and dam mutS strains exhibit the greatest number of transcriptional changes
compared to wildtype. Although gene expression can be regulated by Dam methylation,
most of the gene expression changes observed in these strains appears to be due to
secondary effects of Dam deficiency rather than from direct methylation-mediated gene
regulation. The majority of genes induced in dam and dam mutS strains are genes
encoding products of carbohydrate transport and metabolism, translation, and in the dam
103
strain, energy production and conversion. The up-regulation of genes involved in
metabolism, energy production, and translation in dam E. coil may be indicative of the great
effort this strain must devote to growth and to coping with asynchronous DNA replication
and DNA damage. We also see induction of several exA-regulated genes in dam and dam
mutS strains, which is consistent with the previous findings of others (524,535,558).
Furthermore, mismatch repair appears to be contributing to the transcriptional changes
observed in the dam strain; adding a mutation in mutS suppresses many of the gene
expression changes in the dam strain, as the dam mutS strain shows induction of fewer
genes in categories such as amino acid and carbohydrate transport and metabolism, energy
production and conversion, and translation. Our data suggest that due to the many
functions of adenine methylation, a deficiency in Dam increases the overall stress level in
the cells, including stress caused by DNA damage, and that introducing an additional
mutation in mismatch repair abrogates some of this stress. A deficiency in MutS alone does
not result in many changes at the transcriptional level.
Two previous studies have examined the effects of Dam methylation on global gene
expression patterns. Lobner-Olesen et al. (421) found few gene expression changes in
Dam-deficient strains that were either dam null or that expressed 30% of the level of Dam
relative to wildtype. However their study showed that Dam overexpression resulted in
altered expression of numerous genes, and the effects of Dam overproduction were almost
identical to the gene expression effects they observed in seqA mutant cells, or cells in which
reinitiation of replication occurs at oriC repeatedly during a single replication cycle (72,651).
Because most of the genes whose expression was altered did not contain d(GATC) sites in
their promoter regions, the authors proposed that the gene expression changes observed in
Dam overproducing and seqA mutant strains are due to the increased amount of fully
methylated DNA and the resulting alterations in chromosome structure. Although their study
did not find many gene expression changes in the dam null strain compared to wildtype,
their findings are similar to ours in the respect that Dam methylation appears to have little
direct effect on gene regulation. The second study by Oshima et al. (535) tested the gene
expression changes in dam mutant cells under aerobic and low aerobic conditions. This
study, like ours, found many gene expression changes in the Dam-deficient strain.
Furthermore, genes involved in amino acid metabolism, energy metabolism, and the
environmental stress response were up-regulated in the dam mutant under aerobic
conditions, which is consistent with our data.
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Our data show that several SOS response genes are constitutively induced in the
dam and dam mutS strains. Dam-deficient strains have a high basal level of single-strand
breaks compared to wildtype (447) and thus single-strand breaks may be the primary SOS-
inducing signal. Previous work has indicated that damage in dam strains also consists of
DSBs; expression of recA, recB, recC, ruvA, ruvB, and ruvC is essential for dam mutant
viability although expression of recN, recO, recF, and recR is not required (443,558).
Furthermore, the presence of DSBs and the requirement for DSB recombinational repair is
dependent on functional mismatch repair; Wang and Smith (731) have shown that mutations
in mismatch repair (mutS or mutL) suppress the formation of DSBs and the requirement for
recombination in a dam- rec- background. However the basal level of DSBs in dam mutants
has not been measured in recombination proficient strains. Using a single-cell assay where
we can detect a single DSB per cell, we measured the level of DSBs in dam and dam mutS
E. coli that are proficient in recombinational repair. Based on our data, dam E. coli have on
average 1.2 double strand breaks per cell, whereas wildtype and dam mutS have an
average of 0.17 and 0.37 DSBs per cell, respectively. Therefore, while inactivating MutS
abrogates the need for DSB repair in dam mutant cells, we propose that mismatch repair
contributes to nearly all of DSBs detected in dam cells.
It is important to note that one phenotype of dam mutants is asynchronous cell
division and multiple firings of the origin of replication during the cell cycle (420,603). Such
multiple firings may lead to hyper-ploidy and an increase in DNA fragments as multiple DNA
duplexes are being synthesized. Thus the number of tails in Dam-deficient strains may be
higher due to this phenotype. The contribution of multiple DNA molecules within the cell,
however, should be the same for both dam and dam mutS mutant strains as both strains
lack DNA adenine methylation. While the level of DSBs is higher in dam mutants than it is in
dam mutS mutant cells, DSB formation in dam mutants is therefore dependent on mismatch
repair.
As mentioned in the results, we believe the level of mismatch-repair induced DSBs in
the dam strain to be well above the average of 1.2 breaks per cell. Because we observed a
broad range of values, with the highest level reaching 12 breaks in a dam cell, we speculate
that the DSBs are repaired efficiently and do not persist for long in the cells, and thus we
could only capture a small population of cells with unrepaired DSBs. This scenario would
explain why other methods, such as neutral sucrose-gradients (731) and pulse-field gel
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electrophoresis (522), could only detect an increased level of DSBs in dam-rec-
backgrounds. Our results are also consistent with the findings of McCool et al. (462)
demonstrating that SOS expression in dam mutant cells follows a two-population model in
which some cells show high SOS expression while other cells do not; our data show that at
least one form of DNA damage-DSB formation-in dam mutant cells is stochastically
formed and is not present at uniform levels in the culture at a given moment in time.
Despite the aforementioned correlative data on DSB formation, the dependence on
recombination and functional mismatch repair in a dam mutant strain, SOS induction is not
suppressed by an additional mutation in mutS. Therefore other SOS inducing signals must
be present in dam and dam mutS strains. While recombinational repair, and specifically DSB
repair, is required for dam mutant viability (443,557), induction of SOS is also critical for
survival, and lexA dam double mutants in which the LexA repressor cannot be inactivated
are inviable (558).
The mechanism by which mismatch repair induces DSBs in the absence of Dam
methylation is not fully understood. Mismatch repair may be making dual incisions at
unmethylated d(GATC) sites, forming DSBs (20,245). Alternatively, MutH-catalyzed single
incisions could result in DSBs when these single-strand nicks are encountered by a
replication fork, resulting in replication fork collapse and a DSB (see reference (443) for a
discussion of this model). To account for the increased level of DSBs observed in dam
mutant cells, MutH would need to make more single-strand incisions in dam mutant cells
than in dam+ cells. Increased MutH-catalyzed single-strand incisions may occur in dam
mutant cells because of the higher presence of MutH substrate, or unmethylated d(GATC)
sites, and an increased level of single-strand breaks has indeed been observed in dam cells
(447). In growing dam mutant cells, therefore, the coupling of a high presence of single-
strand gaps with multiple replication forks may result in replication fork collapse and may
account for the increased level of DSBs observed in the dam strain. Under this model and
based on our results, the frequency at which replication forks encounter single-strand gaps
in dam E. coli could result in as many as ten or more DSBs. However due to the up-
regulation of recombinational repair in this strain, dam mutant cells efficiently repair these
DSBs, and thus the average level of DSBs observed in the culture is only one to two breaks
per cell. Unlike the first model where MutH catalyzes two incisions on complementary
strands resulting in a DSB, this second model relies on replication for the formation of DSBs.
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The replication-dependence of DSB formation and recombination in dam mutant cells is
currently being tested.
The present study demonstrates the importance of functional mismatch repair in
contributing to DNA damage and gene expression changes in dam mutant cells. We have
shown that DSB formation in dam mutant cells is dependent on functional mismatch repair;
dam mutant cells have a higher level of DSBs compared to wildtype whereas dam mutS and
mutS mutant cells do not. We have also shown that the SOS response and genes involved
in recombinational repair are induced in dam mutant E. coli. While it has been shown that
mismatch repair sensitizes cells to DNA damaging agents in a dam mutant background
(224), the high level of mismatch repair-induced basal damage in dam mutant cells helps
explain why this strain is hypersensitive to DNA-damaging agents. The following chapter
examines the role of mismatch repair in mediating toxicity to exogenous DNA-damaging
agents using the strains characterized in this chapter.
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Figure 4.1: Global transcriptional changes in dam, dam mutS, and mutS E. coli compared to
wild-type. ANOVA was performed using wild-type expression level as a baseline, and log
p-values are plotted against signal log ratios for dam (A), dam mutS (8), and mutS (C) mutant
cells. Circles represent genes that do not meet the 2-fold cutoff marked by the vertical bold
lines while dark grey squares represent genes expressed at a 2-fold lower level and light grey
triangles represent genes expressed at a 2-fold higher level compared to wild-type. The
horizontal bold line shows thep-value threshold applied to filter the data (p 0.05) and (0) and
(E) show the filtered data. (0) Total number of genesinduced/repressed 2-fold in each of the
strains. Only genes for which the magnitude of induction or repression is at least 2-fold (signal
log ratio 1 and -1) and for which p 0.05 are represented. (E) Genes in (0) categorized
according to general function as provided by the NCBI COG database.
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Figure 4.2: Relative expression levels for several SOS genes determined by
semi-quantitative real-time PCR. Student t-tests were performed to compare the
transcript levels of a gene detected in a mutant strain to that detected in the wild-type
strain. Comparisons for which p 0.05 are designated by an asterisk, and error bars
represent standard deviation. SOS response genes represented include genes
involved in SOSregulation (A), recombination (8), and nucleotide excision repair (C).
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Figure 4.3: E. coli strains analyzed by single-cell microgel electrophoresis. Six hundred
Individual cells for each strain were analyzed by visually counting the number of breaks
and by Kamet analysis software (Kinetic Imaging Ltd.) A) Representative pictures of
individual cells analyzed by microgel electrophoresis. Cells with no tailsindicate no
double-strand breaks (DSBs) in the genome, whereas cells with tailsindicate the number
of strand breaks in the genome. B) Number of DSBs per cellfor each strain determined
by counting the tailsof each cellfor each of the strains. Error bars represent SE,
*Mann-Whitney U test P < .02 C) Results from Komet analysis. Percent of DNA in the .
tailrepresents a percentage of the total DNA (totalfluorescence) detected in both the head
and tail.Box plot shows the distribution of cell data for each strain. Horizontal lines for each
box represent the median value, with the box representing 50% of the data (box upper and
lower limitsrepresent the upper and lower quartiles, respectively). Vertical lines extending
from the box show the fullrange of data, and outliers are shown as individual points
(outliersare defined as values greater than the upper quartile +1.5 X interquartile distance).
Table 4.2: Genes differentially expressed at the basal level ( 2-fold) in dam mutant E. coli
compared to wildtype. Only genes for which ANOVA p < 0.05 are listed.
Amino acid transport and metabolism
Gene Blattner Number Signal Log ANOVA Gene Product and Function
Number of GATC Ratio p-value
sites*
argV b2694 - 1.03 0.020 Arginine tRNA2; tandem quadruplicate genes
aspC b0928 2 1.26 0.026 aspartate aminotransferase
dapA b2478 3 1.24 0.005 dihydrodipicolinate synthase
gcvH b2904 1 1.04 0.018 in glycine cleavage complex, carrier of aminomethyl
moiety via covalently bound lipoyl cofactor
glyA b2551 0 1.32 0.003 serine hydroxymethyltransferase
oppA b1243 1 1.16 0.012 oligopeptide transport; periplasmic binding protein
tdh b3616 1 1.46 0.007 threonine dehydrogenase
tnaB b3709 1 1.48 0.031 low affinity tryptophan permease
ydgR b1634 1 1.61 0.007 putative transport protein
Carbohydrate transport and metabolism
Gene Blattner Number Signal Log ANOVA Gene Product and Function
Number of Ratio p-value
GATC
sites*
crr b2417 1 1.07 0.026 PTS system, glucose-specific IIA component
deoB b4383 1 1.05 0.041 phosphopentomutase
eno b2779 3 1.13 0.045 enolase
fba b2925 0 1.48 0.002 fructose-bisphosphate aldolase, class II
galK b0757 2 1.45 0.003 galactokinase
galM b0756 2 1.15 0.002 galactose-l-epimerase (mutarotase)
glk b2388 2 1.07 0.000 glucokinase
glpF b3927 2 1.58 0.035 facilitated diffusion of glycerol
g1pT b2240 0 1.25 0.010 sn-glycerol-3-phosphate permease
gnd b2029 3 1.17 0.004 gluconate-6-phosphate dehydrogenase,
decarboxylating
gpmA b0755 0 1.09 0.019 phosphoglyceromutase 1
malE b4034 2 2.80 0.000 periplasmic maltose-binding protein; substrate
recognition for transport and chemotaxis
malF b4033 2 1.17 0.002 part of maltose permease, periplasmic
malG b4032 3 1.02 0.001 part of maltose permease, inner membrane
malK b4035 2 2.44 0.001 ATP-binding component of transport system for
maltose
malP b3417 4 1.34 0.006 maltodextrin phosphorylase
mgsA b0963 0 1.36 0.011 methylglyoxal synthase
mtlD b3600 0 1.30 0.030 mannitol-1 -phosphate dehydrogenase
pfkA b3916 4 1.27 0.002 6-phosphofructokinase I
pgk b2926 3 1.44 0.002 phosphoglycerate kinase
ptsG b1101 1 1.24 0.009 PTS system, glucose-specific IIBC component
ptsH b2415 1 1.01 0.030 PTS system protein HPr
ptsl b2416 2 1.15 0.024 PEP-protein phosphotransferase system enzyme I
rbsB b3751 3 1.02 0.030 D-ribose periplasmic binding protein
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Carbohydrate transport and metabolism
talB b0008 1 1.12 0.008 transaldolase B
treB b4240 5 2.30 0.000 PTS system enzyme II, trehalose specific
treC b4239 1 1.19 0.015 trehalase 6-P hydrolase
Cell motility
Gene Blattner Number Signal Log ANOVA Gene Product and Function
Number of Ratio p-value
GATC
sites*
b3836 2 1.28 0.000 orf, hypothetical protein
flgB b1073 1 1.36 0.009 flagellar biosynthesis, cell-proximal portion of basal-
body rod
flgC b1074 1 1.62 0.006 flagellar biosynthesis, cell-proximal portion of basal-
body rod
flgD b1075 0 1.04 0.018 flagellar biosynthesis, initiation of hook assembly
flgE b1076 2 1.75 0.004 flagellar biosynthesis, hook protein
flgF b1077 4 1.51 0.009 flagellar biosynthesis, cell-proximal portion of basal-
body rod
flgG b1078 1 1.59 0.005 flagellar biosynthesis, cell-distal portion of basal-body
rod
flgL b1083 1 1.17 0.023 flagellar biosynthesis; hook-filament junction protein
fliN b1070 2 1.14 0.014 protein of flagellar biosynthesis
fliC b1923 0 1.55 0.023 flagellar biosynthesis; flagellin, filament structural
protein
fliG b1939 3 1.12 0.002 flagellar biosynthesis, component of motor switching
and energizing, enabling rotation and determining its
direction
fliL b1944 0 1.23 0.001 fla ellar biosynthesis
fliN b1946 3 1.18 0.011 flagellar biosynthesis, component of motor switch and
energizing, enabling rotation and determining its
direction
prIA b3300 2 1.67 0.002 putative ATPase subunit of translocase
secB b3609 3 1.08 0.007 protein export; molecular chaperone; may bind to
sianel sequence
secG b3175 0 1.63 0.015 protein export - membrane protein
yajC b0407 1 1.38 0.000 orf, hypothetical protein
Cell wall/membrane biogenesis
Gene Blattner Number Signal Log ANOVA Gene Product and Function
Number of Ratio p-value
GATC
sites*
ompA b0957 1 1.82 0.036 outer membrane protein 3a (11*;G;d)
ompC b2215 1 2.08 0.004 outer membrane protein lb (Ib;c)
ompF b0929 0 2.22 0.002 outer membrane protein la (la;b;F)
ompT b0565 0 1.04 0.012 outer membrane protein 3b (a), protease VII
ompX b0814 1 2.10 0.002 outer membrane protein X
pal b0741 2 1.32 0.007 peptidoglycan-associated lipoprotein
spr b2175 0 1.48 0.002 putative lipoprotein
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El; segregation of daughter chromosomes
Cell division
Gene Blattner Number Signal Log ANOVA Gene Product and Function
Number of Ratio p-value
GATC
sites*
sulA b0958 4 0.95 0.004 suppressor of Ion; inhibits cell division and ftsZ ring
formation
Energy production and conversion
Gene Blattner Number Signal Log ANOVA Gene Product and Function
Number of GATC Ratio p-value
sites*
ackA b2296 0 1.18 0.045 acetate kinase
atpA b3734 0 1.54 0.009 membrane-bound ATP synthase, Fl sector, alpha-
subunit
atpB b3738 1 1.01 0.007 membrane-bound ATP synthase, FO sector, subunit a
atpC b3731 2 1.29 0.025 membrane-bound ATP synthase, F1 sector, epsilon-
subunit
atpD b3732 3 1.69 0.004 membrane-bound ATP synthase, F1 sector, beta-
subunit
atpE b3737 3 1.45 0.002 membrane-bound ATP synthase, FO sector, subunit c
atpF b3736 4 1.41 0.003 membrane-bound ATP synthase, FO sector, subunit b
atpG b3733 1 1.45 0.006 membrane-bound ATP synthase, F1 sector, gamma-
subunit
atpH b3735 1 1.28 0.003 membrane-bound ATP synthase, F1 sector, delta-
subunit
cydA b0733 3 1.11 0.026 cytochrome d terminal oxidase, polypeptide subunit I
fdol b3892 1 1.08 0.015 formate dehydrogenase, cytochrome B556 (FDO)
subunit
frdA b4154 2 1.11 0.002 fumarate reductase, anaerobic, flavoprotein subunit
frdB b4153 0 1.61 0.030 fumarate reductase, anaerobic, iron-sulfur protein
subunit
galT b0758 1 1.52 0.000 galactose-1-phosphate uridylyltransferase
glcB b2976 0 1.89 0.015 malate synthase G
glpC b2243 1 1.10 0.000 sn-glycerol-3-phosphate dehydrogenase (anaerobic),
K-small subunit
glpK b3926 1 1.41 0.039 glycerol kinase
IpdA bO116 0 1.26 0.026 lipoamide dehydrogenase (NADH); component of 2-
oxodehydrogenase and pyruvate complexes; L-
protein of glycine cleavage complex
mdh b3236 0 1.90 0.006 malate dehydrogenase
nuoB b2287 0 1.29 0.009 NADH dehydrogenase I chain B
nuoH b2282 2 1.14 0.019 NADH dehydrogenase I chain H
nuoK b2279 1 1.04 0.004 NADH dehydrogenase I chain K
nuoL b2278 2 1.15 0.004 NADH dehydrogenase I chain L
ppa b4226 0 1.66 0.003 inorganic pyrophosphatase
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Inoraanic ion transport and metabolism
Gene Blattner Number Signal Log ANOVA Gene Product and Function
Number of Ratio p-value
GATC
sites*
b2431 2 1.52 0.000 orf, hypothetical protein
focA b0904 2 1.17 0.008 probable formate transporter (formate channel 1)
phnA b4108 1 1.03 0.005 orf, hypothetical protein
sodB b1656 1 1.29 0.018 superoxide dismutase, iron
Lipid transport and metabolism
Gene Blattner Number Signal Log ANOVA Gene Product and Function
Number of GATC Ratio p-value
sites*
accB b3255 1 1.26 0.006 acetylCoA carboxylase, BCCP subunit; carrier of
biotin
accC b3256 1 1.22 0.002 acetyl CoA carboxylase, biotin carboxylase subunit
accD b2316 2 1.13 0.002 acetylCoA carboxylase, carboxytransferase
component, beta subunit
acpP b1094 0 1.38 0.000 acyl carrier protein
fabB b2323 2 1.40 0.001 3-oxoacyl-[acyl-carrier-protein] synthase I
fabF b1095 1 1.06 0.005 3-oxoacyl-[acyl-carrier-protein] synthase 11
fabl b1288 0 1.11 0.006 enoyl-[acyl-carrier-protein] reductase (NADH)
Nucleotide transport and metabolism
Gene Blattner Number Signal Log ANOVA Gene Product and Function
Number of GATC Ratio p-value
sites*
cdd b2143 3 1.04 0.016 cytidine/deoxycytidine deaminase
deoD b4384 2 1.97 0.005 purine-nucleoside phosphorylase
guaB b2508 2 1.15 0.022 IMP dehydrogenase
nupC b2393 2 1.58 0.005 permease of transport system for 3 nucleosides
prsA b1207 2 1.28 0.008 phosphoribosylpyrophosphate synthetase
purA b4177 2 1.50 0.012 adenylosuccinate synthetase
udp b3831 0 1.05 0.051 uridine phosphorylase
Posttranslational modification, protein turnover, chaperones
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
ahpC b0605 1 1.12 0.011 alkyl hydroperoxide reductase, C22 subunit;
detoxification of hydroperoxides
grpE b2614 3 1.83 0.030 phage lambda replication; host DNA synthesis; heat
shock protein; protein repair
hflB b3178 1 1.47 0.024 degrades sigma32, integral membrane peptidase, cell
division protein
slyD b3349 4 1.20 0.010 FKBP-type peptidyl-prolyl cis-trans isomerase
(rotamase)
sspA b3229 0 1.10 0.020 regulator of transcription; stringent starvation protein A
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Posttranslational modification, protein turnover, chaperones
tig b0436 0 1.42 0.005 trigger factor; a molecular chaperone involved in cell
division
tpx b1324 1 1.14 0.027 thiol peroxidase
yeaA b1778 1 -1.01 0.007 orf, hypothetical protein
Replication, recombination and repair
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
hupA b4000 0 1.04 0.015 DNA-binding protein HU-alpha (HU-2)
hupB b0440 3 1.89 0.001 DNA-binding protein HU-beta, NS1 (HU-1)
priB b4201 4 2.19 0.001 primosomal replication protein N
recA b2699 1 2.02 0.000 DNA strand exchange and renaturation, DNA-
dependent ATPase, DNA- and ATP-dependent
coprotease
smf 1 1 -1.31 0.000 orf, fragment 1
Signal transduction mechanisms
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
crp b3357 0 1.13 0.034 cyclic AMP receptor protein
dksA b0145 1 1.18 0.003 dnaK suppressor protein
yebJ b1831 1 1.16 0.008 orf, hypothetical protein
ygaG b2687 1 1.42 0.005 orf, hypothetical protein
Secondar! metabolites biosynthesis, transport and catabolism
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
fabG b1093 1 1.18 0.001 3-oxoacyl-[acyl-carrier-protein] reductase
srlD b2705 1 1.64 0.000 glucitol (sorbitol)-6-phosphate dehydrogenase
Transcription
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
cspA b3556 0 1.34 0.019 cold shock protein 7.4, transcriptional activator of hns
cspB b1557 0 1.22 0.050 cold shock protein; may affect transcription
fliA b1922 3 1.13 0.008 flagellar biosynthesis; alternative sigma factor 28;
regulation of flagellar operons
fliM b1945 1 1.25 0.006 flagellar biosynthesis, component of motor switch and
energizing, enabling rotation and determining its
direction
lexA b4043 1 1.60 0.001 regulator for SOS(lexA) regulon
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Transcription
rpoA b3295 2.54 0.001 RNA polymerase, alpha subunit
rpoZ b3649 0 1.04 0.014 RNA polymerase, omega subunit
yeeD jb2012 1 1.19 0.009 orf, hypothetical protein
Translation
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
asnS b0930 0 1.50 0.012 asparagine tRNA synthetase
efp b4147 3 1.14 0.026 elongation factor P (EF-P)
fusA b3340 1 1.78 0.004 GTP-binding protein chain elongation factor EF-G
gInS b0680 4 1.10 0.003 glutamine tRNA synthetase
infB b3168 4 1.08 0.029 protein chain initiation factor IF-2
rplA b3984 0 2.02 0.002 50S ribosomal subunit protein L1, regulates synthesis
of L1 and Ll1
rplB b3317 1 2.49 0.004 50S ribosomal subunit protein L2
rplC b3320 8 2.58 0.002 50S ribosomal subunit protein L3
rplD b3319 1 2.68 0.002 50S ribosomal subunit protein L4, regulates
expression of S10 operon
rplE b3308 0 3.06 0.001 50S ribosomal subunit protein L5
rplF b3305 3 2.08 0.006 50S ribosomal subunit protein L6
rpll b4203 3 1.81 0.006 50S ribosomal subunit protein L9
rplJ b3985 0 2.04 0.008 50S ribosomal subunit protein L10
rplK b3983 1 1.80 0.005 50S ribosomal subunit protein L 11
rpL b3986 2 1.29 0.044 50S ribosomal subunit protein L7/L12
rplM b3231 2 1.50 0.003 50S ribosomal subunit protein L13
rplN b3310 1 1.64 0.003 50S ribosomal subunit protein L14
rpIO b3301 1 2.53 0.002 50S ribosomal subunit protein L15
rpP b3313 2 2.26 0.002 50S ribosomal subunit protein L16
rplQ b3294 5 2.21 0.013 50S ribosomal subunit protein L17
rpIR b3304 2 2.53 0.006 50S ribosomal subunit protein L18
rplS b2606 0 1.67 0.005 50S ribosomal subunit protein L19
rplT b1716 3 1.92 0.008 50S ribosomal subunit protein L20, and regulator
rplU b3186 1 1.60 0.003 50S ribosomal subunit protein L21
rplV b3315 1 2.92 0.001 50S ribosomal subunit protein L22
rplW b3318 4 2.55 0.010 50S ribosomal subunit protein L23
rpIX b3309 2 1.83 0.005 50S ribosomal subunit protein L24
rpmA b3185 1 1.46 0.004 50S ribosomal subunit protein L27
rpmB b3637 3 1.91 0.009 50S ribosomal subunit protein L28
rpmC b3312 4 2.06 0.001 50S ribosomal subunit protein L29
rpmD b3302 2 3.07 0.004 50S ribosomal subunit protein L30
rpmF b1089 1 1.40 0.003 50S ribosomal subunit protein L32
rpmG b3636 0 1.88 0.037 50S ribosomal subunit protein L33
rpmH b3703 3 1.92 0.017 50S ribosomal subunit protein L34
_rpml b1717 2 1.85 0.003 50S ribosomal subunit protein A
rpmJ b3299 1 1.33 0.001 50S ribosomal subunit protein L36
rpsA b0911 2 1.63 0.000 30S ribosomal subunit protein S1
_rpsB b0169 1 2.26 0.001 30S ribosomal subunit protein S2
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Translation
rpsC b3314 4 2.56 0.003 30S ribosomal subunit protein S3
rpsD b3296 2 2.34 0.001 30S ribosomal subunit protein S4
rpsE b3303 0 2.94 0.002 30S ribosomal subunit protein S5
rpsF b4200 0 2.58 0.001 30S ribosomal subunit protein S6
rpsG b3341 2 2.61 0.002 30S ribosomal subunit protein S7, initiates assembly
rpsH b3306 2 2.64 0.004 30S ribosomal subunit protein S8, and regulator
rpsl b3230 0 2.01 0.005 30S ribosomal subunit protein S9
rpsJ b3321 1 2.43 0.001 30S ribosomal subunit protein S10
rpsK b3297 4 2.66 0.001 30S ribosomal subunit protein S11
rpsL b3342 1 2.18 0.001 30S ribosomal subunit protein S12
rpsM b3298 1 2.11 0.001 30S ribosomal subunit protein S13
rpsN b3307 4 2.13 0.005 30S ribosomal subunit protein S14
rpsO b3165 3 2.03 0.006 30S ribosomal subunit protein S15
rpsP b2609 0 2.40 0.002 30S ribosomal subunit protein S16
rpsQ b3311 1 1.13 0.011 30S ribosomal subunit protein S17
rpsR b4202 1 1.87 0.005 30S ribosomal subunit protein S18
rpsS b3316 1 1.99 0.006 30S ribosomal subunit protein S19
rpsT b0023 0 1.38 0.010 30S ribosomal subunit protein S20
thrS b1719 2 1.39 0.000 threonine tRNA synthetase
trmD b2607 6 1.82 0.002 tRNA methyltransferase; tRNA (guanine-7-)-
methyltransferase
tsf bOl 170 2 1.54 0.023 protein chain elongation factor EF-Ts
tufA b3339 0 1.93 0.007 protein chain elongation factor EF-Tu (duplicate of
tufB)
tufB b3980 0 2.46 0.004 protein chain elongation factor EF-Tu (duplicate of
tufA)
yfjA b2608 4 1.75 0.004 orf, hypothetical protein
yjgF b4243 4 1.45 0.025 orf, hypothetical protein
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Unclassified, unknown or general function prediction only
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
fliZ b1921 2 1.22 0.002 orf, hypothetical protein
hns b1237 0 1.24 0.002 DNA-binding protein HLP-II (HU, BH2, HD, NS);
pleiotropic regulator
lamB b4036 1 3.15 0.001 phage lambda receptor protein; maltose high-affinity
receptor
malM b4037 0 1.29 0.002 periplasmic protein of mal regulon
slyB b1641 2 1.91 0.003 putative outer membrane protein
smp b4387 0 1.13 0.018 orf, hypothetical protein
wzzB b2027 1 1.06 0.006 regulator of length of O-antigen component of
lipopolysaccharide chains
ybgF b0742 2 1.12 0.016 orf, hypothetical protein
yceD b1088 1 1.49 0.001 orf, hypothetical protein
yeaC b1777 1 -1.09 0.029 orf, hypothetical protein
yebF b1847 1 1.11 0.004 orf, hypothetical protein
yebG b1848 2 1.60 0.001 orf, hypothetical protein
*Number of GATC sites in the upstream sequence regions was determined by searching -400 bp from the
start site of each gene.
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Table 4.3: Genes differentially expressed at the basal level (2-fold) in dam mutS mutant E.
coli compared to wildtype. Only genes for which ANOVA p < 0.05 are listed.
Amino acid transport and metabolism
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
artl b0863 0 1.21 0.002 arginine 3rd transport system periplasmic binding
protein
artQ b0862 2 1.06 0.000 arginine 3rd transport system permease protein
ydgR b1634 1 1.27 0.047 putative transport protein
Carbohydrate trans ort and metabolism
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
b2097 1 1.07 0.000 orf, hypothetical protein
crr b2417 1 1.08 0.050 PTS system, glucose-specific IIA component
fba b2925 0 1.17 0.013 fructose-bisphosphate aldolase, class II
galK b0757 2 1.12 0.024 galactokinase
galM b0756 2 1.04 0.004 galactose-l-epimerase (mutarotase)
l k b2388 2 1.43 0.000 glucokinase
gpmA b0755 0 1.02 0.023 phosphoglyceromutase 1
malE b4034 2 2.12 0.002 periplasmic maltose-binding protein; substrate
recognition for transport and chemotaxis
malK b4035 2 1.60 0.018 ATP-binding component of transport system for
maltose
pfkA b3916 4 1.22 0.006 6-phosphofructokinase I
pgk b2926 3 1.10 0.027 phosphoglycerate kinase
ptsH b2415 1 1.17 0.035 PTS system protein HPr
ptsl b2416 2 1.18 0.045 PEP-protein phosphotransferase system enzyme I
Cell motility
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
flgB b1073 1 1.20 0.023 flagellar biosynthesis, cell-proximal portion of basal-
body rod _
flgC b1074 1 1.43 0.020 flagellar biosynthesis, cell-proximal portion of basal-
body rod_
figE b1076 2 1.41 0.016 flagellar biosynthesis, hook protein
fliL b1944 0 1.02 0.005 flagellar biosynthesis
prlA b3300 2 1.55 0.003 putative ATPase subunit of translocase
Cell wall/membrane biogenesis
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio I p-value
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GATC
sites*
ompA b0957 1 1.86 0.037 outer membrane protein 3a (Il*;G;d)
ompC b2215 1 1.39 0.050 outer membrane protein lb (b;c)
ompX b0814 1 2.41 0.001 outer membrane protein X
Energy production and conversion
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
ppa b4226 0 1.26 0.031 inor anic pyrophosphatase
Inorganic ion transport and metabolism
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
b2431 2 1.54 0.000 orf, hypothetical protein
focA b0904 2 1.13 0.010 probable formate transporter (formate channel 1)
Lipid transport and metabolism
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
accB b3255 1 1.09 0.012 acetylCoA carboxylase, BCCP subunit; carrier of
biotin
accC b3256 1 1.25 0.003 acetyl CoA carboxylase, biotin carboxylase subunit
accD b2316 2 1.05 0.004 acetylCoA carboxylase, carboxytransferase
component, beta subunit
acpP b1094 0 1.19 0.002 acyl carrier protein
fabB b2323 2 1.10 0.010 3-oxoacyl-[acyl-carrier-protein] synthase I
Nucleotide transport and metabolism
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
dut b3640 3 1.07 0.000 deoxyuridinetriphosphatase
guaB b2508 2 1.26 0.012 IMP dehydrogenase
nupC b2393 2 1.24 0.016 permease of transport system for 3 nucleosides
prsA b1207 2 1.01 0.053 phosphoribosylpyrophosphate synthetase
Posttranslational modification, protein turnover, chaperones
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
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slyD b3349 4 1.07 0.028 FKBP-type peptidyl-prolyl cis-trans isomerase
(rotamase)
tig b0436 0 1.29 0.008 trigger factor; a molecular chaperone involved in cell
division
yeaA b1778 1 -1.36 0.001 orf, hypothetical protein
Replication, recombination and repair
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
hupB b0440 3 1.60 0.003 DNA-binding protein HU-beta, NS1 (HU-1)
priB b4201 4 1.63 0.018 primosomal replication protein N
recA b2699 1 1.70 0.000 DNA strand exchange and renaturation, DNA-
dependent ATPase, DNA- and ATP-dependent coprot
smf 1 1 -1.04 0.001 orf, fragment 1
Signal transduction mechanisms
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
ygaG b2687 1 1.47 0.010 putative 2-component transcriptional regulator
Secondary metabolites biosynthesis, transport and catabolism
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
srlD b2705 1 1.16 0.011 glucitol (sorbitol)-6-phosphate dehydrogenase
Transcription
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
rpoA b3295 2 2.15 0.004 RNA polymerase, alpha subunit
Translation
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
fusA b3340 1 1.49 0.022 GTP-binding protein chain elongation factor EF-G
rplA b3984 0 1.41 0.015 50S ribosomal subunit protein L1, regulates synthesis
of L1 and L11
rplB | b3317 1 1.84 0.021 50S ribosomal subunit protein L2
rplC b3320 8 1.84 0.032 50S ribosomal subunit protein L3
rplD b3319 1 1.93 0.025 50S ribosomal subunit protein L4, regulates
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expression of S10 operon
rpE b3308 0 2.27 0.012 50S ribosomal subunit protein L5
rplF b3305 3 1.70 0.023 50S ribosomal subunit protein L6
rplJ b3985 0 1.84 0.030 50S ribosomal subunit protein L10
rplM b3231 2 1.02 0.031 50S ribosomal subunit protein L13
rpO b3301 1 2.42 0.004 50S ribosomal subunit protein L15
rpP b3313 2 1.97 0.010 50S ribosomal subunit protein L16
rp R b3304 2 2.00 0.026 50S ribosomal subunit protein L18
rplU b3186 1 1.10 0.040 50S ribosomal subunit protein L21
rplV b3315 1 2.46 0.007 50S ribosomal subunit protein L22
rplW b3318 4 1.90 0.049 50S ribosomal subunit protein L23
rpmA b3185 1 1.11 0.046 50S ribosomal subunit protein L27
rpmC b3312 4 1.74 0.005 50S ribosomal subunit protein L29
rpmD b3302 2 2.31 0.024 50S ribosomal subunit protein L30
rpmF b1089 1 1.41 0.004 50S ribosomal subunit protein L32
rpml b1717 2 1.54 0.020 50S ribosomal subunit protein A
rpmJ b3299 1 1.24 0.002 50S ribosomal subunit protein L36
rpsA b0911 2 1.27 0.002 30S ribosomal subunit protein S1
rpsB b0169 1 1.76 0.007 30S ribosomal subunit protein S2
rpsC b3314 4 2.40 0.010 30S ribosomal subunit protein S3
rpsD b3296 2 2.03 0.003 30S ribosomal subunit protein S4
rpsE b3303 0 2.44 0.007 30S ribosomal subunit protein S5
rpsF b4200 0 1.69 0.041 30S ribosomal subunit protein S6
rpsG b3341 2 2.28 0.009 30S ribosomal subunit protein S7, initiates assembly
rpsH b3306 2 2.03 0.022 30S ribosomal subunit protein S8, and regulator
rpsl b3230 0 1.61 0.031 30S ribosomal subunit protein S9
rpsJ b3321 1 1.98 0.009 30S ribosomal subunit rotein S10
rpsK b3297 4 2.24 0.007 30S ribosomal subunit protein S11
rpsL b3342 1 1.69 0.016 30S ribosomal subunit protein S12
rpsM b3298 1 1.78 0.004 30S ribosomal subunit protein S13
rpsN b3307 4 1.40 0.045 30S ribosomal subunit protein S14
rpsP b2609 0 1.73 0.052 30S ribosomal subunit protein S16
rpsQ b3311 1 1.13 0.020 30S ribosomal subunit protein S17
rpsS b3316 1 1.42 0.038 30S ribosomal subunit protein S19
rpsT b0023 0 1.05 0.054 30S ribosomal subunit protein S20
thrS b1719 2 1.16 0.002 threonine tRNA synthetase
trmD b2607 6 1.34 0.023 tRNA methyltransferase; tRNA (guanine-7-)-
methyltransferase
tufA b3339 0 1.78 0.023 protein chain elongation factor EF-Tu (duplicate of
tufB)
tufB b3980 0 2.27 0.026 protein chain elongation factor EF-Tu (duplicate of
tufA)
yfjA b2608 4 1.32 0.029 orf, hypothetical protein
Unclassified, unknown or general function prediction only
Gene Blattner Number Signal ANOVA Gene Product and Function
Number of Log Ratio p-value
GATC
sites*
b0332 | b0332 3 | 1.03 | 0.001 | orf, hypothetical protein
122
Unclassified, unknown or general function prediction only
b2655 b2655 2 1.16 0.009 orf, hypothetical protein
ecs0702 b0667 0 1.41 0.003 putative RNA
gigS b3049 2 -1.82 0.033 glycogen biosynthesis, rpoS dependent
insA 2 0 1.39 0.004 IS1 protein InsA
lamB b4036 1 2.18 0.012 phage lambda receptor protein; maltose high-affinity
receptor
pheL b2598 1 1.03 0.002 leader peptide of chorismate mutase-P-prephenate
dehydratase
slyB b1641 2 1.59 0.021 putative outer membrane protein
yadH b0128 2 1.06 0.002 orf, hypothetical protein
ybjX b0877 1 1.42 0.006 putative enzyme
ycdV b1031 0 1.79 0.000 putative ribosomal protein
yceD b1088 1 1.35 0.002 orf, hypothetical protein
yeaC b1777 1 -1.38 0.008 orf, hypothetical protein
yebF b1847 1 1.40 0.001 orf, hypothetical protein
yebG b1848 2 1.11 0.011 orf, hypothetical protein
yecR b1904 0 1.09 0.002 orf, hypothetical protein
ydhl b1643 2 1.00 0.001 orf, hypothetical protein
ydiH b1685 0 1.21 0.000 orf, hypothetical protein
ygiA b3036 1 1.48 0.000 orf, hypothetical protein
yhcE b3217 2 1.21 0.000 orf, hypothetical protein
yi82 1 1 1.23 0.027 IS186 and IS421 hypothetical protein
yihM b3873 1 1.08 0.004 orf, hypothetical protein
yneK b1527 1 1.02 0.025 orf, hypothetical protein
ytfl b4215 0 1.05 0.010 orf, hypothetical protein
*Number of GATC sites in the upstream
from the start site of each gene.
sequence regions was determined by searching -400 bp
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Table 4.4: Genes differentially expressed at the basal level (2-fold) in mutS mutant E.
coli compared to wildtype. Only genes for which ANOVA p < 0.05 are listed.
Amino acid transport and metabolism
Gene Blattner Signal Log ANOVA Gene Product and Function
Number Ratio p-value
gadB b1493 1.10 0.000 glutamate decarboxylase isozyme
trpA b1260 1.71 0.048 tryptophan synthase, alpha protein
trpB b1261 1.65 0.027 tryptophan synthase, beta protein
trpC b1262 1.52 0.013 N-(5-phosphoribosyl)anthranilate isomerase and indole-3-
glycerolphosphate synthetase
trpD b1263 1.49 0.016 anthranilate synthase component II, glutamine
amidotransferase and phosphoribosylanthrani
trpE b1264 1.13 0.023 anthranilate synthase component I
Carbohydrate transport and metabolism
Gene Blattner Signal Log ANOVA Gene Product and Function
Number Ratio p-value
eno b2779 1.12 0.052 enolase
fba b2925 1.12 0.009 fructose-bisphosphate aldolase, class II
malE b4034 1.60 0.017 periplasmic maltose-binding protein; substrate recognition for
transport and chemotaxis
malK b4035 1.35 0.048 ATP-binding component of transport system for maltose
Cell motility
Gene Blattner Signal Log ANOVA Gene Product and Function
Number Ratio p-value
flqE b1076 1.25 0.027 flagellar biosynthesis, hook protein
fliC b1923 1.26 0.045 flagellar biosynthesis; flagellin, filament structural protein
Energy production and conversion
Gene Blattner Signal Log ANOVA Gene Product and Function
Number Ratio p-value
ppa b4226 1.13 0.033 inorganic pyrophosphatase
Replication, recombination and repair
Gene Blattner Signal Log ANOVA Gene Product and Function
Number Ratio p-value
dps b0812 1.02 0.029 1global regulator, starvation conditions
Translation
Gene Blattner Signal Log ANOVA Gene Product and Function
Number Ratio p-value
rpIO b3301 1.42 0.052 50S ribosomal subunit protein L15
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Unclassified, unknown or general function prediction only
Gene Blattner Signal Log ANOVA Gene Product and Function
Number Ratio p-value
lamB b4036 2.00 0.039 phase lambda receptor protein; maltose high-affinity receptor
yfiD b2579 1.20 0.009 putative formate acetyltransferase
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Chapter 5: Cisplatin-induced gene expression and double-
strand break formation in DNA adenine methyltransferase
(dam) deficient and mismatch repair deficient Escherichia
coli
Adapted from:
Jennifer L. Robbins-Manke, Zoran Z. Zdraveski, Peter Rye, Martin Marinus, John M.
Essigmann
Abstract
Loss of DNA mismatch repair (MMR) confers resistance to DNA-damaging agents including the
anticancer drug cisplatin. Cisplatin tolerance in MMR-deficient cells was initially discovered in
E. coli, where methylation deficient dam mutants exhibit hypersensitivity to cisplatin and dam
mutants with an additional mutation in MMR show near wild-type levels of resistance. A
prevalent explanation for this observation is the futile repair model, which proposes in dam
mutants MMR attempts futile cycles of repair opposite cisplatin-DNA adducts. However it has
recently been shown that MutS may contribute to toxicity by preventing the recombinational
bypass of a cisplatin-modified substrate, and recombination is an essential mechanism for
tolerating cisplatin damage. To help elucidate the role of MMR in mediating cisplatin-induced
toxicity, we examine the global transcriptional responses of wild-type, dam, dam mutS, and
mutS mutant E. coli following cisplatin treatment and determine a dose-response of several
SOS and DNA repair genes. While the hypersensitivity of recombination-deficient strains
suggests that cisplatin treatment may induce secondary DNA damage in the form of strand
breaks, we also measure the level of double-strand breaks (DSBs) in each strain by single-cell
electrophoresis. Our results show that Dam-deficient E. coli exhibit the most robust
transcriptional response following cisplatin treatment. In addition, cisplatin treatment induces
DSB formation and the SOS response in a dose-dependent manner, and DSBs are greatest in
the hypersensitive dam mutant strain. The higher level of cisplatin-induced DSBs in dam
mutants is dependent on MutS and may explain why this strain is hypersensitive to cisplatin.
5.1 Introduction
The anticancer drug cisplatin exhibits clinical efficacy in the treatment of testicular
cancer, where cisplatin-based therapies can afford cure rates exceeding 90% (58). However
the effectiveness of the drug in treating other human cancers is limited by harmful side effects
(422), and human cancers can acquire resistance to the drug which further reduces its clinical
utility. While it is generally accepted that the toxic effects of the drug arise from its reaction with
DNA to form mainly cisplatin-DNA intrastrand crosslinks (80,209,775), the mechanisms by
which cisplatin-DNA adducts induce cell death are not well understood. Previous work has
implicated DNA mismatch repair (MMR) in mediating cisplatin-induced toxicity. E. coil (224) and
human cells (177,213,497,540,567) deficient in MMR exhibit increased survival and tolerance to
drug treatment, and similarly loss of MMR in mouse xenografts confers resistance to cisplatin
treatment (216). Moreover, treatment of human tumor cells with cisplatin leads to an
enrichment of MMR-deficient cell populations that are resistant to the drug (214,215). Our lab
and others have also shown that the bacterial mismatch recognition protein MutS (778) and its
human homologue MutSuo (179,473,756) bind cisplatin-modified DNA in vitro. Despite the
aforementioned correlative data, the exact mechanisms by which MMR contributes to the toxic
effects of cisplatin are not known, and the biochemical events downstream of MutS recognition
of cisplatin lesions have not been fully elucidated.
The phenomenon of cisplatin tolerance in mismatch repair deficient cells was initially
discovered in E. coil; methylation deficient dam mutants exhibit high sensitivity to cisplatin
whereas dam mutants with an additional mutation in either of the mismatch repair genes mutS
or mutL show near wild-type levels of resistance (224). Dam encodes DNA adenine
methyltransferase which acts at GATC sites of the E. coil genome. Because Dam methylation
is a postreplicative process, a replicating chromosome is transiently hemimethylated following
the replication fork. This hemimethylated state allows MMR to distinguish between the parent
and the newly synthesized, or unmethylated, daughter strand when initiating repair of a
misincorporation error. Mismatch recognition requires MutS, which specifically binds
mismatches and small insertion/deletion loops (670). MutS, along with MutL and ATP, are
required to activate the latent endonuclease MutH (2,257), which preferentially binds
hemimethylated DNA and makes an incision 5' to the G at a GATC site in the unmethylated
strand (20,740). While fully methylated DNA is resistant to MutH incision, in adenine
unmethylated DNA such as the genomic DNA found in dam mutants, both strands can be
substrates for MutH incision (20).
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A prevalent explanation for MMR-mediated sensitivity to DNA damage is the futile-
cycling model originally proposed to explain MMR-mediated sensitivity of cells to alkyation
damage (351). According to this model, in the case where error-prone polymerases bypass a
cisplatin adduct and insert an incorrect base opposite the adduct or in the case of dam mutants
where the strand discrimination signal is lost, mismatch repair attempts repair at the sites
opposite cisplatin-DNA adducts. The cisplatin lesion remains, however, and thus another repair
cycle is initiated leading to futile repair cycling and a persistent gap in the DNA; futile cycling
coupled with replication leads to replication fork collapse and a lethal double-strand break (DSB)
at the site of the gap. Previous findings have supported this model to the extent that MutS
specifically recognizes DNA modified with cisplatin (778). However it has recently been shown
in vitro that MutS can inhibit RecA-mediated strand exchange of two recombination substrates
when one substrate is modified with cisplatin (90); this observation indicates that MMR may
recognize two DNA molecules as divergent sequences when one molecule contains cisplatin
and may abort the strand exchange reaction (in this way MMR is functioning not in post-
replicative MMR but in antirecombination (398,662,748,749)). Therefore MutS binding to a
cisplatin adduct may prevent recombinational bypass of the adduct, and we have previously
shown that recombination is an essential mechanism for tolerating cisplatin damage (779).
It is important to note that E. coil deficient in Dam are hyper-recombinogenic (445,446)
and require recombination for viability (443,557). The requirement for recombination in dam
mutants is dependent on functional MMR and is most likely due to the higher level of DNA
double-strand breaks (DSBs) found in dam mutants, which is likewise dependent on functional
MMR (593,731). Thus in a dam mutant cell treated with cisplatin, where both MMR and
cisplatin are independently generating recombination substrates, the recombinational repair
capacity of the cell may simply be overloaded, thus causing cell death; inactivating mismatch
repair alleviates some of the burden on the recombination machinery and thus increases
tolerance to exogenous or cisplatin-induced damage. It is also possible, however, that the
hypersensitivity of dam mutants to cisplatin treatment is not due to an additive level of MMR-
induced and cisplatin-induced recombination substrates; rather MMR may mediate toxicity to
cisplatin by mechanisms such as futile cycling or antirecombination as described above. While
futile cycling and antirecombination mechanisms of MMR-mediated toxicity to cisplatin have not
been directly tested in vivo, more work is necessary to describe the role of MMR in mediating
cisplatin-induced toxicity.
In the present study we examine the global transcriptional responses of wild-type, dam,
dam mutS, and mutS mutant E. coil after treatment with a toxic dose of cisplatin in order to help
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elucidate the role of mismatch repair in mediating cisplatin-induced toxicity. We also determine
the dose-response at the transcriptional level of several SOS response genes and other genes
involved in DNA repair by real-time reverse transcription-polymerase chain reaction (RT-PCR).
Furthermore, in order to examine the role of MMR in the production of DSBs following cisplatin
treatment, we determine by neutral single-cell microgel electrophoresis the number of DSBs in
each strain following treatment with increasing doses of cisplatin. Our results show that the
hypersensitive dam mutant strain responds to cisplatin treatment with the most robust
transcriptional response with over 180 genes differentially expressed following drug treatment.
Our results also show that cisplatin induces DSBs in a dose-dependent manner and that dam
mutants exhibit the greatest level of cisplatin-induced DSBs as well as the greatest up-
regulation of SOS genes. The level of DSBs in dam mutants surpasses the level that would be
expected if both MMR and cisplatin were inducing strand breaks only by independent
mechanisms (i.e., the level of strand breaks is not additive). Thus these results support a
model whereby mismatch repair proteins increase the level of secondary lesions resulting from
cisplatin damage in a Dam-deficient background.
5.2 Results
5.2.1 MutS binds to the major cisplatin adduct
The observation that MutS binds to DNA globally modified with a low number of cisplatin
adducts-on the average of three adducts per 162-bp oligonucleotide (778)-suggests that
MutS may recognize an oligonucleotide modified with a single cisplatin adduct as well. We
constructed a 24-bp probe containing a single, centrally located 1,2-d(GpG) cisplatin crosslink,
the major and presumably most cytotoxic cisplatin-DNA adduct (Fig. 5.1 B), and we examined
the binding by purified E. coli MutS to the modified probe by a DNA-retardation band shift assay
(Fig. 5.1C). The binding of MutS to the radiolabeled probe modified to contain a 1,2-d(GpG)
cisplatin crosslink was readily observed by a discrete, retarded band in the polyacrylamide gel
specific to the lanes that included MutS and the platinated probe. The fraction of the retarded
band shifted for the platinated probe increased with the increase of MutS concentration. For
example, the percentage of the shifted probe doubled (from 0.59% to 1.24%, relative to the
amount of total probe in each lane) when the MutS concentration was increased from 50 nM to
100 nM. Under identical conditions, MutS did not cause a shift of the unmodified control
homoduplex 24-bp probe. This result is consistent with previous reports showing that the MutS
homologue hMSH2 binds to a 100-bp probe site specifically modified with one 1,2-d(GpG)
intrastrand cisplatin crosslink (473) and that the hMutSu complex can recognize a 32-bp probe
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modified with a single 1,2-d(GpG) intrastrand crosslink (179). We also show that MutS retains
its ability to bind a G/T mismatch substrate when this substrate is modified with cisplatin (Fig.
5.1D)
5.2.2 Dam mutant E. coli are hypersensitive to cisplatin
We treated log-phase cultures of wild-type, dam, mutS, and dam mutS E. coli strains
with varying doses of cisplatin and show that the dam mutant is hypersensitive to cisplatin
treatment compared to the isogenic derivatives dam mutS and mutS (Fig. 5.2). Our data thus
confirm previous results that E. coli lacking DNA adenine methylation are more sensitive to DNA
damage and that a mutation in the mismatch repair protein MutS abrogates this sensitivity
1224). We also examined the sensitivity of a mutH derivative of the dam mutant (dam mutH)
and show that a mutation in the endonuclease also abrogates sensitivity.
5.2.3 Cisplatin-induced global gene expression
We used Affymetrix E. coli genome microarrays to determine the gene expression
changes in each strain after treatment with 150 pM cisplatin. Exponentially growing cultures
were treated for two hours in minimal salts medium containing drug, after which the cultures
were allowed to recover in LB broth for 90 minutes before RNA isolation. Conditions such as
(dose and recovery time were optimized to yield the greatest transcriptional response overall
(data not shown) as well as the greatest differential toxicity between the strains (Fig. 5.2).
Although our survival data show that 150 pM is a highly toxic dose, at the time we isolated total
RNA 90 minutes after drug treatment, the wild-type, dam mutS, and mutS treated cultures grew
by approximately 1 doubling while the dam treated culture had maintained a cell density of 2.1-
2.3 x 108 cells/ml by OD600, or a cell density slightly higher than the original starting cell density
when treatment began (data not shown). Mock treated cultures at this time had grown to a cell
density of -6 x 108 cells/ml and had underwent -1.5 doublings. Therefore treatment with a high
dose of drug did not cause massive cell death 90 minutes after exposure, even in the
hypersensitive dam mutant strain, and we were thus able to determine changes in gene
expression following cisplatin treatment.
We used the local-pooled-error (LPE) test (324) to compare gene expression levels of
each strain treated with drug to the gene expression levels measured in each mock-treated
strain. Strain-specific pairwise comparisons for each gene were made by taking the ratio of the
transcript level measured in the drug-treated strain to the transcript level in the mock-treated
strain, and changes in transcript levels between drug-treated and untreated cultures are
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expressed as signal log ratios (treated/untreated, log base 2). Fig. 5.3 shows the signal log
ratios for all -4,200 open reading frames plotted against the log 10p-value for all four strains.
Differentially expressed genes were filtered based on signal log ratio and p-value thresholds;
only genes with signal log ratios 1 < X < -1, which is at least a + 2-fold change, and LPE p-
values adjusted by the Benjamini and Hochberg method (40) to give a false discovery rate of
10% are included in Table 5.1. The most genes that exhibited at least a two fold-change and
that were removed based on high p-values (i.e., genes that exhibited high fold-change but also
high variability-open circles in Fig. 5.3) were found for dam and dam mutS strains. All genes
with an adjusted p-value < 0.10 and signal log ratios meeting the 2-fold change threshold are
listed in Tables 5.3-5.6. We also listed genes that meet the p-value threshold but that only show
moderate (less than 2-fold) differential gene expression to include genes with small changes in
transcript levels that may result in significant biological effects.
The data show that the mutant strains respond to cisplatin treatment at the
transcriptional level with many changes, both induction and repression, while wild-type E. coil do
not show many gene expression changes (Table 5. 1). Both dam and mutS strains exhibit
down-regulation of a large number genes involved in carbohydrate transport and metabolism
following cisplatin treatment, including genes encoding products of the sugar
phosphotransferase system (PTS). We have previously shown that many of these genes
exhibit higher basal transcript levels in dam mutant E. coli compared to wild-type (593). We
also see down-regulation of many genes encoding products in energy production and
conversion in dam mutant E. coil; interestingly several of these same genes are also up-
regulated at the basal level in dam E. coli compared to wild-type (593). Of these down-
regulated genes, dam E. coli show strong down-regulation of genes encoding subunits of
fumarate reductase, an enzyme that reduces fumarate to succinate in anaerobic respiration
(Table 5.4). In all four strains genes encoding products in flagellar biosynthesis are down-
regulated following cisplatin treatment (Tables 5.3-5.6). In addition to the large number of
down-regulated genes following cisplatin treatment, dam mutants also exhibit up-regulation of
many transcripts including genes involved in inorganic ion transport and metabolism as well as
in DNA metabolism (Table 5.4). Overall the data show that the hypersensitive dam mutant
strain responds to cisplatin treatment with the most robust transcriptional response with both up-
and down-regulation of many genes following drug exposure.
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Table 5.1: Total number of differentially expressed genes following cisplatin treatment (at
least 2-fold change, adjusted p < 0.10)
Gene Category Wild-type dam dam mutS mutS
Repressed Induced Repressed Induced Repressed Induced Repressed Induced
Amino acid transport 6 2 2 1 10 2
and metabolism
Carbohydrate transport 3 18 2 2 12 1
and metabolism
Cell division - 1 2 2 - 1
Cell motility 2 - 19 3 4 1 10 1
Cell processes 1 1 1
(adaptation/ protection)
Cell wall/membrane 1 4 2 2 1
biogenesis
Coenzyme transport 1
and metabolism
Energy production and 2 1 19 3 1 3
conversion
Inorganic ion transport 1 8 3 1
and metabolism
Intracellular trafficking,
secretion, and -- 1 - -
vesicular transport
Lipid transport and 1 1 1
metabolism
Nucleotide transport
- 5 4 - - -
and metabolism
Phage, transposon, or 1
plasmid
Posttranslational
modification, protein - 1 - 1
turnover, chaperones
Replication,
recombination and 1 2 3 12 1 4
repair
Secondary metabolites
biosynthesis, transport - 1 1 - - 2
and catabolism
Signal transduction 1 1 2
- 1 1 - _ 2 -
mechanisms
Transcription 1 1 6 4 1 - 1 4
Translation 1 - 3 8 - 4 2 5
Unknown or4 9 15 24 1 6 9 13
unclassified
Total 15 16 104 82 11 16 52 37
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:5.2.4 Cisplatin induces the SOS response
The SOS response is characterized by the coordinated de-repression of over 30 genes
regulated by the LexA repressor. The SOS response is induced when RecA is activated in the
presence of single-strand DNA; activated RecA then facilitates the proteolytic cleavage of the
LexA repressor, which binds a -20 base pair consensus sequence in the promoter/operon
regions of certain genes and thus prevents transcription in the absence of an SOS inducing
signal (723). Previous studies have shown that cisplatin induces the SOS response in E. coli
(44,366). A comparison of the expression of LexA-regulated genes in drug-treated versus
untreated strains shows that several SOS genes are induced following drug treatment. In wild-
type E. coli, seven of the 16 induced genes (p < 0.10) following cisplatin treatment are the SOS
response genes dinl, recA, oraA, recN, lexA, sulA, and yebG, and in mutS E. coli some of the
genes with the highest level of induction are SOS genes (e.g., dinl, recA, recN, yebG, sbmC,
and sulA all show a greater than 8-fold change in expression level, or signal log ratios above 3).
The gene yebG also shows induction in dam mutS E. coli following cisplatin treatment. The
genes dinl, recA, oraA, ruvB, uvrA, uvrB, and yebG are also significantly induced in dam treated
E coli; however several of these genes, such as lexA and recA, exhibit a lower level of
induction in dam mutants compared to wild-type and mutS treated strains (Table 5.2). The
lower level of SOS induction following cisplatin treatment in both dam and dam mutS strains
may be due to the high basal level of SOS gene expression in these strains; because dam and
(dam mutS E. coli show constitutive up-regulation of several SOS response genes compared to
wild-type (SOS sub-induction) (524,558,593,607), the level of induction following drug treatment
may be lower in these strains than the level observed for wild-type and mutS strains. Indeed,
examining the relative probe set signal intensities for these genes shows that the expression
level following cisplatin treatment is similar for the mutant strains; however the basal expression
levels for several SOS response genes (and lexA in particular) is higher in the dam mutant
strain (Fig. 5.4).
We performed real-time RT-PCR to confirm our array results showing that the SOS
response and DNA repair are induced upon drug treatment. The same drug treatment
conditions and RNA isolation procedure used in the array analysis were also used for the RT-
PCR experiments. However in addition to the high dose of 150 pM cisplatin used in the array
experiments, we used intermediate doses to determine any dose response at the transcriptional
level. Three independent experiments were performed, and the transcript levels for each gene
measured from each experiment were averaged. Real-time RT-PCR results confirm the array
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data in showing that SOS is highly induced in all strains following cisplatin treatment. With the
exception of sbmC, we see the highest expression level in the dam mutant strain for all of the
SOS genes tested at each drug dose (Fig. 5.5). Dam mutS E. coli also show a high level of
induction of the SOS response genes, with the exception of cho endonuclease, which shows
induction only in dam mutant E. coli following cisplatin treatment. Cho encodes for an
endonuclease homologue to uvrC and has been shown to be part of the SOS regulon (494).
'The RT-PCR results also show that, with the exception of lexA and sbmC, SOS gene
expression following cisplatin treatment is dose-dependent. However, whereas microarray
analysis showed similar relative expression values for SOS genes among the mutant strains,
real-time RT-PCR shows that SOS gene induction is greatest in the dam mutant following drug
treatment.
The SOS gene with the greatest fold induction, by RT-PCR, among all the strains is
sulA, which shows at least a 20-fold induction in all strains at the highest dose. OraA also shows
high induction by RT-PCR, especially in the dam and dam mutS strains (40- and 30-fold
induction, respectively). This gene shows over an 11-fold change in dam E. coli by array
analysis. OraA is a readthrough product of the recA transcript (537); it encodes for a repressor
of RecA called RecX, and previous work has shown that RecX can inhibit both recombinase and
coprotease functions of RecA (665). Like the recA gene, oraA is inducible and was shown to
have a 10-fold induction after UV exposure (137).
A cluster of genes located approximately at 1,200,000 bp on the E. coli chromosome
show up-regulation following cisplatin treatment in all strains by array analysis. These genes
are ymfG, J, L, M (Tables 5.3-5.6). Although these genes have no known function, they have
previously been shown to be induced in a LexA-dependent manner following UV irradiation
(137). We confirmed by real-time RT-PCR that the gene ymfG (b1141) is induced after
treatment with cisplatin (Table 5.2 and Fig. 5.6).
In addition to real-time RT-PCR, we used a lacZ gene reporter assay to determine the
dose-dependency of SOS response in each of the strains. For this assay wild-type, dam, and
dam mutS mutant strains that carry a sulA-lacZ fusion gene were used to visualize SOS
induction; increased expression of sulA, and consequently of lacZ, is visualized by 3-
galactosidase activity. The dose-dependent induction of sulA-lacZ is shown in Fig. 5.7. This
assay also clearly shows the high level of SOS sub-induction in dam mutant cells as the number
of red colonies, or colonies expressing LacZ, is higher throughout the area of the plate. As
mentioned above, constitutive SOS induction has previously been reported for E. coli lacking
DNA adenine methyltransferase (524,558,593).
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5.2.5 Expression of genes involved in DNA maintenance and metabolism
Because the cytotoxic effects of cisplatin are believed to arise from the drug's reaction
with DNA, we examined changes in expression of non-SOS genes known to be involved in DNA
repair and maintenance. Array analysis shows that the genes hupA and hupB are down-
regulated only in the dam mutant strain following cisplatin treatment (Table 5.4). These similar
yet distinct genes encode the two subunits HUuc and HUP, respectively, of the E. coli nucleoid-
associated protein HU. The dimeric protein HU acts as a histone-like protein and is capable of
introducing negative supercoiling in the presence of toposiomerase 1 (41). HU also shows a
binding preference for particular DNA structures such as cruciform DNA (56) as well as ssDNA
or gaps (96) and plays a critical role in recombination and SOS induction (411,484). In addition
to hupA and hupB, the genes encoding the primosomal proteins, PriA and PriB, also show
unique regulation following drug treatment. PriA and PriB are involved in the assembly of the
replication fork at recombination intermediates (254,325,613); PriA initiates reloading of the
replicative helicase DnaB at branched DNA structures, and PriA along with PriB, PriC, Rep, and
DnaT, reassembles the replication fork at recombination intermediates (613,614). Previous
work has shown that a priA dam double mutant is inviable (522) and that priA mutant E. coli are
very sensitive to cisplatin (521). In addition, we have previously shown that priB is expressed at
a higher basal level in dam (4-fold) and dam mutS (3-fold) mutant strains when basal gene
expression levels in the mutants are compared to the basal transcript levels in wild-type (593).
RT-PCR analysis shows that priA and priB are induced following high doses of cisplatin in dam
and to a lesser extent in dam mutS E. coli. We also examined gene expression changes for the
two genes encoding DNA gyrase, gyrA and gyrB. The array data show that these genes are
induced following cisplatin treatment in the dam mutant strain and real-time RT-PCR confirms
this observation (Table 5.2 and Fig. 5.6). DNA gyrase, a type IIA topoisomerase, has the ability
to actively introduce negative supercoils in DNA and is essential for viability (239,476). In
addition, DNA gryase, along with HU (629), plays a role in suppressing illegitimate
recombination (316,317,509,635).
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Table 5.2: Differential gene expression of SOS response genes and genes involved in
DNA repair and maintenance determined by microarray analysis and RT-PCR
LexA-regulated Array RT-PCR
SOS response Signal log ratio* Signal log ratio*
genes
Gene Blattner WT dam dam mutS WT dam dam mutS
name Number mutS mutS
lexA b4043 2.43 .58c 1.69 c 2.79 2.06 2.47 c 1.00C 1.82
recA b2699 5.45 2.06 c 2.55 c 4.62 3.87 4.67 c 3.67 3.23
oraA b2698 1.02 3.47 1.73 1.63 3.99 5.45 4.84 3.79
recN b2616 2.17 2.04c 1.52c 3.24 3.25 3.69c 2.57c 3.42
sulA b0958 3.66 1.89c 2.76c 3.64 4.73 4.81C 4.49c 4.49
yebG b1848 4.62 2.42C 3.48c 5.60 3.49 3.94 c 2.82C 2.63
ruvA b1861 .34 1.37 1.04 1.35 1.57 2.63 c 1.49 1.33
ruvB b1860 .38 1.75 1.48 .67 1.89 2.63 c 2.17c 1.18
dinl b1061 4.46 2.96 3.70 4.22 3.43 4.15c 4.24 4.13
uvrA b4058 .19 2.57 .69 .27 1.90 3.99 2.73 1.04
uvrB b0779 .52 2.88 1.81 1.33 2.23 3.33c 2.91 c 2.11
chol b1741 -.02 .89 .06 .04 0.80 1.68 0.13c 0.16
_ ydjQ
umuC b1184 .07 1.68 .97 .97 3.60 3.72 3.49 4.06
umuD b1183 1.40 1.23 1.87 2.22 5.07 4.80 4.07 4.81
sbmC b2009 2.09 -.22 .53 3.23 1.36 0.95 -.72 1.35
ymfG** b1141 2.99 1.38 3.40 3.61 5.68 4.47 4.50 6.03
Genes involved in Array RT-PCR
DNA Signal log ratio* Signal log ratio*
repair/replication
restart (non-SOS)
Gene Blattner WT dam dam mutS WT dam dam mutS
name Number mutS mutS
gyrA b2231 .88 2.73 1.26 .17 1.15 3.32 3.09 0.54
gyrB b3699 .10 2.11 1.31 .19 0.82 3.62 2.17 0.51
ITable 2: *Signal log ratios represent the log 2 of expression ratios (drug treated 150pM /untreated) for each strain
('WT, wild-type); therefore a signal log ratio of 1 is the equivalent to a 2-fold change in expression level. Genes listed
were tested by both array and RT-PCR. Signal log ratios in bold indicate that the p-value is below the threshold for
significance (p < 0.10 for microarray and 0.05 for RT-PCR). Genes that show sub-induction (at least 2-fold) in mutant
versus wild-type when tested by this method (i.e., microarray or RT-PCR) (593). **Open reading frames in the intE
region, including ymfG (b1141), were shown to be induced following UV exposure in a LexA-dependent manner (137).
5.2.6 Cisplatin induces double-strand break formation in a dose-dependent
manner and dam mutant E. coli exhibit the highest level of DSBs following
cisplatin treatment
It has previously been shown that cisplatin induces recombination and that DSB
recombinational repair is an important mechanism for tolerating cisplatin treatment (779).
These observations suggest that cisplatin damage leads to the formation of DNA strand breaks
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that require recombination for repair, and possible mechanisms for cisplatin-induced strand
breaks include replication fork collapse at sites of cisplatin-DNA adducts. It has also been
shown that dam mutant E. coli have an increased level of DSBs whose formation is dependent
on functional mismatch repair (593,731). In dam mutants, the combination of mismatch repair-
dependent and cisplatin-induced recombination substrates could explain why this strain is
hypersensitive to cisplatin treatment. However it has also been shown previously (778) as well
,as in the present study that the mismatch damage recognition protein MutS recognizes
cisplatin-modified DNA in vitro, and Calmann and Marinus (90) have recently shown in vitro that
adding MutS protein can inhibit RecA-mediated strand exchange of two recombination
substrates when one substrate is modified with cisplatin. Thus dam mutants may be
hypersensitive to cisplatin due to an additive effect of mismatch repair-induced damage and
cisplatin-induced damage; alternatively, in addition to inducing DSBs in a Dam-deficient
background, mismatch repair may also increase the level of cisplatin-induced damage by either
blocking the recombinational repair of this damage or by acting at sites of cisplatin adducts.
Under both scenarios, a deficiency in Dam leads to an increased level of DSB formation in a
mutS+ background. However under the latter scenario where MutS binding to cisplatin adducts
leads to an increased level of DNA damage, we would expect the level of DSBs in dam mutants
treated with drug to be higher than the sum of DSBs that occurs at the basal level in dam
mutants and that occurs following drug treatment in wild-type cells. Furthermore, if there is a
synergistic effect between mismatch repair and cisplatin in generating strand breaks, we expect
this effect to be dependent on Dam deficiency, since survival data show that mutS mutant and
wild-type strains are equally sensitive to treatment and thus a mutation in mutS alone does not
lead to increased resistance. Accordingly, if a mechanism involving the interplay between MutS
and cisplatin under the latter scenario described above requires a deficiency in Dam, then the
level of damage in wild-type and mutS strains should be relatively the same following cisplatin
treatment.
We performed neutral single-cell electrophoresis (54,641,644) to determine the level of
DNA double-strand breaks in each of the strains following cisplatin treatment. This method
allows the detection of a single DSB per cell (54) (Fig. 5.8A). Our data show that cisplatin
induces DSBs in each of the strains and that the number of breaks increases with increasing
dose of drug (Fig. 5.8B). We performed the Mann-Whitney U test to compare the frequency of
DSBs per cell with increasing drug dose for each strain. Comparisons for which P < .05 are
designated by an asterisk in Fig. 5.8B. The data show that 25 pM cisplatin causes a significant
(P < .05) increase in the frequency of DSBs per cell in all strains except in the dam mutant
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strain. Although there is an increase in the average number of DSBs per cell in dam mutant
cells following 25 pM cisplatin, the lack of significance by the Mann-Whitney test may be
attributed to the high basal frequency of DSBs in dam untreated cells (593). Along the same
lines, the relatively small increase in DSBs in dam mutants observed at 100 and 150 pM doses
is most likely due to the high percent of highly damaged cells at these doses (Fig. 5.8C), and
therefore the data for dam mutant cells at these drug doses in Fig. 5.8B likely represent an
underestimation of the level of DSBs.
The results in Fig. 5.8B show that the level of cisplatin-induced DSBs is higher in the
dam mutant strain compared to the other strains. In addition to determining the dose-
dependence of DSB formation within each strain, we performed the Mann-Whitney U test to
compare the frequency of DSBs per cell between mutant and wild-type strains at each dose to
determine the effect of genotype on cisplatin-induced DSB formation. By the Mann-Whitney U
test, the frequency of DSBs per cell in dam mutants differs significantly (P < .05) from the
frequency observed in the wild-type strain at doses 25 and 100 pM. The other strains did not
show significant differences compared to wild-type in the frequency of DSBs per cell at each
dose.
The data in Figure 5.8B include cells with as many as fifteen double-strand breaks
because fifteen approaches the maximum number of DSBs we could accurately count visually.
Any cell with more than fifteen DSBs was considered highly damaged and the percent of cells
for each strain with a highly damaged chromosome are represented in Fig 20C. The dam
mutant strain shows the greatest percent of cells with highly damaged chromosomes following
cisplatin treatment. Taken together the data show that the level of DSBs following cisplatin
treatment is greatest in dam mutant cells and that an additional mutation in mutS reduces the
level of DSBs to the level observed in wild-type and mutS strains, and thus the DSB data
correlates with drug sensitivity for these strains. The dependence on a mutS+ background for
the high level of cisplatin-induced DSBs in dam mutant cells supports a mechanism by which
mismatch repair contributes to the level of cisplatin-induced damage. Furthermore, because
mrutS and wild-type strains show similar levels of damage following treatment, this mechanism
requires a deficiency in Dam.
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In wild-type, dam mutS, and mutS strains, the number of cisplatin-induced DSBs
increases from 1-2 breaks to 4-5 breaks at the highest drug dose. The average number of
DSBs per cell in dam mutants is -1 DSB at the basal level. If we assume that DSBs are
additive and take the level of DSBs induced by cisplatin in wild-type cells and add the
number of basal DSBs occurring in dam untreated cells, then the level of DSBs in dam
mutants upon increasing drug dose should range from 2-3 breaks to 5-6 breaks per cell.
While the level of DSBs in dam mutants surpasses these estimations upon increasing drug
dose, MMR processing of cisplatin adducts, based on our data, is contributing at least 4-5
DSBs per dam mutant cell at the two highest drug doses tested. However because of the
percent of highly damaged cells at these doses, this calculation is most likely an
underestimation of the number of MMR-mediated DSBs following drug treatment in dam
mutant cells.
In addition to visually counting the number of tails, we used image analysis software
to determine the level of DNA damage in each strain following drug treatment. Komet
(Kinetic Imaging, UK) image analysis software quantifies the fluorescence of the head and
tail regions for each cell as well as the tail length. Cells with a high level of DSBs exhibit
higher percentage of fluorescence in the tail region (Fig. 5.9A) as well as longer DNA
migration, and one measurement to represent the data is the Olive tail moment, or the
product of the fluorescence of migrated DNA and the distance between the head and center
of gravity of DNA in the tail. A high Olive tail moment thus corresponds to a high level of
DNA damage. Fig. 5.9B shows a box plot representation of the Olive tail moments and
shows that damage is dose-dependent and reaches the highest level in the dam mutant
strain. As with the visual quantification of DSBs, cells with very high damage that showed
little or no head could not be analyzed by the software and were not included in this
analysis; therefore the apparent decrease in damage at 150 pM cisplatin in dam mutants
can be accounted for by those cells that exhibited such high levels of damage.
5.3 Discussion
A significant shortcoming of cisplatin-based chemotherapy is acquired resistance or
tolerance to the drug. Drug tolerance has been associated with MMR status, where cells
deficient in MMR exhibit a higher tolerance to drug treatment compared to their MMR-
proficient counterparts (177,213,216,497,540,567). To help elucidate the role of mismatch
repair in mediating cisplatin toxicity, we performed gene expression analysis and measured
DSB formation following cisplatin treatment in E. coli strains differing in MMR status. It has
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previously been shown that in a dam mutant background, where the signal distinguishing
between parent and newly synthesized daughter strands is lost, cells are hypersensitive to
cisplatin; however introducing an additional mutation in a mismatch repair gene (i.e., a
mutation in either mutS or mutL) abrogates this sensitivity and essentially restores wild-type
levels of resistance. Importantly, purified MutS interacts with the major cisplatin-DNA adduct,
supporting the possibility that a direct interaction between MMR and cisplatin lesions
influences cisplatin-induced toxicity. While we sought to uncover possible mechanisms of
drug-induced toxicity that are dependent on MMR by comparing the global gene expression
profiles of sensitive (dam mutant) and resistant (dam mutS mutant) strains, our results show
that genome-wide expression patterns following cisplatin treatment show a general toxicity
response. Cisplatin treatment caused the down-regulation of many genes involved in
amino acid and carbohydrate metabolism as well as in energy production and conversion.
Down-regulation of transcripts in amino acid metabolism and energy production gene
groups has also been shown for E. coli exposed to cadmium (726). The lower expression of
these genes in drug-treated cells may be the result of decreased cell growth; cells
experiencing high levels of DNA damage may not be initiating cell division and may
therefore be shutting down processes required for cell growth.
While global transcriptional responses reflect general toxicity, the expression
changes of certain genes involved in DNA repair and maintenance follow patterns of drug
sensitivity. The real-time RT-PCR results show that the SOS response is induced in a dose-
dependent manner and to the greatest extent in the hypersensitive dam mutant strain. The
high level of SOS induction indicates the presence of an SOS-inducing signal, which is most
likely single-stranded DNA. The level of SOS induction also correlates with the level of
DSBs detected in each strain, with dam mutants showing the highest level of DSB formation
following cisplatin treatment. While it has been suggested that recombinational repair and
the SOS response may be functioning near maximum capacity in dam mutants in order to
deal with endogenous MMR-induced DSBs (443), our data show that the SOS response is
largely induced in the dam mutant strain following cisplatin treatment and thus this mutant
has the capacity to further induce SOS following exogenous stress. Further SOS induction
beyond the basal level may be attributable to the fact that our data represents the average
of 108 cells in a cell culture, and McCool et al. have shown that constitutive SOS in dam
mutants can best be represented by a two-population model where SOS expression is
highly induced only in a small population of cells (462). We have also previously shown that
DSB formation in dam mutants is a stochastic process and that at a certain point in time a
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dam mutant cell may have as many as ten or more DSBs produced endogenously by
mismatch repair, though the average level of DSBs in the culture may only be between one
and two (593). Thus only at certain times in the life of a dam mutant cell may
recombinational repair be functioning near maximal capacity, and thus upon cisplatin
treatment SOS is further induced.
Although the SOS response is induced in all strains following cisplatin treatment,
certain genes show differential regulation between the strains. For example, gyrA and gyrB,
which encode DNA gyrase, are only induced in the Dam-deficient strains. DNA gyrase is an
essential protein for DNA replication and is a unique topoisomerase due to its ability to
introduce negative supercoils in the presence of ATP (239). In addition, DNA gyrase may
interact with the histone-like protein HU to suppress short-homology-independent illegitimate
recombination (629). Interestingly, sbmC, which is an SOS-inducible gene encoding an
endogenous gyrase inhibitor (Gyrl), is only up-regulated in wild-type and mutS strains and
not in the Dam-deficient strains following cisplatin treatment. SbmC (Gyrl) was shown to
reduce the level of DSBs mediated by other non-chromosomal gyrase inhibitors and
induction of sbmC as part of the SOS response may be important in reducing exogenous
DNA-damage that is amplified by gyrase activity (100,101). In support of this role for Gyrl,
overexpression of sbmC was shown to confer resistance to mitomycin C (MMC) treatment
(738) whereas a null mutation in sbmC leads to 2-fold more sensitivity to MMC (26). While
DNA gyrase mediates short-homology-independent illegitimate recombination, this
protective effect of sbmC expression may also be due to increased recombination in sbmC
overexpressing cells; although such increased recombination upon sbmC induction has not
been tested, overexpression of the DNA gyrase A subunit suppresses the illegitimate
recombination observed in HU null cells (629). In addition to DNA gyrase and SbmC (Gyrl)
differential expression, oraA, a gene located down-stream of recA encoding an inhibitor of
RecA called RecX, is induced to a greater degree in dam mutants. While recA and oraA
genes are separated by a hairpin terminator that limits the level of the read-through recA-
oraA transcript to approximately 5-10% of the level of the recA transcript (537), SOS
induction of recA may lead to higher read-through and a proportionately higher amount of
RecX protein. Thus although SOS induction and induced expression of recA serve to
protect cells against strand breaks, perhaps higher read-through of recA-oraA in dam
mutants is contributing to the hypersensitivity of these cells.
The present study shows that cisplatin induces DSBs in a dose-dependent manner
and thus supports previous observations that cisplatin is highly recombinogenic and that
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tolerance to cisplatin requires both RecBCD and RecFOR pathways of recombinational
repair (521,779). In addition, cisplatin-DNA adducts are replication-blocking lesions
(116,123,266,277,333) and E. coli priA mutants are hypersensitive to cisplatin treatment
(521), indicating that replication restart in double-strand break repair (385) is important in
tolerating cisplatin damage. Thus one mechanism for DSB formation following cisplatin
treatment involves replication fork collapse at sites of cisplatin lesions. In our experiments
the 90 minute recovery time following treatment allowed the cultures to undergo DNA
replication, and thus DSBs may have occurred by replication fork collapse. Indeed,
preliminary data indicate that the majority (-75%) of DSBs induced by cisplatin occur during
DNA replication while the remaining -25% of DSBs occur in non-replicating DNA
(Nowosielska and Marinus, unpublished results).
In addition to the dose-dependence of DSB formation following cisplatin treatment,
the data show that the level of DSBs is greatest in dam mutant cells. Because dam mutS
cells show similar levels of cisplatin-induced DSBs as wild-type and mutS mutant cells,
MMR contributes to the level of cisplatin-induced strand breaks in a dam mutant
background. To address the role of MMR in the production of cisplatin-induced strand
breaks, it is worthwhile to first consider the basal level of DSBs in dam mutants. We and
others have previously shown that endogenous strand breaks in dam mutant cells depend
on functional mismatch repair (593,731). While MutS may be introducing nicks on both
strands at a GATC site (20), the inviability of dam priA double mutants (522) suggests DSBs
arise when the replication fork encounters a single nick, which in dam mutants lacking
adenine methylation may be more prevalent due to the abundance of MutH substrates, or
unmethylated GATC sites, as well as the presence of multiple replication forks (420). The
MMR-dependent production of endogenous DSBs in dam E. coli renders these mutants
dependent on recombination for survival, and accordingly this requirement for recombination
is eliminated by an additional mutation in mismatch repair (443). In the present study,
because the level of DSBs in dam mutants surpasses the level expected if both MMR and
cisplatin were inducing strand breaks only by independent mechanisms, the data support
the idea that mismatch repair is contributing to the level of cisplatin-induced DSBs in dam
mutants; in other words, mismatch repair and cisplatin are interacting to produce a higher
level of damage than would otherwise occur if the two mechanisms-replication fork
collapse at cisplatin adducts and fork collapse at MutH-catalyzed nicks-were operating
independently.
142
One mechanism to describe how MMR and cisplatin produce strand breaks is futile
cycling (Fig. 5.10A) (351). MMR may be introducing single nicks after recognition of
cisplatin adducts in an attempt to initiate repair. In the absence of the strand discrimination
signal, repair may be initiated on the strand opposite the lesion, and thus the lesion remains
leading to additional repair cycles and a persistent single-strand gap. If this single nick is
encountered by a replication fork, a lethal DSB will occur. Thus the presence of cisplatin
adducts and recognition of these adducts by MutS may trigger downstream mismatch repair
processes and increase the level of single MutH incisions. Such an increase in MutH
incisions would require that the DNA be unmethylated, as fully methylated DNA is resistant
to MutH cleavage. This mechanism may explain why mismatch repair-mediated
sensitization of cells to cisplatin requires a dam mutant background, and genetic studies
support this model to the extent that a mutH mutation was recently shown to abrogate the
sensitivity of dam mutants (522). It is also worth mentioning that due to multiple firings of
the origin of replication during the cell cycle (420), the presence of multiple replication forks
in dam mutants provides these mutants with more opportunities to encounter both cisplatin
lesions as well as single-strand gaps produced by MMR.
An alternative model to the mechanism described above involves the blocking of
recombinational repair (Fig. 5.10B). It has recently been shown that MutS, performing its
role in antirecombination (91,398,662), can inhibit RecA-mediated strand exchange of two
recombination substrates when one substrate is modified to contain cisplatin adducts (90).
While recombination is a critical mechanism for tolerating cisplatin damage (521,779), MMR
may be contributing to cisplatin toxicity by blocking the recombinational bypass of cisplatin
adducts, which would lead to an increased level of strand breaks in the cell. Importantly, it
was recently demonstrated that a mutSDelta800 mutation, which retains function in mutation
avoidance but not in anti-recombination, rescues dam mutants from cisplatin
hypersensitivity, thus supporting the hypothesis that anti-recombination may play a
predominant role in MMR-mediated cisplatin toxicity (90). However for this mechanism to
account for the hypersensitivity of dam mutants to cisplatin, which is dependent on MMR,
MutS inhibition of recombinational repair would need to occur with greater efficiency in dam
mutants compared to the other strains. Calmann and Marinus (90) propose that MutS
inhibition of strand exchange is reversible but may require RuvAB proteins. While the basal
level of damage in dam mutants requires recombination and specifically the RecA and
RuvAB proteins for repair (443), this reversal may not occur in dam mutants in which RuvAB
proteins are occupied (perhaps near full capacity) in dealing with the high level of basal
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damage (i.e., the proteins are less available to enable the reversal of strand exchange
inhibition). Dam-deficient cells also deficient in mismatch repair, however, have better
recombinational repair abilities as they lack endogenous damage. Wild-type and mutS
mutants have a similar basal state of damage as dam mutS cells (593), and thus these
strains are better equipped to deal with cisplatin damage as their recombinational repair
machinery is more available.
The present study shows that cisplatin induces double-strand breaks in a dose-
dependent manner and that dam mutants exhibit the greatest level of cisplatin-induced
strand breaks as well as the greatest up-regulation of SOS genes. Furthermore, MutS is
required to enhance the level of cisplatin-induced strand breaks in dam mutant cells. While
it is not clear if DSBs are arising by MMR-catalyzed incisions or by MMR-mediated
antirecombination, the level of DSBs can account for the differential sensitivity and SOS
induction observed in the strains. Thus these results support a model whereby mismatch
repair proteins increase the level of secondary lesions resulting from cisplatin damage in a
Dam-deficient background. Furthermore, these findings, in conjunction with previous results
showing that recombination is important in tolerating cisplatin damage, suggest that DSBs
may be the primary lethal lesions following cisplatin treatment. Unfolding the exact
mechanisms by which mismatch repair contributes to the level of cisplatin-induced double-
strand breaks requires further study.
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Table 5.3: Wild-type E. coli treated with cisplatin compared to wildtype mock-treated
E. coli.
A. Differentially expressed genes ( 2-fold) in wildtype E. coli treated with cisplatin compared to
wildtype mock-treated E. coli (LPE p < 0. 10).
Carboh drate trans port and metabolism
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
manX b1817 -2.06 0.000 0.056 PTS enzyme IIAB, mannose-specific
galactose-binding transport protein; receptor for
mglB b2150 -2.06 0.000 0.024 galactose taxis
deoB b4383 -1.58 0.000 0.005 phosphopentomutase
Cell division
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
suppressor of Ion; inhibits cell division and ftsZ ring
sulA b0958 3.66 0.000 0.000 formation
Cell motility
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
flagellar biosynthesis; flagellin, filament structural
fliC b1923 -2.98 0.000 0.027 protein
flagellar biosynthesis, cell-proximal portion of basal-
fieF b1077 -2.21 0.000 0.019 body rod
Cell processes (adaptation/protection)
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
dinl b1061 4.46 0.000 0.000 damage-inducible protein I
Cell wall/membrane biogenesis
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
murE b0085 -2.62 0.001 0.088 meso-diaminopimelate-adding enzyme
Energy production and conversion
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
dctA b3528 -2.10 0.000 0.059 uptake of C4-dicarboxylic acids
cyoA b0432 -1.48 0.000 0.023 cytochrome o ubiquinol oxidase subunit II
yfaE b2236 1.13 0.001 0.085 orf, hypothetical protein
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Lipid transport and metabolism
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
fabD b1092 1.93 0.000 0.027 malonyl-CoA-[acyl-carrier-protein] transacylase
Replication, recombination, DNA repair and modification
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
yi21 6 b4272 -1.96 0.000 0.000 IS2 hypothetical protein
recN b2616 2.17 0.000 0.043 protein used in recombination and DNA repair
DNA strand exchange and renaturation, DNA-
dependent ATPase, DNA- and ATP-dependent
recA b2699 5.45 0.000 0.043 coprotease
Transcription
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
flgM b1071 -1.21 0.000 0.062 anti-FliA (anti-sigma) factor; also known as RflB protein
lexA b4043 2.43 0.001 0.078 regulator for SOS(lexA) regulon
Translation
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
rmf b0953 -3.18 0.000 0.006 ribosome modulation factor
General function prediction or unknown function
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
yodD b1953 -2.21 0.000 0.059 orf, hypothetical protein
yccJ b1003 -2.17 0.001 0.093 orf, hypothetical protein
b2080 -1.75 0.001 0.083 orf, hypothetical protein
ydjK b3100 -1.34 0.000 0.013 orf, hypothetical protein
oraA b2698 1.02 0.000 0.001 regulator, OraA protein
- yhdG b3260 1.59 0.000 0.039 putative dehydrogenase
b1541 1.89 0.000 0.002 orf, hypothetical protein
ymfM b1148 2.76 0.000 0.000 orf, hypothetical protein
ymfG b1141 2.99 0.000 0.006 Excisionase-like protein from lambdoid prophage 14
yebF b1847 3.02 0.000 0.006 orf, hypothetical protein
ymfL b1147 3.42 0.000 0.000 orf, hypothetical protein
_ybG b1848 4.62 0.000 0.000 orf, hypothetical protein
ymfJ b1144 4.92 0.000 0.000 orf, hypothetical protein
B. Genes with signal log ratios -1 x < 1 but for which LPE p < 0.10.
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Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
| b2335 -0.67 0.000 0.035 putative fimbrial protein
b2641 -0.14 0.000 0.001 orf, hypothetical protein
gmd b2053 -0.09 0.000 0.000 GDP-D-mannose dehydratase
b1579 0.30 0.000 0.059 putative transposase
ybaP b0482 0.46 0.000 0.000 putative ligase
ribonucleoside diphosphate reductase 1, alpha subunit,
nrdA b2234 0.78 0.001 0.078 B1
Table 5.4: Dam mutant E. coli treated with cisplatin compared to dam mock-treated E.
coli.
5.4A Differentially expressed genes (+ 2-fold) in dam E. coli treated with cisplatin compared to
dam mock-treated E. coli (LPE p < 0. 10).
Amino acid trans ort and metabolism
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
tnaA b3708 -5.61 0.000 0.000 tryptophanase
in glycine cleavage complex, carrier of aminomethyl
gcvH b2904 -3.85 0.000 0.001 moiety via covalently bound lipoyl cofactor
ansB b2957 -3.82 0.000 0.002 periplasmic L-asparaginase II
glycine decarboxylase, P protein of glycine cleavage
gcvP b2903 -2.33 0.003 0.069 system
aspC b0928 -2.22 0.001 0.042 aspartate aminotransferase
asd b3433 -1.50 0.005 0.103 aspartate-semialdehyde dehydrogenase
ATP-binding protein of glutamate/aspartate transport
gltL b0652 1.51 0.002 0.051 system
cysH b2762 1.58 0.000 0.000 3'-phosphoadenosine 5'-phosphosulfate reductase
Carboh ydrate trans port and metabolism
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
periplasmic maltose-binding protein; substrate
malE b4034 -6.34 0.000 0.000 recognition for transport and chemotaxis
phage lambda receptor protein; maltose high-affinity
lamB b4036 -5.62 0.000 0.000 receptor; Maltoporin precursor
ATP-binding component of transport system for
malK b4035 -4.61 0.000 0.000 maltose
rbsB b3751 -3.95 0.000 0.000 D-ribose periplasmic binding protein
treB b4240 -3.87 0.000 0.001 PTS system enzyme II, trehalose specific
!gpF b3927 -3.68 0.000 0.001 facilitated diffusion of glycerol
ptsG b1101 -3.60 0.000 0.004 PTS system, glucose-specific IIBC component
manX b1817 -3.53 0.000 0.002 PTS enzyme IIAB, mannose-specific
galK b0757 -3.42 0.000 0.011 galactokinase
manY b1818 -3.23 0.001 0.027 PTS enzyme IIC, mannose-specific
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mgsA b0963 -3.11 0.004 0.087 methylglyoxal synthase
galactose-binding transport protein; receptor for
mlB b2150 -2.96 0.000 0.009 galactose taxis
malP b3417 -2.58 0.000 0.006 maltodextrin phosphorylase
ptsH b2415 -2.44 0.004 0.089 PTS system protein HPr
malM b4037 -2.44 0.003 0.073 periplasmic protein of mal regulon
gatZ b2095 -2.40 0.001 0.037 putative tagatose 6-phosphate kinase 1
ptsl b2416 -1.82 0.003 0.074 PEP-protein phosphotransferase system enzyme I
glgB b3432 -1.52 0.001 0.044 1,4-alpha-glucan branching enzyme
b2386 1.07 0.001 0.022 putative transport protein
yidY b3710 1.08 0.001 0.027 putative transport protein
Cell division
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
cell division inhibitor, a membrane ATPase, activates
minD b1175 -1.70 0.004 0.092 minC
ftsN b3933 -1.61 0.002 0.051 essential cell division protein
gidA b3741 1.70 0.000 0.009 glucose-inhibited division; chromosome replication?
regulator of ftsl, penicillin binding protein 3, septation
mreB b3251 1.95 0.002 0.053 function
Cell motility
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
flagellar biosynthesis; flagellin, filament structural
fliC b1923 -4.83 0.000 0.000 protein
flagellar biosynthesis, cell-proximal portion of basal-
flgF b1077 -4.60 0.000 0.000 body rod
flagellar biosynthesis, cell-proximal portion of basal-
flgC b1074 -4.43 0.000 0.000 body rod
flgN b1070 -4.27 0.000 0.000 protein of flagellar biosynthesis
flagellar biosynthesis, cell-distal portion of basal-body
b1078 -4.21 0.000 0.000 rod
flagellar biosynthesis, cell-proximal portion of basal-
flgB b1073 -4.03 0.000 0.000 body rod
flqE b1076 -3.72 0.000 0.000 flagellar biosynthesis, hook protein
flgD b1075 -3.67 0.000 0.005 flagellar biosynthesis, initiation of hook assembly
fliL b1944 -3.60 0.001 0.030 flagellar biosynthesis
flagellar biosynthesis, component of motor switching
and energizing, enabling rotation and determining its
fliG b1939 -3.52 0.000 0.009 direction
flagellar biosynthesis, component of motor switch and
energizing, enabling rotation and determining its
fliN b1946 -3.13 0.002 0.055 direction
flagellar biosynthesis, component of motor switch and
energizing, enabling rotation and determining its
fliM b1945 -3.06 0.000 0.004 direction
fliZ b1921 -2.93 0.001 0.040 orf, hypothetical protein; Flagellar biogenesis protein
_f l b1083 -2.72 0.001 0.027 flagellar biosynthesis; hook-filament junction protein
fliS b1925 -2.48 0.001 0.025 flagellar biosynthesis; repressor of class 3a and 3b
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b4314
b1080
b1924
b1948
b0915
b2969
b3005
-2.44
-2.28
-2.21
-1.17
0.98
1.13
2.60
0.000
0.000
0.000
0.003
0.002
0.001
0.000
0.019
0.015
0.010
0.068
0.058
0.036
0.002
operons (RflA activity)
major type 1 subunit fimbrin (pilin)
homolog of Salmonella P-ring of flagella basal body
flagellar biosynthesis; filament capping protein; enables
filament assembly
flagellar biosynthesis
putative EC 1.2 enzyme
putative general secretion pathway for protein export
(GSP)
uptake of enterochelin; tonB-dependent uptake of B
colicins
Cell processes (adaptation/protection)
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
dinl b1061 2.96 0.004 0.088 damage-inducible protein I
Cell wall/membrane biogenesis
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
ompC b2215 -3.66 0.000 0.000 outer membrane protein lb (b;c)
ompF b0929 -3.24 0.000 0.002 outer membrane protein la (la;b;F)
galE b0759 -2.92 0.001 0.025 UDP-galactose-4-epimerase
gigS b3049 -2.29 0.005 0.106 glycogen biosynthesis, rpoS dependent
glucosyltransferase I; lipopolysaccharide core
rfaG b3631 1.20 0.000 0.011 biosynthesis
gidB b3740 2.46 0.000 0.000 glucose-inhibited division; chromosome replication?
Coenzyme transport and metabolism
Signal Adjusted
Gene Number Ratio value value Gene Product and Function
lipA b0628 1.86 0.000 0.016 lipoate synthesis, sulfur insertion
Energy production and conversion
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
lpK b3926 -5.65 0.000 0.000 glycerol kinase
mdh b3236 -4.58 0.000 0.000 malate dehydrogenase
PTS system, mannitol-specific enzyme IIABC
mtlA b3599 -4.40 0.000 0.000 components
fumarate reductase, anaerobic, iron-sulfur protein
frdB b4153 -3.92 0.000 0.014 subunit
fumarate reductase, anaerobic, membrane anchor
frdD b4151 -3.51 0.002 0.055 polypeptide
gIcB b2976 -3.47 0.000 0.000 malate synthase G
pflB b0903 -3.38 0.000 0.000 formate acetyltransferase 1
galT | b0758 -3.16 0.000 0.009 galactose-1-phosphate uridylyltransferase
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fimA
figl
fliD
fliP
ycaH
yghE
exbD
l
sucD b0729 -3.06 0.005 0.100 succinyl-CoA synthetase, alpha subunit
frdA b4154 -2.91 0.000 0.016 fumarate reductase, anaerobic, flavoprotein subunit
sn-glycerol-3-phosphate dehydrogenase (anaerobic),
glpC b2243 -2.61 0.003 0.077 K-small subunit
nuol b2281 -2.07 0.001 0.029 NADH dehydrogenase I chain I
yhdH b3253 -1.51 0.002 0.055 putative dehydrogenase
nuoE b2285 -1.42 0.002 0.058 NADH dehydrogenase I chain E
glcF b2978 -1.21 0.001 0.030 glycolate oxidase iron-sulfur subunit
fdhF b4079 -1.20 0.003 0.073 selenopolypeptide subunit of formate dehydrogenase H
b1588 -1.19 0.001 0.046 putative oxidoreductase, major subunit
fdoH b3893 -1.19 0.000 0.005 formate dehydrogenase-O, iron-sulfur subunit
D-lactate dehydrogenase, FAD protein, NADH
did b2133 -1.13 0.001 0.035 independent
b1628 1.28 0.000 0.012 orf, hypothetical protein
yqhD b3011 2.02 0.000 0.004 putative oxidoreductase
ndh b1109 2.84 0.000 0.000 respiratory NADH dehydrogenase
Inorganic ion trans port and metabolism
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
bfr b3336 -3.24 0.000 0.000 bacterioferrin, an iron storage homoprotein
cysP b2425 1.22 0.000 0.002 thiosulfate binding protein
high-affinity phosphate-specific transport system;
pstS b3728 1.36 0.000 0.007 periplasmic phosphate-binding protein
negative regulator for pho regulon and putative enzyme
phoU b3724 1.49 0.000 0.017 in phosphate metabolism
cysJ b2764 1.69 0.001 0.038 sulfite reductase (NADPH), flavoprotein beta subunit
ATP-binding component of high-affinity phosphate-
pstB b3725 1.76 0.001 0.030 specific transport system
cysl b2763 1.95 0.000 0.000 sulfite reductase, alpha subunit
mgtA b4242 2.65 0.000 0.000 Mg2+ transport ATPase, P-type 1
sodA b3908 2.73 0.000 0.000 superoxide dismutase, manganese
Intracellular trafficking, secretion, and vesicular transport
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
periplasmic protein related to spheroblast formation; P
pilus assembly/Cpx signaling pathway, periplasmic
spy b1743 1.79 0.000 0.012 inhibitor/zinc-resistance associated protein
Lipid transport and metabolism
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
yhaE b3125 -2.81 0.001 0.044 putative dehydrogenase
fadD b1805 1.36 0.002 0.055 acyl-CoA synthetase, long-chain-fatty-acid--CoA ligase
Nucleotide transport and metabolism
Blattner Signal Raw p- Adjusted
Gene Number Log value LPE p- Gene Product and Function
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Ratio value
_udp b3831 -5.16 0.000 0.000 uridine phosphorylase
deoD b4384 -2.97 0.001 0.023 purine-nucleoside phosphorylase
deoC b4381 -2.61 0.000 0.018 2-deoxyribose-5-phosphate aldolase
nupC b2393 -2.21 0.004 0.089 permease of transport system for 3 nucleosides
ybeK b0651 -1.99 0.002 0.063 putative tRNA synthetase
orf, hypothetical protein; Xanthine dehydrogenase,
b2084 1.12 0.000 0.006 molybdopterin-binding subunit B
apt b0469 1.33 0.004 0.089 adenine phosphoribosyltransferase
pyrF b1281 1.41 0.001 0.029 orotidine-5'-phosphate decarboxylase
ribonucleoside diphosphate reductase 1, alpha subunit,
nrdA b2234 2.16 0.000 0.017 B1
Ph age, transp oson, or plasmid
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
pspB b1305 2.30 0.000 0.006 phage shock protein
Posttranslational modification, protein turnover, chaperones
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
hslJ b1379 1.18 0.001 0.033 heat shock protein hslJ
Replication, recombination, DNA repair and modification
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
hupB b0440 -3.16 0.000 0.002 DNA-binding protein HU-beta, NS1 (HU-1)
dps b0812 -3.10 0.001 0.035 global regulator, starvation conditions
hupA b4000 -2.57 0.003 0.068 DNA-binding protein HU-alpha (HU-2)
mutM b3635 1.18 0.003 0.074 formamidopyrimidine DNA glycosylase
DNA biosynthesis; initiation of chromosome replication;
dnaA b3702 1.49 0.003 0.067 can be transcription regulator
Holliday junction helicase subunit A; branch migration;
ruvB b1860 1.75 0.000 0.005 repair
dnaG b3066 1.80 0.000 0.006 DNA biosynthesis; DNA primase
DNA strand exchange and renaturation, DNA-
dependent ATPase, DNA- and ATP-dependent
recA b2699 2.06 0.003 0.072 coprotease
DNA gyrase subunit B, type II topoisomerase, ATPase
gyrB b3699 2.11 0.003 0.072 activity
ntpA b1865 2.17 0.003 0.077 dATP pyrophosphohydrolase
uvrA b4058 2.57 0.000 0.002 excision nuclease subunit A
gyrA b2231 2.73 0.005 0.100 DNA gyrase, subunit A, type II topoisomerase
uvrB b0779 2.88 0.001 0.028 DNA repair; excision nuclease subunit B
tpr b1229 3.26 0.000 0.000 a protaminelike protein
deaD b3162 3.27 0.001 0.025 inducible ATP-independent RNA helicase
Secondary metabolites biosynthesis, transport and catabolism
Gene J Blattner I Signal Rawp- I Adiusted IGene Product and Function
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Number Log value LPE p-
Ratio value
srlD b2705 -2.61 0.003 0.068 glucitol (sorbitol)-6-phosphate dehydrogenase
b1519 1.19 0.002 0.057 putative enzyme
Si nal transduction mechanisms
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
rseA b2572 -1.60 0.005 0.102 sigma-E factor, negative regulatory protein
response regulator, positive activator of uhpT
uhpA b3669 1.15 0.000 0.003 transcription (sensor, uhpB)
Transcription
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
flagellar biosynthesis; alternative sigma factor 28;
fliA b1922 -4.13 0.000 0.000 regulation of flagellar operons
flgM b1071 -3.12 0.000 0.000 anti-FliA (anti-sigma) factor; also known as RflB protein
cspG b0990 -2.79 0.000 0.002 homolog of Salmonella cold shock protein
cspB bl 557 -2.65 0.000 0.017 cold shock protein; may affect transcription
cspl b1552 -2.32 0.004 0.082 cold shock-like protein
trpR b4393 -1.17 0.000 0.000 regulator for trp operon and aroH; trp aporepressor
putative a membrane protein; citrate carrier; response
ybdS b0612 1.02 0.005 0.103 regulator of citrate/malate metabolism
yqfE b2915 1.05 0.001 0.032 orf, hypothetical protein
arsR b3501 1.29 0.004 0.087 transcriptional repressor of chromosomal ars operon
site-specific DNA inversion stimulation factor; DNA-
fis b3261 3.34 0.000 0.000 binding protein; a trans activator for transcription
Translation
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
jgF b4243 -3.80 0.000 0.001 orf, hypothetical protein
_sV b1480 -3.42 0.002 0.053 30S ribosomal subunit protein S22
rmf b0953 -2.24 0.003 0.067 ribosome modulation factor
10-formyltetrahydrofolate:L-methionyl-tRNA(fMet) N-
fmt b3288 1.13 0.004 0.087 formyltransferase
rbfA b3167 1.50 0.001 0.029 ribosome-binding factor A
serU b1975 1.68 0.003 0.077 Serine tRNA2
yciL b1269 2.12 0.001 0.031 orf, hypothetical protein
yabO b0058 2.13 0.000 0.006 orf, hypothetical protein
ileX b3069 2.24 0.001 0.038 Isoleucine tRNA2
arS b1876 2.31 0.000 0.001 arginine tRNA synthetase
argW b2348 2.35 0.003 0.072 Arginine tRNA5
General function prediction or unknown
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
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_)fiD b2579 -4.47 0.000 0.000 putative formate acetyltransferase
hdeA b3510 -4.09 0.000 0.009 orf, hypothetical protein
yahO b0329 -3.28 0.002 0.049 orf, hypothetical protein
orf, hypothetical protein; Uncharacterized conserved
elaB b2266 -3.25 0.002 0.059 protein
tnaL b3707 -3.24 0.001 0.024 tryptophanase leader peptide
yliH b0836 -3.09 0.000 0.002 putative receptor
glcG b2977 -2.73 0.000 0.001 orf, hypothetical protein
yccJ b1003 -2.71 0.001 0.025 orf, hypothetical protein
activator of ntrL gene; Osmotically inducible lipoprotein
osmE b1739 -2.70 0.001 0.033 E precursor
DNA-binding protein HLP-II (HU, BH2, HD, NS);
hns b1237 -2.59 0.000 0.016 pleiotropic regulator
orf, hypothetical protein; Predicted HD superfamily
b1044 -2.33 0.000 0.013 hydrolase
ygiW b3024 -2.32 0.004 0.087 orf, hypothetical protein
ygdl b2809 -2.28 0.005 0.102 orf, hypothetical protein
yecR b1904 -2.21 0.002 0.057 orf, hypothetical protein
ybgO b0716 -1.53 0.002 0.058 orf, hypothetical protein
b2641 1.00 0.000 0.002 orf, hypothetical protein
orf, hypothetical protein; Uncharacterized protein
yijF b3944 1.00 0.001 0.045 conserved in bacteria
yjjX b4394 1.07 0.001 0.025 orf, hypothetical protein
b1152 1.18 0.005 0.096 orf, hypothetical protein
glpG b3424 1.19 0.002 0.048 protein of glp regulon
b2511 1.26 0.000 0.017 putative GTP-binding factor
ycfJ bl110 1.65 0.004 0.085 orf, hypothetical protein
thdF b3706 1.72 0.001 0.034 GTP-binding protein in thiophene and furan oxidation
yeeE b2013 1.78 0.000 0.001 putative transport system permease protein
yfgB b2517 1.83 0.000 0.003 orf, hypothetical protein
_ymfM b1148 2.02 0.001 0.031 orf, hypothetical protein
ybeB bO637 2.04 0.000 0.005 orf, hypothetical protein
ymfL b1147 2.18 0.000 0.004 orf, hypothetical protein
yhdG b3260 2.24 0.001 0.040 putative dehydrogenase
b1970 2.40 0.000 0.000 orf, hypothetical protein
yebG b1848 2.42 0.005 0.103 orf, hypothetical protein
b0100 2.50 0.000 0.001 orf, hypothetical protein
ycfR b1112 2.62 0.000 0.011 orf, hypothetical protein
yebF b1847 2.64 0.002 0.055 orf, hypothetical protein
yjcB b4060 2.81 0.000 0.000 orf, hypothetical protein
_yebE b1846 3.29 0.000 0.000 orf, hypothetical protein
ymfJ b1144 3.39 0.000 0.000 orf, hypothetical protein
oraA b2698 3.47 0.000 0.000 regulator, OraA protein
yhcN b3238 3.48 0.000 0.000 orf, hypothetical protein
5.4B Genes with signal log ratios -1.0 < x 1.0 but for which LPE p < 0.10.
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
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Dpg.i b4025 -0.95 0.004 0.085 glucosephosphate isomerase
narH b1225 -0.94 0.000 0.010 nitrate reductase 1, beta subunit
ygfJ b2877 -0.86 0.001 0.035 orf, hypothetical protein
ynfE b1587 -0.70 0.001 0.039 putative oxidoreductase, major subunit
predicted membrane-associated, metal-dependent
yhjW b3546 -0.62 0.000 0.010 hydrolase
rzpR b1362 -0.59 0.001 0.029 putative Rac prophage endopeptidase
gtV b4008 -0.54 0.000 0.009 Glutamate tRNA2
methyl-accepting chemotaxis protein I, serine sensor
tsr b4355 -0.54 0.000 0.001 receptor
glyY b4165 -0.53 0.002 0.055 Glycine tRNA3
ucpA b2426 -0.53 0.000 0.002 putative oxidoreductase
exonuclease 1, 3' --> 5' specific;
sbcB b201 1 -0.53 0.005 0.103 deoxyribophosphodiesterase
gtW b2590 -0.51 0.000 0.009 Glutamate tRNA2
gItT b3969 -0.50 0.000 0.002 Glutamate tRNA2
gtU b3757 -0.48 0.000 0.002 Glutamate tRNA2
menB b2262 -0.48 0.002 0.055 dihydroxynaphtoic acid synthetase
mdoG b1048 -0.47 0.002 0.062 periplasmic glucans biosynthesis protein
membrane glycosyltransferase; synthesis of
mdoH b1049 -0.40 0.003 0.068 membrane-derived oligosaccharide (MDO)
ybjT b0869 -0.36 0.000 0.000 putative dTDP-glucose enzyme
hcaA2 b2539 -0.35 0.000 0.000 small terminal subunit of phenylpropionate dioxygenase
b3956 -0.34 0.004 0.085 phosphoenolpyruvate carboxylase
t150 b3558 -0.33 0.003 0.070 IS150 putative transposase
dcd b2065 -0.24 0.002 0.046 2'-deoxycytidine 5'-triphosphate deaminase
thiF b3992 -0.20 0.000 0.002 thiamin biosynthesis, thiazole moiety
qlnA b3870 -0.15 0.004 0.087 glutamine synthetase
basS b4112 -0.12 0.000 0.003 sensor protein for basR
acs b4069 -0.07 0.000 0.000 acetyl-CoA synthetase
cyoA b0432 0.14 0.005 0.104 cytochrome o ubiquinol oxidase subunit II
hsdM b4349 0.23 0.000 0.000 host modification; DNA methylase M
yhiP b3496 0.28 0.000 0.012 putative transport protein
uptake of enterochelin; tonB-dependent uptake of B
exbB b3006 0.28 0.000 0.007 colicins
ATP-binding component of sulfate permease A protein;
cysA b2422 0.30 0.001 0.026 chromate resistance
hyfB b2482 0.37 0.005 0.094 hydrogenase 4 membrane subunit
betB b0312 0.39 0.003 0.067 NAD+-dependent betaine aldehyde dehydrogenase
uxuB b4323 0.41 0.004 0.081 D-mannonate oxidoreductase
DNA helicase, resolution of Holliday junctions, branch
recG b3652 0.44 0.004 0.082 migration
b4212 0.49 0.001 0.031 orf, hypothetical protein
purD b4005 0.50 0.001 0.038 phosphoribosylglycinamide synthetase
ydiE b1705 0.55 0.005 0.103 orf, hypothetical protein
arqB b3959 0.56 0.000 0.001 acetylglutamate kinase
_ yhiQ b3497 0.56 0.003 0.068 orf, hypothetical protein
yjbF b4027 0.58 0.001 0.029 orf, hypothetical protein
transcriptional regulator for pyruvate dehydrogenase
pdhR b0113 0.60 0.001 0.033 complex
_ yjf b0859 0.60 0.002 0.054 putative enzyme
mreC b3250 0.63 0.005 0.101 rod shape-determining protein
b1297 0.63 0.004 0.092 putative glutamine synthetase (EC 6.3.1.2)
154
ATP-dependent serine activating enzyme (may be part
entF b0586 0.64 0.004 0.087 of enterobactin synthase as component F)
high-affinity amino acid transport system; periplasmic
livJ b3460 0.65 0.002 0.057 binding protein
gntU_ low-affinity gluconate transport permease protein,
2 b3435 0.67 0.002 0.059 fragment 2
enhances synthesis of sigma32 in mutant; extragenic
suhB b2533 0.67 0.005 0.105 suppressor, may modulate RNAse III lethal action
hisG b2019 0.67 0.002 0.051 ATP phosphoribosyltransferase
yhcP b3240 0.68 0.004 0.087 orf, hypothetical protein
air b4053 0.68 0.001 0.028 alanine racemase 1
putative N-acetylgalactosamine-6-phosphate
agaA b3135 0.70 0.003 0.068 deacetylase
yhjY b3548 0.72 0.002 0.053 putative lipase
DNA helicase, ATP-dependent dsDNA/ssDNA
recD b2819 0.73 0.001 0.028 exonuclease V subunit, ssDNA endonuclease
putative general secretion pathway for protein export
yheG b3326 0.73 0.004 0.089 (GSP) (TYPE II TRAFFIC WARDEN ATPASE)
yjal b4002 0.77 0.000 0.000 orf, hypothetical protein
b3122 0.77 0.003 0.076 orf, hypothetical protein
IgtD b3213 0.78 0.004 0.089 glutamate synthase, small subunit
yhiN b3492 0.78 0.000 0.015 orf, hypothetical protein
yjcD b4064 0.78 0.004 0.089 orf, hypothetical protein
yjdL b4130 0.80 0.002 0.058 putative peptide transporter
bisZ b1872 0.81 0.004 0.090 biotin sulfoxide reductase 2
yi82_1 b0017 0.82 0.002 0.052 IS186 and IS421 hypothetical protein
exuT b3093 0.83 0.004 0.085 transport of hexuronates
dnaC b4361 0.84 0.004 0.087 chromosome replication; initiation and chain elongation
PTS system N-acetylgalactosameine-specific IIC
agaW b3134 0.85 0.002 0.046 component 2
uvrD b3813 0.88 0.002 0.048 DNA-dependent ATPase I and helicase II
rnd b1804 0.90 0.002 0.047 RNase D, processes tRNA precursor
yjaB b4012 0.91 0.002 0.056 orf, hypothetical protein
outer membrane receptor for iron-regulated colicin I
cirA b2155 0.91 0.001 0.032 receptor; porin; requires tonB gene product
yjeN b4157 0.92 0.000 0.014 orf, hypothetical protein
SWIB-domain-containing proteins implicated in
rem b1561 0.93 0.003 0.072 chromatin remodeling
phnN b4094 0.94 0.000 0.011 ATP-binding component of phosphonate transport
smf 1 b3286 0.95 0.004 0.083 orf, fragment 1
Table 5.5: Dam mutS mutant E. coli treated with cisplatin compared to dam mutS
mock-treated E. coli.
5.5A Differentially expressed genes (+ 2-fold) in dam mutS E. coli treated with cisplatin
compared to dam mutS mock-treated E. coli (LPE p < 0. 10).
Amino acid transport and metabolism
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
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tnaA b3708 -5.01 0.000 0.000 tryptophanase
phosphoanhydride phosphorylase; pH 2.5 acid
appA b0980 -1.01 0.000 0.042 phosphatase; periplasmic
trpL b1265 2.10 0.000 0.002 trp operon leader peptide
Carboh drate transport and metabolism
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
periplasmic maltose-binding protein; substrate
malE b4034 -4.94 0.000 0.000 recognition for transport and chemotaxis
phage lambda receptor protein; maltose high-affinity
lamB b4036 -4.71 0.000 0.001 receptor; Maltoporin precursor
Cell motility
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
flagellar biosynthesis; flagellin, filament structural
fliC b1923 -3.90 0.000 0.003 protein
flagellar biosynthesis, cell-proximal portion of basal-
fIgB b1073 -3.68 0.000 0.012 body rod
flagellar biosynthesis, cell-proximal portion of basal-
-fgC b1074 -3.55 0.000 0.004 body rod
flagellar biosynthesis, cell-proximal portion of basal-
_fjjF~ b1077 -3.31 0.000 0.000 body rod
uptake of enterochelin; tonB-dependent uptake of B
exbB b3006 1.00 0.000 0.012 colicins
Energy production and conversion
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
PTS system, mannitol-specific enzyme IIABC
mtlA b3599 -2.92 0.001 0.085 components
Inorganic ion transport and metabolism
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
ATP-binding component of sulfate permease A protein;
cysA b2422 1.07 0.000 0.047 chromate resistance
cysl b2763 2.18 0.000 0.051 sulfite reductase, alpha subunit
sodA b3908 3.46 0.000 0.003 superoxide dismutase, manganese
Replication, recombination, DNA repair and modification
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
tpr b1229 2.03 0.000 0.000 a protaminelike protein
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Transcription
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
flagellar biosynthesis; alternative sigma factor 28;
fliA b1922 -3.53 0.000 0.043 regulation of flagellar operons
Translation
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
leuX b4270 3.13 0.000 0.012 Leucine tRNA5 (amber [UAG] suppressor)
ileY b2652 3.72 0.000 0.000 Isoleucine tRNA2 variant
ileX b3069 4.00 0.000 0.000 Isoleucine tRNA2
argW b2348 4.07 0.000 0.052 Arginine tRNA5
General function prediction or function unknown
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
tnaL b3707 -3.18 0.000 0.009 tryptophanase leader peptide
bO100 1.64 0.000 0.052 orf, hypothetical protein
ymfM b1148 2.69 0.000 0.039 orf, hypothetical protein
ymfL b1147 3.37 0.000 0.035 orf, hypothetical protein
ymfG b1141 3.40 0.000 0.001 Excisionase-like protein from lambdoid prophage 14
yebG b1848 3.48 0.000 0.031 orf, hypothetical protein
ymfJ b1144 4.76 0.000 0.007 orf, hypothetical protein
5.5B Genes with signal log ratios -1 < x < 1 but for which LPE p < 0.10.
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
ybbA b0495 -0.93 0.000 0.052 putative ATP-binding component of a transport system
yafW b0246 -0.91 0.000 0.047 orf, hypothetical protein
yafV b0219 -0.84 0.000 0.008 putative EC 3.5. amidase-type enzyme
ybaP b0482 -0.83 0.000 0.059 putative ligase
yjfJ b4182 -0.64 0.000 0.008 putative alpha helical protein
yi9la b0255 -0.64 0.000 0.000 IS911 hypothetical protein, variant (IS911A)
yrfH b3400 -0.01 0.000 0.000 orf, hypothetical protein
b1706 0.23 0.000 0.012 orf, hypothetical protein
ilvA b3772 0.26 0.000 0.000 threonine deaminase (dehydratase)
yigB b3812 0.60 0.000 0.016 putative phosphatase
formate dehydrogenase-N, nitrate-inducible, iron-sulfur
fdnH b1475 0.63 0.001 0.064 beta subunit
_parC b3019 0.64 0.001 0.068 DNA topoisomerase IV subunit A
high-affinity transport system for glycine betaine and
proW b2678 0.68 0.001 0.073 proline
livK b3458 0.72 0.000 0.062 high-affinity leucine-specific transport system;
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__ I ~~I I I periplasmic binding protein
b2084 0.91 0.001 0.101 orf, hypothetical protein
Table 5.6: MutS mutant E. coli treated with cisplatin compared to mutS mock-treated
E. coli.
5.6A Differentially expressed genes (+ 2-fold) in mutS E. coli treated with cisplatin compared to
mutS mock-treated E. coli (LPE p < 0. 10).
Amino acid trans ort and metabolism
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
mtr b3161 -5.00 0.000 0.000 tryptophan-specific transport protein
trpA b1260 -4.23 0.000 0.000 tryptophan synthase, alpha protein
trpB b1261 -2.80 0.000 0.000 tryptophan synthase, beta protein
N-(5-phosphoribosyl)anthranilate isomerase and indole-
b1262 -2.73 0.000 0.000 3-glycerolphosphate synthetase
anthranilate synthase component II, glutamine
amidotransferase and phosphoribosylanthranilate
trpD b1263 -2.58 0.000 0.000 transferase
orf, hypothetical protein; Lactoylglutathione lyase and
yqjC b3097 -2.53 0.001 0.035 related lyases
trpE b1264 -2.49 0.000 0.000 anthranilate synthase component I
fliY b1920 -1.53 0.000 0.011 putative periplasmic binding transport protein
ybjU b0870 -1.14 0.002 0.058 putative arylsulfatase
ycjl b1326 -1.13 0.001 0.030 putative carboxypeptidase
hisL b2018 1.19 0.001 0.034 his operon leader peptide
peptidase E, a dipeptidase where amino-terminal
pepE b4021 1.77 0.000 0.000 residue is aspartate
Carboh drate transport and metabolism
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
galactitol-specific enzyme IIB of phosphotransferase
gatB b2093 -3.25 0.000 0.000 system
manY b1818 -2.98 0.000 0.000 PTS enzyme IIC, mannose-specific
manX b1817 -2.85 0.000 0.002 PTS enzyme IIAB, mannose-specific
phage lambda receptor protein; maltose high-affinity
lamB b4036 -2.72 0.000 0.000 receptor; Maltoporin precursor
periplasmic maltose-binding protein; substrate
malE b4034 -2.32 0.000 0.000 recognition for transport and chemotaxis
ATP-binding component of transport system for
malK b4035 -2.15 0.000 0.000 maltose
_manZ b1819 -2.14 0.001 0.029 PTS enzyme IID, mannose-specific
galactitol-specific enzyme IIA of phosphotransferase
gatA b2094 -1.79 0.000 0.006 system
malP b3417 -1.69 0.000 0.000 maltodextrin phosphorylase
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gatZ b2095 -1.22 0.005 0.101 putative tagatose 6-phosphate kinase 1
malQ b3416 -1.07 0.001 0.021 4-alpha-glucanotransferase (amylomaltase)
gapC_ glyceraldehyde 3-phosphate dehydrogenase C,
1 b1417 -1.07 0.002 0.055 interrupted/erythrose-4-phosphate dehydrogenase
rpiA b2914 1.01 0.000 0.008 ribosephosphate isomerase, constitutive
Cell division
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
suppressor of Ion; inhibits cell division and ftsZ ring
sulA b0958 3.64 0.000 0.000 formation
Cell motility
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
flagellar biosynthesis; repressor of class 3a and 3b
fliS b1925 -2.34 0.000 0.000 operons (RflA activity)
flagellar biosynthesis, basal-body outer-membrane L
flgH b1079 -2.04 0.000 0.001 (lipopolysaccharide layer) ring protein
__fgE b1076 -2.04 0.000 0.016 flagellar biosynthesis, hook protein
flagellar biosynthesis, cell-proximal portion of basal-
fIgF b1077 -1.97 0.001 0.038 body rod
fliZ b1921 -1.91 0.000 0.013 flagellar biogenesis protein
flagellar biosynthesis, component of motor switch and
energizing, enabling rotation and determining its
fliN b1946 -1.91 0.000 0.004 direction
flagellar biosynthesis, component of motor switch and
energizing, enabling rotation and determining its
fliM b1945 -1.79 0.000 0.005 direction
sensory transducer kinase between chemo- signal
cheA b1888 -1.70 0.000 0.003 receptors and CheB and CheY
flagellar biosynthesis, cell-distal portion of basal-body
flgG b1078 -1.57 0.005 0.101 rod
flagellar biosynthesis, component of motor switching
and energizing, enabling rotation and determining its
fliG b1939 -1.17 0.003 0.074 direction
yhcD b3216 1.11 0.004 0.081 putative outer membrane protein
Cell processes (adaptation/protection/stress response)
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
dinl b1061 4.22 0.000 0.000 damage-inducible protein I
Cell wall/membrane bio enesis and cell structure
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
yaeT b0177 -1.21 0.000 0.018 orf, hypothetical protein
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curli production assembly/transport component, 2nd
csgF b1038 -1.12 0.004 0.078 curli operon
rhsC b0700 1.80 0.000 0.008 rhsC protein in rhs element
Energy production and conversion
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
cydA b0733 -1.68 0.001 0.041 cytochrome d terminal oxidase, polypeptide subunit I
hybD b2993 -1.24 0.000 0.002 probable processing element for hydrogenase-2
dmsA b0894 -1.22 0.002 0.051 anaerobic dimethyl sulfoxide reductase subunit A
InorSanic ion transport and metabolism
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
trkG b1363 -1.16 0.000 0.005 trk system potassium uptake; part of Rac prophage
Lipid transport and metabolism
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
b1394 1.05 0.000 0.013 putative enzyme
Posttranslational modification, protein turnover, chaperones
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
ppiC b3775 1.87 0.000 0.004 peptidyl-prolyl cis-trans isomerase C (rotamase C)
Replication, recombination, DNA repair and modification
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
dinD b3645 2.18 0.000 0.000 DNA-damage-inducible protein
sbmC b2009 3.23 0.000 0.000 SbmC protein
recN b2616 3.24 0.000 0.000 protein used in recombination and DNA repair
DNA strand exchange and renaturation, DNA-
dependent ATPase, DNA- and ATP-dependent
recA b2699 4.62 0.000 0.000 coprotease
Secondar metabolites biosynthesis, transport and catabolism
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
ynbF/ orf, hypothetical protein; Phenylacetic acid degradation
paaB |b1389 1.17 0.000 0.007 protein paab
b1011 1.56 0.000 0.012 putative synthetase
Signal transduction mechanisms
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Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
yeaG b1783 -1.64 0.003 0.071 orf, hypothetical protein
chemotaxis regulator transmits chemoreceptor signals
cheY b1882 -1.31 0.004 0.089 to flagelllar motor components
Transcription
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
cysB b1275 -1.61 0.002 0.045 positive transcriptional regulator for cysteine regulon
adiY b4116 1.04 0.000 0.018 putative ARAC-type regulatory protein
yhiE/ transcriptional regulator gade; regulates the expression
gadE b3512 1.35 0.000 0.018 of several genes involved in acid resistance
SOS mutagenesis; error-prone repair; processed to
umuD b1183 2.22 0.000 0.000 UmuD'; forms complex with UmuC
lexA b4043 2.79 0.000 0.001 regulator for SOS(lexA) regulon
Translation
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
yadB b0144 -1.90 0.001 0.024 putative tRNA synthetase
phenylalanyl-tRNA synthetase (pheST) operon leader
pheM b1715 -1.04 0.002 0.052 peptide
iadA b4328 1.16 0.000 0.003 isoaspartyl dipeptidase
tyrT b1231 1.33 0.005 0.102 tyrosine tRNA1; tandemly duplicated
b1809 1.97 0.000 0.000 orf, hypothetical protein
argW b2348 2.01 0.001 0.021 arginine tRNA5
ileY b2652 2.67 0.000 0.000 isoleucine tRNA2 variant
General function prediction or unknown
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
trpL b1265 -3.69 0.000 0.000 trp operon leader peptide
ygaM b2672 -2.61 0.000 0.014 orf, hypothetical protein
yebV b1836 -1.48 0.001 0.041 orf, hypothetical protein
b1028 -1.44 0.000 0.000 orf, hypothetical protein
yahL b0326 -1.21 0.000 0.010 orf, hypothetical protein
ynhD b1682 -1.21 0.002 0.058 putative ATP-binding component of a transport system
b1044 -1.20 0.002 0.058 predicted HD superfamily hydrolase
yccE b1001 -1.14 0.000 0.017 orf, hypothetical protein
ykgH b0310 -1.01 0.000 0.007 orf, hypothetical protein
ygiN b3029 1.40 0.004 0.079 orf, hypothetical protein
oraA b2698 1.63 0.000 0.000 regulator, OraA protein
ydcH b1426 1.64 0.000 0.005 orf, hypothetical protein
mfM bb148 2.08 0.000 0.000 orf, hypothetical protein
ydfZ b1541 2.19 0.000 0.000 orf, hypothetical protein
orf, hypothetical protein; Phage terminase-like protein,
ymfN b1149 2.31 0.000 0.001 large subunit
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yebF b1847 2.83 0.000 0.006 orf, hypothetical protein
ymfH b1142 2.95 0.000 0.000 orf, hypothetical protein
ymfG b1141 3.61 0.000 0.000 excisionase-like protein from lambdoid prophage 14
ymfL b1147 3.86 0.000 0.000 orf, hypothetical protein
tnaL b3707 4.46 0.000 0.000 tryptophanase leader peptide
yebG b1848 5.60 0.000 0.000 orf, hypothetical protein
ymfJ b1144 6.18 0.000 0.000 orf, hypothetical protein
5.6B Genes with signal log ratios -1 < x < 1 but for which LPE p < 0.10. Genes listed by
ascending signal log ratios.
Signal Adjusted
Blattner Log Raw p- LPE p-
Gene Number Ratio value value Gene Product and Function
yqaD b2658 -0.94 0.002 0.060 Glycosidases
yciG b1259 -0.94 0.002 0.054 orf, hypothetical protein
ydjO b1730 -0.93 0.002 0.051 orf, hypothetical protein
ybcV b0558 -0.92 0.001 0.035 putative an envelop protein
flagellar biosynthesis; filament capping protein; enables
fliD b1924 -0.85 0.000 0.018 filament assembly
fimZ b0535 -0.81 0.001 0.037 fimbrial Z protein; probable signal transducer
mviM b1068 -0.79 0.003 0.062 putative virulence factor
fliP b1948 -0.78 0.004 0.077 flagellar biosynthesis
ymgC b1167 -0.78 0.004 0.077 orf, hypothetical protein
yddK b1471 -0.75 0.001 0.024 putative glycoportein
perR b0254 -0.73 0.003 0.074 putative transcriptional regulator LYSR-type
flagellar biosynthesis; possible export of flagellar
flhA b1879 -0.68 0.003 0.063 proteins
gatD b2091 -0.66 0.002 0.053 galactitol-1-phosphate dehydrogenase
phoR b0400 -0.65 0.002 0.056 positive and negative sensor protein for pho regulon
cspG b0990 -0.60 0.000 0.008 homolog of Salmonella cold shock protein
b1976 -0.58 0.005 0.094 orf, hypothetical protein
3-deoxy-D-arabinoheptulosonate-7-phosphate
aroH b1704 -0.56 0.005 0.102 synthase (DAHP synthetase, tryptophan repressible)
aspU b0206 -0.53 0.002 0.059 Aspartate tRNA1 triplicated gene, in rrnH operon
cutF b0192 -0.46 0.004 0.087 copper homeostasis protein (lipoprotein)
yafV b0219 -0.44 0.000 0.000 putative EC 3.5. amidase-type enzyme
modC b0765 -0.43 0.005 0.102 ATP-binding component of molybdate transport
transcriptional regulator for pyruvate dehydrogenase
pdhR b0113 -0.41 0.001 0.027 complex
ybbA b0495 -0.34 0.000 0.015 putative ATP-binding component of a transport system
rrlG b2589 -0.34 0.002 0.048 23S rRNA of rrnG operon
ppdA b2826 -0.33 0.000 0.010 prepilin peptidase dependent protein A
inaA b2237 -0.31 0.005 0.099 pH-inducible protein involved in stress response
ydhT b1669 -0.28 0.003 0.069 orf, hypothetical protein
formate dehydrogenase-N, nitrate-inducible, alpha
fdnG b1474 -0.25 0.000 0.004 subunit
eutK b2438 -0.24 0.002 0.058 Ethanolamine utilization protein eutk precursor
b2611 -0.14 0.002 0.044 orf, hypothetical protein
yhfZ b3383 -0.13 0.004 0.077 orf, hypothetical protein
162
yehQ b2122 -0.11 0.002 0.046 orf, hypothetical protein
cysP b2425 -0.11 0.000 0.002 thiosulfate binding protein
yphC b2545 -0.08 0.000 0.000 putative oxidoreductase
yibH b3597 -0.07 0.000 0.000 putative membrane protein
Ethanolamine utilization protein, possible chaperon in
eutA b2451 -0.07 0.000 0.017 protecting eutbc lyase from inhibition
ynjA b1753 -0.06 0.000 0.000 orf, hypothetical protein
rhaA b3903 -0.05 0.000 0.000 L-rhamnose isomerase
yicP b3665 -0.02 0.000 0.000 probable adenine deaminase (synthesis xanthine)
ybjT b0869 -0.02 0.000 0.017 putative dTDP-glucose enzyme
rrfA b3855 -0.01 0.000 0.000 5S rRNA of rrnA operon
uxuA b4322 -0.01 0.002 0.053 mannonate hydrolase
basS b4112 0.05 0.000 0.000 sensor protein for basR
yhiV b3514 0.08 0.001 0.042 putative transport system permease protein
periplasmic cytochrome c(552): plays a role in nitrite
nrfA b4070 0.08 0.003 0.063 reduction
yhaL b3107 0.09 0.004 0.084 orf, hypothetical protein
yjaG b3999 0.14 0.001 0.037 orf, hypothetical protein
yjbR b4057 0.15 0.001 0.037 orf, hypothetical protein
gmd b2053 0.17 0.005 0.103 GDP-D-mannose dehydratase
thiF b3992 0.23 0.000 0.000 thiamin biosynthesis, thiazole moiety
asnA b3744 0.29 0.000 0.008 asparagine synthetase A
yhhW b3439 0.29 0.004 0.084 orf, hypothetical protein
yidW b3695 0.30 0.000 0.000 regulator protein for dgo operon
yhcS b3243 0.31 0.005 0.101 putative transcriptional regulator LYSR-type
mrcA b3396 0.31 0.000 0.000 peptidoglycan synthetase; penicillin-binding protein 1A
b1297 0.32 0.000 0.013 putative glutamine synthetase (EC 6.3.1.2)
yegl b2070 0.32 0.000 0.013 putative chaperonin
b2710 0.33 0.001 0.031 putative flavodoxin
b3642 0.35 0.001 0.036 orotate phosphoribosyltransferase
yihl b3866 0.37 0.000 0.000 orf, hypothetical protein
ytfJ b4216 0.38 0.005 0.098 orf, hypothetical protein
yhiN b3492 0.42 0.005 0.090 orf, hypothetical protein
b2868 0.42 0.002 0.049 putative dehydrogenase
ytfL b4218 0.45 0.001 0.037 putative transport protein
ygjH b3074 0.47 0.000 0.000 putative tRNA synthetase
mlc b1594 0.47 0.003 0.064 putative NAGC-like transcriptional regulator
pflD b3951 0.49 0.002 0.052 formate acetyltransferase 2
yagP b0282 0.51 0.000 0.008 putative transcriptional regulator LYSR-type
yi82_1 b0017 0.51 0.000 0.000 IS186 and IS421 hypothetical protein
ybiH b0796 0.51 0.001 0.023 putative transcriptional regulator
b3042 0.52 0.002 0.054 orf, hypothetical protein
alaX b2396 0.52 0.004 0.077 Alanine tRNA 2; tandemly duplicated alaW
tra5 1 0.55 0.001 0.035 IS3 putative transposase
bglB b3721 0.55 0.005 0.097 phospho-beta-glucosidase B; cryptic
b3122 0.56 0.000 0.000 orf, hypothetical protein
gadA b3517 0.58 0.000 0.008 glutamate decarboxylase isozyme
yial b3573 0.59 0.005 0.101 orf, hypothetical protein
yjbK b4046 0.59 0.001 0.026 putative regulator
ycdB b1019 0.61 0.004 0.081 orf, hypothetical protein
ydcY b1446 0.63 0.001 0.026 orf, hypothetical protein
clpB b2592 0.64 0.000 0.002 heat shock protein
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CoA:apo-[acyl-carrier-protein]
acpS b2563 0.66 0.000 0.011 pantetheinephosphotransferase
molR
3 b2117 0.67 0.000 0.015 molybdate metabolism regulator, third fragment
cybC b4236 0.67 0.000 0.000 cytochrome b(562)
xerD b2894 0.68 0.001 0.039 site-specific recombinase
phnC b4106 0.68 0.000 0.002 ATP-binding component of phosphonate transport
slyX b3348 0.69 0.000 0.008 host factor for lysis of phiX174 infection
moaA b0781 0.70 0.004 0.088 molybdopterin biosynthesis, protein A
yhiK b3529 0.70 0.000 0.006 orf, hypothetical protein
membrane channel protein component of Pn
phnE b4104 0.71 0.002 0.057 transporter
yfgl b2506 0.71 0.001 0.039 orf, hypothetical protein
b2373 0.72 0.000 0.011 putative enzyme
fbp b4232 0.73 0.002 0.052 fructose-bisphosphatase
ybdF b0579 0.73 0.003 0.061 orf, hypothetical protein
valS b4258 0.77 0.000 0.014 valine tRNA synthetase
b1776 0.78 0.001 0.038 putative oxidoreductase
pdxH b1638 0.81 0.002 0.049 pyridoxinephosphate oxidase
yqfB b2900 0.82 0.000 0.000 orf, hypothetical protein
yeeA b2008 0.82 0.000 0.017 orf, hypothetical protein
fucU b2804 0.85 0.001 0.034 protein of fucose operon
yjhP b4306 0.86 0.000 0.000 putative methyltransferase
phnl b4099 0.89 0.001 0.035 phosphonate metabolism
tyrV b1230 0.90 0.005 0.093 Tyrosine tRNA1; tandemly duplicated
yghB b3009 0.90 0.000 0.011 orf, hypothetical protein
ivbL b3672 0.90 0.000 0.005 ilvB operon leader peptide
yggU b2953 0.92 0.003 0.073 orf, hypothetical protein
heat shock protein hslVU, ATPase subunit,
hslU b3931 0.93 0.003 0.067 homologous to chaperones
umuC b1184 0.97 0.000 0.008 SOS mutagenesis and repair
fhuE b1102 0.99 0.000 0.002 outer membrane receptor for ferric iron uptake
proK b3545 0.99 0.001 0.022 Proline tRNA1
ileT b3852 1.00 0.005 0.094 Isoleucine tRNA1, triplicate
GroES, 10 Kd chaperone binds to Hsp60O in pres. Mg-
mopB b4142 1.00 0.002 0.058 ATP, suppressing its ATPase activity
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Fig. 5.1 MutS binds to cisplatin-modified DNA. The substrates used are shown in B). The
two bold letters indicate the site of the adduct.
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Figure 5.2: Survival determined by colony formation of wildtype (.), dam (.),
dam mutS (0), and mutS (.) mutant strains following exposure to increasing
doses of drug. Error bars represent SEM; no error bars indicates SEM is
too small to be visualized on the scale of the plot.
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Figure 5.3: Volcano plots of gene expression changes for each strain:
wildtype (A), dam (8), dam mutS (C), mutS (D). Each shape represents a
gene. Signal log ratio represents the log2 fold change and is plotted
against the log10 p-value. Horizontal bold lines show the p-value threshold
and vertical bold lines show the fold change threshold applied to filterthe
data to include genes for which p ~ 0.10 (false discovery rate 10°,10, grey
filledshapes) and that exhibit at least a 2-fold change in expression level
(circles).
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Figure 5.4: Relative probe set intensitiesfor several 50S response genes.Dotted red lines indicate the basal level of induction between mutant and
wild-type strains. COOP = cisplatin
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Figure 5.5: Relative expression levels for several SOS genes determined by
semi-quantitative real-time RT-PCR. Expression levels represent the average of threE
independent experiments; error bars represent SO. Wild-type (blue bars), dam (red
bars), dam mutS (yellow bars), and mutS (green bars).
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Fig. 5.6: Real-time peR analysis of genes with known and potential roles in DNA
metabolism. PriA and priB encode for proteins involved in replication restart, gyrA
and gyrB encode the subunits of DNA gyrase, and ymfG is a potential LexA-regulated
gene.
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Figure 5.7: Su/A::/acZ gene reporter assay. The disk at the top of each plate served
as the control and 5, 10 and 20 ul cisplatin was added to the disks in a c10ckwis
manner. The strains used were GM4352 (wildtype), GM4355 (dam-16) and
GM5878 (dam-16 mutS215). Expression of su/A, visualized by LacZ activity, is
induced upon increasing dose of cisplatin. The dam mutant strain also
shows a high level of constitutive su/A expression.
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Figure 5.8: E. coli strains analyzed by single-cell microgel electrophoresis.
600 individual cells for each strain were analyzed by visually counting
the number of breaks A) Representative pictures of individual cells analyzed
by microgel electrophoresis. Cells with no tails indicate no breaks in the
genome, whereas cells with tails indicate the number of strand breaks in the
genome. B) Number of double-strand breaks per cell for each strain determined
by counting the tails for each cell. Error bars represent SE, *Mann-Whitney U
test P < .05 C) The percentage of highly damaged cells for each strain and dose.
Cells that showed more than 15 tails were considered highly damaged.
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Figure 5.9A: Percent of DNA in the tail region. Percent DNA in tail reflects the
flourescence in the tail as a percentage of total flourescence in tail and head region ..
Horizontal lines for each box represent the median value, with the box respresenting
500/0 of the data (box upper and lower limits represent the upper and lower quartiles,
respectively). Vertical lines extending from the box show the full range of data, and
outliers are shown as individual points (outliers have values that are greater than the
upper quartile +1.5 X interquartile distance).
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Figure 5.9B: Olive tail moments determined using Komet image analysis software.
Horizontal lines for each box represent the median value, with the box respresenting
500/0 of the data (box upper and lower limits represent the upper and lower quartiles,
respectively). Vertical lines extending from the box show the full range of data, and
outliers are shown as individual points (outliers have values that are greater than the
upper quartile +1.5 X interquartile distance). Olive tail moment: migrated DNA X
distance between the head and center of gravity of DNA in the tail.
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Figure 5.10: Models of the contribution of mismatch repair to cisplatin-induced
double-strand break formation. A) Mismatch-repair recognizes a cisplatin-DNA adduct
(pentagonal shape) and attempts repair. An incision made on the strand opposite the
adduct leads to futile repair cycling and a persistent single-strand gap. Futile cycling
coupled with DNA replication would lead to a double-strand break. Alternatively, Mut
may catalyze dual incisions on unmethylated DNA, where the strand discrimination
signal is absent, thus forming a double-strand break independent of DNA replication.
B) MutS may contribute to cisplatin-induced double-strand break formation by preventing
the recombinational bypass of cisplatin adducts. The replication fork stalls at the site of
the adduct and undergoes fork regression to remove the replication machinery from the
cisplatin blocking lesion, and flush ends of the newly synthesized complementary strands
may be substrates for RecBCD digestion. MutS binding to the cisplatin adduct may
reverse or prevent RecA-catalyzed strand exchange and inhibit recombinational bypass
of the adduct. Alternatively, Rec proteins may process and maintain the strands of
he replication fork until excision repair has taken place, and MutS binding to the adduct
may similarly block excision repair of the adduct.
Chapter 6: Future directions
6.1 DSB formation in dam mutants: MutH-catalyzed DSBs versus
replication fork collapse at MutH-catalyzed sinqle-strand breaks
Work in Chapter 4 showed that mismatch repair produces double-strand breaks in
dam mutant cells. Mismatch repair may introduce dual incisions on complementary strands
in unmethylated DNA. Alternatively, MutH may catalyze single incisions (which may occur
at greater efficiency dam mutants where the genome is unmethylated) and these single
incisions may be converted to DSBs following replication fork collapse. The replication
dependence of DSB formation therefore may shed light as to which of these mechanisms of
DSB formation occurs in cells. For example, if MutH is introducing single nicks, then
replication would be required to convert these single nicks into DSBs. However, DSB
formation by MutH-catalyzed dual incisions would be independent of DNA replication. Thus
a determination of the level of DSBs in replicating and non-replicating E. coil may reveal the
role of replication in DSB formation. In addition to measuring DSBs in replicating and non-
replicating cells, the level of single-strand breaks (SSBs) in each of the strains may provide
support for one over the other mechanism of DSB formation. The single-cell electrophoresis
method performed under alkaline conditions may be used to determine the level of SSBs in
E. coil (642,645). If dam mutants exhibit a higher level of SSBs than the other strains, and
if the level of SSBs is greater than the level of DSBs, then we would suspect that SSBs
precede DSB formation and that MutH catalyzes single incisions in dam mutants that are
only converted to DSBs after collapse of the replication complex. Therefore, determining
the level of SSBs and DSBs in replicating and non-replicating E. coil dam, dam mutS, and
wild-type strains may reveal the mechanism of MMR-dependent DSB formation.
6.2 Cisplatin-induced DSBs: MMR futile cycling versus abortive
recombinational bypass
As shown in Chapter 5, cisplatin induces double-strand breaks in E. coli.
Interestingly, the level of cisplatin-induced DSBs is enhanced by MMR in a dam mutant
background. The DSB data therefore parallel the phenotypes of the four strains; dam
mutants exhibit the highest degree of sensitivity as well as the greatest level of cisplatin-
induced DSBs, while an additional mutation in mutS abrogates sensitivity and reduces the
number of drug-induced DSBs to the number observed in wild-type and mutS strains.
Recent in vitro data suggest that the influence of MMR on the level of cisplatin-induced
DSBs may be due to MMR-mediated inhibition of recombination involving a cisplatin-
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modified substrate (90), and this inhibition may be more detrimental to dam mutants where
the recombination machinery is pre-occupied with repairing endogenous MMR-dependent
strand breaks (see Chapter 4). However, similar to the proposed mechanisms of
endogenous DSB formation in dam mutants, MMR, after recognizing a cisplatin adduct as
heterologous DNA, may initiate repair and catalyze dual incisions in a dam mutant (directly
forming a DSB) or introduce a single incision that is converted to a DSB during replication.
The latter mechanism has been termed futile cycling: MMR initiates repair on the strand
opposite the adduct, and repair synthesis (which may involve error-prone bypass of the
adduct resulting in a mismatch compound lesion) reproduces the substrate for MMR, and
repair is thus initiated again. Repeated repair cycles (i.e., futile cycling) results in a
persistent single-strand gap, which when coupled with replication would result in a double-
strand break. One way to approach this problem is to determine if MMR initiates repair of a
cisplatin modified substrate in vitro. Such a study would be the complement to the in vitro
strand-exchange assay testing the abortive recombinational bypass in vitro. Reconstituted
MMR would require a site specific cisplatin adduct in duplex DNA containing a d(GATC) site
located up- or down-stream of the adduct. Such a substrate could be constructed by
inserting an oligo containing an adduct into M13 single-strand DNA (using a scaffold oligo
and ligase), converting the DNA into duplex DNA in NER-deficient cells (which may result in
mismatches opposite the platinated guanine residues), and recovering the duplex plasmid
by extraction and isolation. After incubation with the components required for in vitro MMR
(based on studies by Modrich and colleagues (20,151,394,395,757)), running the reaction
product on a gel and determining the nature of the product (i.e., a circular duplex (no
incision was made), a linear and circular species (MutH made a single incision), or two linear
strands (MutH made dual incisions)) may answer the question if MMR can initiate repair of a
cisplatin adduct.
In addition to determining if a cisplatin adduct can stimulate MutH activity on plasmid
DNA, we can examine other events downstream of MutH incision to determine the extent of
a MMR reaction on platinated DNA. For example, if MutH makes an incision to initiate
repair, can the exonucleases digest DNA past a cisplatin adduct? Simple in vitro assays
can determine the extent of exonuclease digestion of an oligo containing a site specific
adduct.
The two functions of MMR-mutation avoidance and anti-recombination-may be
separated by examining MMR mutants that are impaired in one function but proficient in the
other. Recently, Calmann et al. (91) demonstrated that a mutSDelta800 mutation (which
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removes the C-terminal 53 amino acids of MutS) retains function in mutation avoidance but
not in anti-recombination. Interestingly, this mutant form of mutS rescues dam mutants from
cisplatin hypersensitivity (but not from MNNG-induced toxicity), thus supporting the
hypothesis that anti-recombination rather than futile-cycling may play a predominant role in
MMR-mediated cisplatin toxicity. Different mutS and mutL mutants, perhaps proficient in
adduct binding but not in other activities required for repair initiation (such as ATPase
activity or interactions with MutH), would be useful in further examining the differential role of
mutation avoidance and anti-recombination in cisplatin toxicity.
6.3 MMR effects in eukarvotes
Studies analogous to the above experiments investigating MMR mutants deficient in
either mutation avoidance or anti-recombination (but not both) would also be helpful to
examine the role of MMR in cisplatin toxicity in eukaryotic cells. Such MMR mutants in
yeast have already been identified (741); two alleles affecting only the anti-recombination
function of Pmslp have been identified, and one of these mutations changes an amino acid
within the highly conserved ATPase domain. The in vitro experiments using the E. coli
recombination and MMR proteins would be more difficult to transfer to eukaryotic or
mammalian cells. Although in vitro MMR by human nuclear extracts has been demonstrated
(729,730), such studies on a cisplatin-modified substrate may prove problematic due to the
relatively high number of nuclear proteins that recognize and bind cisplatin adducts,
including other repair proteins (such as NER proteins) that might initiate repair. However
studies examining the damage signaling role of MMR in response to cisplatin treatment may
shed light on the mechanism of reduced apoptosis in MMR-deficient cells and how such
MMR loss contributes to cisplatin resistance. For example, is MMR required for ATM
activation of Chk2 kinase in response to cisplatin (as was shown for IR-induced S phase
arrest (76))? Similar to experiments using separation-of-function mutants to sparse out the
contribution of anti-recombination and mutation avoidance pathways in MMR-mediated
cisplatin toxicity, experiments using different eukaryotic mutants proficient in MMR-mediated
apoptosis but deficient in the repair of mismatches may provide insight as to which
mechanism is critical for cisplatin-induced toxicity. One such MSH2 mutant-a point
mutation in the ATPase domain of MSH2 (G674A)-results in increased tumorigenesis in
mice; yet this mutant protein retains its ability to bind to a G:T mismatch in vitro and tumors
carrying the mutant allele remain responsive to cisplatin (413). In addition to studying the
MMR-dependent pathways of cisplatin-induced toxicity, the MMR-independent (and p53-
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dependent) pathways for cisplatin-induced apoptosis also require further study.
Furthermore, is not known whether these pathways are differentially activated for the
different cisplatin analogues.
6.4 Lessons learned from cisplatin: the development of novel
anticancer agents
Based on the data presented and summarized in this work, cells that are deficient in
Dam are essentially "repair deficient" as their recombinational repair machinery is pre-
occupied with endogenous mismatch repair-induced strand breaks. Such repair deficiency
renders these cells more susceptible to the effects of additional DNA damage. Thus one
mechanism for the development of new cancer treatment strategies is to make cancer cells
similar to dam mutant cells in regard to their DNA repair status. As mentioned in Chapter 1,
cisplatin-based therapies are very effective in treating TGCTs, which naturally express lower
levels of certain DNA repair proteins. Furthermore, breast and ovarian tumors deficient in
BRCA1 or BRCA2, and consequently deficient in recombinational DNA repair mechanisms,
are exceptionally sensitive to PARP inhibitors as PARP may be able to compensate for
deficient BRCA1/2 pathways (199). Thus, cells whose DNA repair capacity is constitutively
under a state of stress present good targets for treatment with DNA damaging agents.
While not all tumor cells are inherently repair deficient, other tumor cell characteristics may
be exploited to induce selective adduct persistence in tumor versus non-tumor cells (see
below).
The need for new chemotherapeutics is based on the fact that although cisplatin is
effective in the treatment of TGCTs, for other cancers, including ovarian cancer, platinum-
based chemotherapies extend life but unfortunately rarely cure disease. For example,
ovarian cancer remains the leading cause of death due to gynecologic malignancies.
Recent estimates for 2005 predict that there will be 22,220 new cases of ovarian cancer
diagnosed in the United States; these new cases are predicted to be accompanied by
16,210 deaths (330), which would make ovarian cancer the fourth deadliest cancer among
women. Current front-line therapies for advanced ovarian cancer include cisplatin/paclitaxel
combination therapy, with carboplatin/paclitaxel presenting an alternative treatment with less
severe side-effects (Table 1.1). However with an 80% relapse rate, additional and improved
therapies are needed. Because of the dose-limiting toxicity and acquired drug resistance,
new drugs selectively toxic to cancer cells may be successful in killing cancer cells while
proving less toxic to patients.
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As discussed in Chapter 1, the trans isomer of cisplatin is clinically ineffective, most
likely due to the better capacity of DNA repair to remove adducts formed by transplatin.
Furthermore, many studies have shown that ovarian cancer resistant cell lines display
increased repair capacity. Based on the proposed mechanisms of cisplatin toxicity, namely
repair shielding and transcription factor hijacking discussed in Chapter 1, one proposed
mechanism for targeting toxicity to ovarian cancer cells is to treat patients with a DNA
damaging drug that would be blocked from repair only in the cancer cells and not in normal
healthy cells and that would disrupt normal cellular function by hijacking proteins essential
for cell growth. To mimic the repair-shielding mechanism of cisplatin toxicity, the drug's
design would need to exploit the differential expression of cellular proteins in cancer cells
versus normal cells, and in so doing make adduct repair shielding only operative in the
cancer cells. One such protein expressed in many ovarian cancers is the hormone steroid
receptor, estrogen receptor alpha. Thus a drug designed to selectively target estrogen
receptor positive (ER+) ovarian tumors would bind to the ER and would therefore carry the
ER ligand. However to elicit toxicity by a mechanism similar to the platinum compounds
(i.e., repair shielding), this drug will also need to damage DNA. In addition to repair
shielding, by binding to ERalpha, this new drug will also hijack the receptor away from its
natural DNA binding sites (estrogen response elements) and therefore will disrupt the
activation of genes important for cell growth. Therefore, this new drug will mimic the
property of cisplatin to form DNA adducts that attract nuclear proteins; the hijacking of those
proteins is anticipated to block DNA repair and to disrupt the normal functions of those
proteins in gene regulation. However unlike cisplatin, this drug will be selective to cancer
cells-specifically ER+ cancer cells.
In keeping with the principles outlined above, a novel drug designed by the Essigmann
lab contains a non-platinum warhead that reacts with DNA; tethered to the warhead is a
ligand for the estrogen receptor (Fig. 6.1). This bifunctional compound will display, in
principle, both shielding- and hijacking-based mechanisms of toxicity. As with cisplatin, the
compound will react with the N7 atom of purines to form mono and bis-DNA adducts. Also,
as with cisplatin, this compound will theoretically persist in DNA by attracting cellular
proteins, specifically the ER, to the adduct site. Binding of the ER to the estradiol moiety will
prevent repair of the adduct, while ER binding will also prevent the ER from serving its role
in promoting cell growth (i.e., the ER will be hijacked away from estrogen response elements
in the promoter regions of survival and pro-growth genes, resulting in inhibition of tumor cell
growth). Because the ER is expressed in sixty percent of epithelial ovarian cancers (142)
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and in nearly seventy percent of breast tumors (318), this agent will in principle selectively
target tumor cells by exploiting the differential expression of the ER in tumor and non-tumor
cells. Indeed, work in the ER+ breast cancer cell line MCF-7 and a ER- cell line shows that
this agent is specifically toxic to ER+ cells and that adducts formed by this agent are
differentially repaired in ER+ and ER- cells ((631) and Hillier and Marquis, unpublished
results).
Previous work using xenograft tumors in mice have shown that E27a reaches
pharmacologic concentration in animals (with acceptable attendant animal toxicity) as well
as antitumor activity. However this compound has yet to be tested in an ovarian cancer
model. To test the potential of E27a in the treatment of ovarian cancer, a mouse model
developed in the Jacks lab may provide an appropriate system. This model is the first
mouse model of well-differentiated endometrioid adenocarcinoma of the ovary, and
moreover the tumors of these mice express the ER (169). Preliminary work with cisplatin
and E27a show nearly identical toxicity profiles on mouse ovarian cancer cells derived from
this mouse model (Figs. 6.2 and 6.3). The two compounds show superior characteristics, so
far, to carboplatin, the other drug used in front line ovarian cancer therapy. Furthermore,
these cell lines are comparably sensitive to cisplatin as two human cell lines-HeLa and the
ovarian Caov-3 cell lines (Fig. 6.4). Additional in vitro work characterizing the cytotoxic
effects of these drugs (such as colony formation assays, cell cycle analysis, and mechanistic
studies using different forms of E27a with different abilities to bind the ER and/or DNA) are
needed to determine the relative cytotoxic potential of E27a compared to cisplatin.
Furthermore, in vivo work in this mouse model will hopefully demonstrate that E27a is better
tolerated than cisplatin while eliciting similar effects in blocking tumor progression.
Mechanistic studies of E27a may include a determination of ER binding to E27a
adducts in cells. ER bound to E27a may be quantitated in cells by chromatin
immunoprecipitation experiments in which ER+ cells are treated with 14 C-labeled compound,
and any cellular proteins bound to DNA are then crosslinked by formaldehyde treatment.
After DNA fragmentation and chromatin immunoprecipitation, a determination of 14C will
reveal if the compound is bound to DNA, and anti-ER staining will reveal if ER is bound to
the compound. Similarly, a pull-down of ERoc with any bound substrates using immobilized
ERo antibodies may reveal an interaction of compound with the receptor in cells.
In order to determine if E27a treatment limits ER-mediated transcriptional activation,
the transcript levels of endogenous estrogen-responsive genes (e.g., c-myc, fos, pS2 and
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PR (272,301,389-391)) can be measured following treatment with E27a. First the level of
transcriptional activation achieved by estradiol stimulation in ER+ cells can be determined to
ensure that ER-mediated transcription is responsive to an agonist. Then semiquantitative
real-time RT-PCR and Northern analysis can be used to measure the transcript levels of
estrogen-responsive genes in ER+ cells +/-estradiol stimulation. Next the reduction in
transcriptional activation achieved by first treating ER+ cells with E27a (and vehicle for the
control) followed by estradiol stimulation may show that the estrogen receptor is hijacked in
cells; the transcript levels of estrogen-responsive genes such as PR and c-myc may exhibit
reduced transcriptional activation in E27a pre-treated cells. In addition to examining the
expression of endogenous estrogen-responsive genes, a gene reporter assay may be used
to examine the effect of E27a treatment on the transcription of a reporter gene under the
control of estrogen response elements. The consensus ERE is a 13-base pair palindromic
sequence consisting of inverted repeats 5-GGTCA-3 separated by a 3-bp spacer (e.g.,
GGTCANNNTGACC) and is found in the 5-flanking region of the Xenopus and chicken
vitellogenin A2 genes (377,378,724). Cells transfected with the firefly luciferase gene under
control of an estrogen-responsive promoter and treated with E27a, control compounds, or
vehicle, followed by estradiol stimulation can be used to determine if E27a reduces
luceriferase activity and hence the transcriptional activation of genes under the control of
EREs.
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Fig 6.1: The basic features of E27a are (a) a nitrogen mustard DNA-damaging warhead, (b) a linker that enhances
solubility and is stable to hydrolytic cleavage, and (c) a covalently tethered estradiol moiety, which serves as an
estrogen receptor ligand. It was recently reported that the E27a compound binds DNA, and.it also binds the ER with
the excellent relative binding affinity (RBA) of 46 (the RBA of estradiol is 100).
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Appendix: Base excision repair and cisplatin damage
A. 1 Base excision repair: Cisplatin may hijack base excision repair
proteins
A.1.1 AAG binds to cisplatin-DNA adducts, leading to increased mutagenesis
Work by P. Hopkins (307) revealed that some cisplatin crosslinks have a base that is
extruded from the helix. This unusual architecture is reminiscent of the structure of
damaged DNA bases in the active sites of glycosylases (294,400). Surprisingly, the human
3-methyladenine DNA glycosylase (AAG) can bind each of the cisplatin intrastrand
crosslinks in vitro (353). AAG is a DNA glycosylase involved in initiation of the first step in
base excision repair of a variety of DNA adducts, including 1,N-ethenoadenine (A).
Kartalou et al. (353) demonstrated that AAG protein binds cisplatin intrastrand crosslinks
with high affinity in vitro. Although AAG was unable to release platinum adducts from the
DNA, despite the high binding affinity, the presence of cisplatin adducts very effectively
inhibited the excision of LA adducts by AAG, suggesting that binding to cisplatin adducts
made AAG less available for binding to its natural substrates. Accordingly, if cisplatin could
lure away AAG from its natural substrates in vivo, the presence of cisplatin adducts could
result in decreased repair of other damage in cells, leading to enhanced toxicity and
mutagenicity of cisplatin due to the persistence of other DNA lesions normally repaired by
AAG (A in DNA is a natural product derived from lipid oxidation). Such enhanced
mutagenicity was observed, and as a parallel Saparbaev et al. (258) recently showed that
etheno cytosine in DNA can also hijack AAG away from LA lesions, leading to LA
persistence. Thus the mechanism of cisplatin toxicity as it relates to BER is consistent with
the hijacking model proposed earlier.
A.2.2 MutY binds to cisplatin-DNA adducts, leading to increased mutagenesis
In addition to AAG, the E. coil glycosylase MutY and the human MutY homologue
(hMYH) may affect cisplatin mutagenesis in vivo. MutY is thought a bifunctional DNA
glycosylase (i.e., exhibits both glycosylase and AP lyase activity (611), though the AP lyase
activity of MutY is controversial) that is responsible for initiating repair of adenine
misincorporated opposite the oxidized lesion 8-oxoG. MutY also shows activity on adenine
mispair substrates such as A:G and A:C, albeit with much lower activity (261,654).
Escherichia coli MutY is a 39 kDa sulfur-iron protein member of the helix-hairpin-helix
187
and a 13 kDa (p13) domain important in the enzyme's substrate specificity and catalytic
efficiency (440). Both the full length protein and p26 bind cisplatin-modified oligonucleotides
in vitro (Kartalou et al., unpublished results). The role of MutY glycosylase in protecting
against oxidized-induced damage and mutagenesis is shown in Fig. A. 1. Following MutY
activity, the AP site is repaired by the sequential action of an AP endonuclease and gap-
filling polymerase that preferentially incorporates dCMP opposite to 8-oxoG and DNA ligase.
The resulting C/8-oxoG base pair is then a substrate for the 8-oxoguanine DNA glycosylase
(Fpg or MutM). Removal of the 8-oxoG opposite C by Fpg, followed by a gap repair of the
abasic site, results in the final restoration of the original C/G base pair.
The bacterial MutY and hMYH exhibit significant sequence homology, and both
proteins can bind and cleave at the site of a cisplatin lesion in vitro (Kartalou et al., paper in
progress). Specifically, the bacterial protein shows enzymatic activity on adenine in a A:G
mispair when either the A or G is platinated; hence this protein can initiate a repair event at
the site of a cisplatin adduct directly. Mutagenesis analysis also shows that MutY enhances
cisplatin-induced mutations in E. coli. Such mutations may arise from fixation of the bypass
polymerase errors made during translesion synthesis. This mutation fixation would depend
on MutY-mediated repair activity on the AG crosslink. For example, if G is misincorporated
opposite a platinated A in an AG crosslink, MutY may trigger repair of the crosslink, leaving
the G in the opposite strand. The opposite strand containing the bypass error then serves
as the template in repair synthesis, leading to an A:T to C:G transversion mutation. The
human protein hMYH also binds cisplatin adducts; this protein however was only shown to
exhibit enzymatic activity on adenine opposite a platinated G and not a platinated A
(opposite G). Thus, based on the model of MutY-dependent mutagenesis just described,
the influence of hMYH on cisplatin-induced mutagenesis in human cells may be different
than the effects of MutY in bacterial cells. Although MutY does not alter cellular sensitivity to
cisplatin in E. coil, the effects of hMYH enzymatic activity on sensitivity to cisplatin in human
cells have not been studied.
A.2 Construction of a human cell line with deficient expression of
hMYH protein
To address the potential roles of hMYH in cisplatin-induced toxicity and/or
mutagenesis, RNA interference was used to construct human cells with deficient expression
of the hMYH protein. At the time this project was started (in 2001), investigators were
testing different duplex siRNAs for knock-down effect by trial-and-error. However today,
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many commercial suppliers of siRNAs (including Qiagen, Ambion, among others), sell
validated siRNAs for many different proteins. To determine a siRNA sequence that would
knock-down hMYH expression, siRNAs designed for five different target sequences of the
hMYH cDNA were tested (Fig. A.2). Because the human transcript occurs as several
different splice variants (315,529,681), target sites were chosen based on the conserved
transcript regions (i.e., only sequences common to all splice variants were considered). A
functional assay as well as immunohistochemistry with a polyclonal anti-hMYH antibody
were used to assess the extent of knock-down (Figs. A.3 and A.4) Due to factors such as
the half-life of the protein and a dilution effect of the siRNAs over time, the extent of knock-
down is very transient. Therefore construction of a stable knock-down was attempted.
Because targeting the untranslated regions (UTR) would permit functional complementation
studies using hMYH cDNA under different UTRs, target #55 was chosen as a target
sequence with which to construct a stable-knockdown cell line. Target #11 was also used
for stable knock-down expression in order to use two different target sequences and confirm
that any knock-down phenotype was not do to off-target effects. In addition to the two
hMYH specific targets, a non-specific (control) sequence was used in the stable knock-down
clone development. To construct stable human clones with reduced expression of hMYH , a
vector containing cDNA encoding for hairpin RNA corresponding to the #55 and #11 target
sites as well as a non-specific siRNA sequence were cloned into the psilencer plasmid
(Ambion). HeLa cells were transfected with the plasmid DNA and selected by G418. G418
resistant cells were seeded so that individual clones could be harvested and characterized.
Because the genomic sites containing the hairpin-encoding vector could include genes that
affect growth rate and other cellular processes, several clones for each target were
selected. Thirty-two clones containing #11, forty-four containing #55, and six negative
control clones containing the vector encoding non-specific siRNA were characterized by
PCR (Fig. A.5) to ensure that their genomic DNA contained the hairpin encoding construct.
Further characterization of these clones is required to determine the level of hMYH protein
expression.
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